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The HIV-1 Nef accessory protein plays a prominent role in viral pathogenesis, immune 
evasion of HIV-infected cells, and AIDS progression. Nef lacks intrinsic biochemical activity, and 
instead functions through interactions with multiple host cell effector proteins. Previous studies 
have shown that Nef homo-dimerizes at a hydrophobic interface between two Nef molecules. As 
Nef dimerization has been implicated in several Nef functions, it may represent a novel and 
effective target for antiretroviral drug development. Research that further expands our 
understanding of Nef dimerization may aid in the development of future therapeutics. 
Therefore, for the first part of my dissertation, I explored the role of Nef dimerization in 
Nef antagonism of the host restriction factor SERINC5. We showed that Nef homodimers are 
required for the AP-2 dependent downregulation of SERINC5, trafficking to late endosomes, and 
exclusion from newly synthesized viral particles. Disruption of Nef dimerization impaired 
antagonism of SERINC5, rescuing SERINC5 inhibition of viral infectivity. In addition, 
dimerization-defective Nef mutants retained interaction with both SERINC5 and AP-2 by 
fluorescence complementation assay, suggesting that the Nef dimer bridges SERINC5 with AP-2 
to drive endocytosis of cell-surface SERINC5.  
For the second part of my dissertation, I examined the dynamics and individual 
contribution of predicted dimer-stabilizing residues towards dimerization and complex formation 
in solution. Crystal structures have revealed distinct orientations of the Nef dimer interface within 
vi 
complexes of Nef bound to Src family kinase SH3 domain vs. Nef complexes bound to SH3-SH2 
domain. I was able to validate the orientation of the dimer interface captured in each structure 
using biophysical and biochemical studies. As part of a collaborative study, I was able to confirm 
that Nef Asp123 contributes to Nef dimerization within the SH3-bound but not the SH3-SH2 
bound structure of Nef. I also identified a Nef residue (Tyr115) that stabilizes Nef dimerization 
within both complexes, suggesting that it is a consistent feature of Nef dimerization across two 
potential stages of kinase domain engagement. Taken together, this dissertation helps to further 
illuminate the mechanics of Nef dimerization, and implicates Nef dimerization in one of the more 
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1.1 Human Immunodeficiency Virus (HIV-1) 
1.1.1 History and Global Burden of HIV/AIDS 
The shadows of the human immunodeficiency virus (HIV) epidemic first appeared in 1981 
within a corner of the Center for Disease Control’s Morbidity and Mortality Weekly Report 
(MMWR). One article within the June 5th report recounted the appearance of Pneumocystis carinii 
pneumonia within five men in the Los Angeles area, a diagnosis commonly found within severely 
immunosuppressed patient populations (1) but unexpected for healthy men in their 20s and 30s 
(2). This localized outbreak of P. carinii pneumonia was unique enough to warrant reporting 
within the medical literature, and so a case report outlining the symptoms, medical history, and 
outcomes of these patients was written and published within the MMWR. Without realizing it, the 
authors penned the first description of what would become HIV/AIDS in the medical literature, 
suggesting “the possibility of a cellular-immune dysfunction related to a common exposure that 
predisposes individuals to opportunistic infections.” 
That “common exposure” continued to spread across the United States, manifesting as 
opportunistic infections, the rare cancer Kaposi’s Sarcoma, non-Hodgkin’s lymphoma (3). In 
1982, the CDC settled on a term to describe this mysterious immunosuppression and the 
assortment of opportunistic conditions that characterized it - Acquired Immunodeficiency 
Syndrome or AIDS (4). The causative agent of AIDS, the Human Immunodeficiency Virus (HIV), 
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would be identified just one year later by the laboratory of Dr. Luc Montagnier (5), providing 
researchers a definitive target to combat AIDS.  
HIV transmission peaked in the United States during 1984-1985, with nearly 130,000 new 
cases reported each year (6).  This number began to recede as HIV testing and prevention efforts 
became more widespread (7, 8). Today, the number of new HIV infections within the US has 
dropped to 37,000 each year (9), but the disease burden of HIV is still keenly felt across the world. 
There are almost 38 million people infected with HIV worldwide, and each year brings over 
700,000 HIV-related deaths and 1.7 million new infections (10). HIV has particularly devasted 
regions of southern and eastern Africa, where over half of current HIV infections currently exist 
(10).  
1.1.2 Background on human and simian retroviruses  
“HIV hasn’t happened to humanity just once. It has happened at least a 
dozen times—a dozen that we know of, and probably many more times in earlier 
history. It wasn’t a singular piece of vastly unlikely bad luck, striking humankind 
with devastating results—like a comet come knuckleballing across the infinitude 
of space to smack planet Earth and extinguish the dinosaurs. No. The arrival of 
HIV in human bloodstreams was, on the contrary, part of a small trend. Due to 
the nature of our interactions with African primates, it seems to occur pretty 
often.” 
― David Quammen, Spillover: Animal Infections and the Next Human Pandemic (11) 
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The global HIV pandemic can be linked primarily to viruses within the main group (Group 
M) of HIV-1, and it is this lineage that is responsible for over 97% of HIV infections around the 
world today (12). Group M can be further broken down into at least 9 subtypes or clades-A, B, C, 
D, F, G, H, K, and potentially a newly discovered L subtype (13). The most prevalent subtype is 
clade C, which makes up nearly half of HIV infections and circulates within Eastern and Southern 
Africa. However, most HIV research has centered around HIV-1 Clade B, which represents only 
11% of global HIV-1 infections, and is found within the Americas, Western Europe, East Asia, 
and Oceania (14, 15). Initial human transmission of HIV-1 Group M can be traced to a region of 
Central Africa within the Democratic Republic of Congo during the early 20th century (16), and 
the earliest evidence of human HIV-1 infection is a 1959 sample from this area (17). Although it 
is unclear when and where HIV-1 Group M first crossed over from non-human primate hosts, the 
high similarity of HIV-1 Group M to a simian immunodeficiency virus (SIV) strain that infects 
chimpanzees (SIVcpz) within southeast Cameroon suggests the initial zoonotic transmission 
occurred within that region (18, 19). 
HIV-1 Group M has rightfully commanded scientific attention over the last forty years, but 
the existence of other pathogenic lineages of HIV demonstrates that the arrival of HIV is the 
product of a consistent zoonotic interplay between humans and other primates (20). Over 40 
primate species have been shown to harbor SIV infections, and each species typically harbors their 
own strain of the virus without the onset of pathogenesis (21). However, instances of cross-species 
transmission of SIV into humans has led to the creation of over a dozen different lineages of 
pathogenic HIV. In addition to Group M, there are three viral lineages from three separate 
transmission events that encompass HIV-1- Groups N (new), O (Outlier) and P (Pending)(18). 
Group N is also believed to have originated from chimpanzees within Cameroon, however, its 
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origin is distinct from Group M, and fewer than 20 human infections have been identified to date 
(22). The final two groups of HIV-1, Group O and P, appear to be closely related to strains of SIV 
native to Western lowland gorillas (23). Group O is the second most common lineage of HIV-1 to 
infect humans, however, it represents fewer than 1% of total HIV-1 infections (23). Group P is the 
rarest form of HIV-1, and has been isolated from only two patients to date (20). 
While HIV-1 is the product of four separate instances of zoonotic transmission between 
humans and primates, the distantly related HIV-2 is believed to be comprised of nine separate 
transmission events (Groups A to I). HIV-2 is responsible for the final 1 to 2 million of the world’s 
HIV infections (24, 25), and though it causes AIDS in infected humans, it consistently displays 
reduced transmission and a lower rate of AIDS progression compared to HIV-1 (25). Overall 
nucleotide sequence homology hovers around 40% between both viruses (26), and early 
characterization of HIV-2 showed that it was serologically dissimilar enough to strains of HIV-1 
to warrant its own classification (27). 
In contrast, HIV-2 has a greater degree of sequence homology with SIV, a link which 
served as one of the earliest pieces of evidence that HIV was of simian origin (28). Around the 
time that HIV-2 was initially isolated, the first strain of SIV was discovered from a research colony 
of rhesus macaques suffering from simian AIDS (SIVmac)(29). Serologic analysis of HIV-2 
showed greater reactivity for serum isolated from SIVmac-infected macaques than for serum 
isolated from HIV-1 infected humans, suggesting a close relationship between HIV-2 and SIVmac 
(27). Interestingly, SIVmac is not endemic to rhesus macaques, but derives from a lineage of SIV 
that infects sooty mangabeys (SIVsmm). SIVmac was itself the product of a cross-species 
transmission between research primates used during the 1970s (30). It is a fascinating coincidence 
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that both HIV-2 and SIVmac, two separate zoonotic transmissions of SIVsmm into two distinct 
primate species, were discovered within the span of just three years. 
1.1.3 HIV-1 Genome  
 
Figure 1: Organization of the HIV-1 Genome 
Schematic illustrating the 9kb HIV-1 genome, which is organized into nine open reading frames encoding 15 proteins. 
Highlighted in dark gray (Vif, Vpr, Vpu) and red (Nef) are the HIV-1 accessory proteins. 
 
The HIV-1 genome (Figure 1) is comprised of a 9 kb single-stranded positive sense RNA, 
and encodes fifteen proteins across nine open reading frames (31).These open reading frames are 
flanked on either side by the 5’ and 3’ Long Terminal Repeats (LTR), which contribute to viral 
transcription and insertion of the HIV-1 proviral DNA into the genomes of infected cells (32, 
33).The three fundamental genes common to HIV-1 and all retroviruses are those that encode Pol, 
Gag, and Env, the polyprotein precursors to all structural and enzymatic HIV proteins. 
The Gag polyprotein (p55) bundles together the major structural proteins of HIV-1 and is 
recruited to the host cell membrane of infected cells via a myristoylated N-terminus. At the host 
cell membrane, Gag directs recruitment of the viral genome and coordinates budding of the viral 
lipid membrane. Cleavage of Gag by the HIV protease (PR) initiates virion maturation, and results 
in the creation of individual structural proteins required to form the viral capsid core (overviewed 
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in the virion structure section). The primary Gag products are the matrix protein (MA), capsid (CA 
or p24), and nucleocapsid (NC); however, cleavage by PR also creates two spacer proteins (SP1 
and SP2) and the p6 peptide (34). 
The Pol gene encodes the critical enzymatic machinery that drive HIV replication- the viral 
protease (PR), reverse transcriptase (RT), and integrase (IN). RT, the enzyme for which the 
retrovirus family is named, converts single-stranded viral RNA into double-stranded cDNA (35). 
Following reverse transcription, the Pol-derived IN protein catalyzes the insertion of viral cDNA 
into the host cell genome (36), driving viral replication. PR is involved in the processing and 
maturation of viral proteins, especially the Pol and Gag polyproteins (37). 
The Env gene expresses the gp160 polyprotein, which in contrast to Gag and Pol is cleaved 
by the cellular protease Furin instead of PR. Cleavage of gp160 by Furin produces the 
transmembrane glycoprotein 41  (gp41) and the surface glycoprotein 120 (gp120), which work in 
tandem to direct viral recognition of host cell receptors (CD4 and CCR5 or CXCR4) and viral 
fusion with the host cell membrane (38). 
The HIV genome also encodes two regulatory proteins, the transactivator protein (Tat) and 
the regulator of virion expression (Rev). Tat amplifies the transcription of integrated viral DNA, 
accelerating viral replication within infected cells (39). The regulator Rev also plays an important 
role in viral replication, and hijacks the host nuclear export machinery to transport unspliced viral 
RNA out of the nucleus and into the cytoplasm (40).  
The final four proteins encoded by HIV are the accessory proteins Vif, Vpr, Vpu, and Nef. 
These accessory proteins are not required for viral replication but play an important role in viral 
pathogenesis, immune escape, and viral spread in vivo (41). The accessory protein Nef is the major 
focus of this thesis project and will be explored thoroughly within Section 2 of the introduction.  
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1.1.4 HIV-1 Structure  
 
Figure 2: Structure of the HIV-1 Virion 
Cartoon illustration of the HIV virion, and a depiction of the structural (MA, CA, gp120/gp41) and enzymatic proteins 
(RT, IN) that are incorporated into the virus. Figured is adapted from the NIH NIAID website, and is licensed under 
the Creative Commons Attribution 4.0 International License. 
 
The HIV virion is encapsulated by a lipid envelope roughly 100-120 nm in diameter, and 
contains two copies of the single-stranded RNA genome surrounded by a conical protein core (42). 
The lipid envelope of HIV originates from the cellular membrane of infected cells, as virions bud 
off from the host cell membrane following assembly. While budding, HIV inherits any host cell 
membrane proteins that reside within the borrowed lipid bilayer, some of which have been shown 
to have a direct impact on HIV infectivity and attachment (43, 44). Env glycoprotein complexes 
are also incorporated into the viral membrane, which control viral receptor recognition and fusion 
during viral spread. Three molecules of the gp120 surface protein associate with three molecules 
of the transmembrane protein gp41 to form the HIV Env spike, and around 72 of these spikes dot 
the surface of the newly synthesized virion (38, 42). 
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Directly inside the viral membrane is a shell comprised of 2000-5000 monomers of the 
matrix (MA) protein, which associate with the viral membrane via an N-terminal myristoylation 
group and positively charged residues (45). Tucked within the MA lattice shell is the conical viral 
core comprised of 1000-1500 copies of the p24 capsid (CA) protein (46). Inside the capsid core 
lies both copies of the RNA viral genome, which are coated and chaperoned by the nucleocapsid 
(NC) protein into a stable and tight conformation (47). The viral core also incorporates several 
non-structural viral proteins, including components of the viral replication machinery (RT, PR, 
and IN) and the accessory proteins Nef, Vpr, and Vpu (48). 
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1.1.5 HIV Life Cycle 
 
Figure 3: Illustration of the HIV-1 Life Cycle 
Depiction of the major stages of the HIV-1 life cycle. 1) Env spike proteins bind to viral receptors and co-receptors 
on the surface of target cells. Fusion is initiated between the viral membrane and target cell membrane following 
insertion of the gp41 fusion peptide. 2) The viral core is delivered into the cytoplasm after fusion, and the capsid 
begins to uncoat. 3) RT is initiated during or after capsid uncoating, viral RNA is transcribed into viral DNA. 4) 
Integrase mediates the insertion of viral DNA into the host cell genome. 5) Host machinery initiates transcription of 
proviral DNA, production and export of viral RNA is aided by Tat and Rev. 6) Viral proteins and genome assemble 
at the cell surface of the infected cell. 7) HIV-1 virion (with host-derived membrane) buds off from infected cells, PR 
activity processes the immature virion into a mature virus. Figured is adapted from the NIH NIAID website, and is 
licensed under the Creative Commons Attribution 4.0 International License. 
 
HIV primarily infects CD4+ T lymphocytes and macrophages, but can also infect several 
other myeloid lineage cells including dendritic cells, osteoclasts, and microglia (49). Host cell 
recognition and viral entry require the receptor CD4, with viral tropism directed by the co-receptor 
10 
CXCR4 or CCR5. HIV tropism can be split into three categories- viruses with a preference for 
CCR5 are classified as R5 or macrophage (M-tropic), CXCR4-preferring viruses are known as X4 
or T-lymphocyte tropic (T-tropic), and viruses that can bind to both co-receptors are labeled as 
X4/R5 viruses (50). 
Initiation of the viral life cycle begins with the first step of viral entry and fusion- the 
binding of infectious HIV-1 virions to CD4 through the gp120 component of HIV Env (Figure 2). 
Engagement of gp120 by CD4 reveals the co-receptor binding site within gp120, allowing for the 
virion to associate with its preferred co-receptor. Receptor and co-receptor binding by gp120 
induce a conformational change within gp41, which initiates the insertion of the gp41 fusion 
peptide into the cell membrane. The gp41 fusion peptide, now anchored on either side by the viral 
and cellular membrane, bends into a six-helix bundle that serves as a mechanical lever to trigger 
membrane fusion. Expansion of the resulting fusion pore between the HIV and cell membranes 
then allows for the release of the viral core into the cytoplasm (38), and begins the next stage of 
viral infection.   
Following fusion and entry, the viral capsid disassembles, and reverse transcription of viral 
RNA begins within the cytoplasm. Reverse transcription may initiate while the capsid uncoats or 
immediately following disassembly, however, the exact timing of the two processes is contentious 
(51). During reverse transcription, viral RNA is converted from single-stranded RNA into double-
stranded cDNA by reverse transcriptase/RNase H in preparation for nuclear transport and 
integration. First, RT utilizes host tRNA to synthesize a complementary strand of DNA using the 
RNA genome strand as a template, forming a DNA-RNA complex which is processed by RNase 
H. RT then initiates synthesis of the second complementary strand of DNA, resulting in a dsDNA 
copy of the viral genome that is amenable to insertion into the host cell genome (35). 
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The double-stranded DNA product then associates with viral and cellular proteins to form 
the pre-integration complex (PIC)(52), and is transported into the nucleus of the infected cell. Once 
inside the nucleus, IN orchestrates the processing and integration of the viral genome into host 
DNA, starting with the hydrolytic digest of the 3’ termini of each strand of viral DNA to create a 
two-nucleotide overhang. The 3’ overhangs within the viral DNA then attack and infiltrate target 
DNA in a process known as strand transfer, creating an integration intermediate that connects the 
viral DNA to host chromosomal DNA. Overhangs and nicks created by this process are then 
resolved by host cell enzymes to yield a single integrated proviral product within host 
chromosomes (36).  
In the presence of cellular activation, transcription of the integrated proviral DNA is 
initiated at the 5’ LTR by RNA Polymerase II (RNAPII) and host cell transcription 
factors. However, efficient generation of full-length transcripts requires engagement of the viral 
Tat protein with a region within the LTR referred to as the trans-activation response (TAR) 
element. Tat association with TAR aids transcription elongation, and serves to boost the rate of 
viral transcription within infected cells (32, 53). Transcription yields unspliced full-length 
transcripts of the HIV-1 genome, as well as spliced and partially spliced mRNAs for viral proteins. 
While the fully spliced mRNA transcripts are transported into the cytoplasm to initiate early 
translation of Rev, Tat, and Nef, partially spliced and unspliced viral transcripts (including the 
viral genome) require the recruitment of the viral Rev protein to be transported out of the nucleus 
(54).  
Following translation and post-translational modification within the Golgi, the Gag 
polyprotein directs assembly of the HIV virion using the uncleaved Gag domains (55). The 
myristoylated MA domain stabilizes Gag association with the cell membrane, and promotes but is 
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not required for Env incorporation into the virion (46, 56). Both copies of the RNA genome are 
recruited by the NC domain of Gag, and the other domains within Gag drive protein-protein 
interactions required for assembly of the immature viral particle at the cell membrane, as well as 
budding. Critically, the p6 domain of Gag recruits the cellular ESCRT (endosomal sorting 
complexes required for transport) machinery, which mediates budding and eventual fission of the 
HIV membrane from the infected cell (55). During or immediately after budding, viral maturation 
initiates with PR cleavage of the Gag polyprotein, yielding an infectious virion that can begin the 
viral life cycle anew.  
1.1.6 HIV-1 Transmission and Pathogenesis.  
Most HIV infections occur through sexual transmission, wherein mucosal surfaces within 
the male or female genital tract or rectum are exposed to HIV-contaminated fluids (57). However, 
alternative and less frequent modes of transmission exist, including vertical transmission from an 
infected mother, and exposure to infected blood (commonly from shared needles used for 
intravenous drug use) (58). Following exposure, the virus infiltrates the lamina propria, and within 
hours infects resident CD4+ lymphocytes, macrophages, and dendritic cells (59, 60). The virus 
then establishes an initial seeding population of infected cells over the order of several days, before 
being transferred into draining lymph nodes and lymphoid tissues. 
Once HIV-1 is disseminated into lymphoid tissue, the virus takes advantages of abundant 
and heavily concentrated CD4+ T cells to replicate at high levels, which produces a burst of 
viremia about 10-14 days following initial infection (61).  It is during this acute phase that flu-like 
symptoms of HIV infection emerge, which include fever, swelling of lymph nodes, nausea, muscle 
aches, sore throat, headache, and diarrhea (62). An initial and dramatic depletion of CD4+ T cells 
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occurs during this phase, particularly within the gut-associated lymphoid tissue (GALT)(63), and 
the viral reservoir is firmly established at this point.  Toward the end of the acute phase, antibodies 
and cytotoxic CD8+ T-lymphocytes mount a futile response against viral replication, which along 
with the depletion of viral target cells contribute to a reduction in plasma viral loads to a stable set 
level known as the viral set point (58, 61).  
As viral load reaches its set point, CD4+ T cell levels partially rebound, and the virus 
reaches the chronic or “clinical latency” stage. This is the longest stage of HIV infection, wherein 
HIV replicates steadily and asymptomatically over a span of anywhere from 1-20 years, gradually 
infecting and depleting the body’s supply of CD4+ T cells (64). The final stage of HIV infection 
is the onset of AIDS, which is marked by a decline in CD4+ levels to under 200 cells/µL of blood. 
At this depleted level, the immune system is unable to mount a response against replicating HIV, 
and viral levels spike as CD4 T cell counts continue to plummet. Symptoms from opportunistic 
infections emerge, which typically prove fatal to the late-stage AIDS patient (64). 
If left untreated, most patients will progress towards AIDS within 8-10 years, and succumb 
to AIDS by 10 years following initial infection (65). However, a small number of infected patients 
maintain CD4+ T cell levels in the presence of detectable viral loads without progressing to AIDS. 
Patients who maintain this activity for at least 10 years are referred to as long-term non-progressors 
(LTNPs)(66). An even smaller subset of LTNPs are Elite Controllers (ECs), which make up only 
1% of HIV-infected individuals. ECs do not only fail to develop AIDS, but are able to control viral 
loads below detectable levels in the absence of antiretroviral therapy (67).  While some LTNPs 
and ECs may simply benefit from being infected with competent viruses that display poor viral 
fitness (e.g., defects in the viral Nef gene as described in more detail below), it is likely that there 
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are host attributes that may explain the robust protective responses against HIV that these patients 
exhibit (58, 68).  
1.1.7 HIV-1 Treatments and Curative Strategies 
Immediately following the identification of HIV as the causative agent of AIDS, work 
began to identify pharmacological treatments for this viral infection. The first class of therapeutics 
developed against HIV were nucleoside reverse transcriptase inhibitors (NRTI), which are 
nucleoside/nucleotide analogs that impair reverse transcription by causing early chain termination 
following incorporation into viral cDNA (69). The first antiretroviral drug and first NRTI was the 
thymidine analog zidovudine (ZDV, also known as 3′-azido-2′,3′-dideoxythymidine/AZT), which 
was initially synthesized in the 1960s during a failed effort to develop novel anti-cancer 
therapeutics. ZDV received a second life in the mid-70s when it was found to inhibit retroviral 
replication for the murine leukemia virus (MLV) (70, 71). After HIV was identified and isolated, 
ZDV was incorporated into a screen of potential antiretroviral compounds, and was confirmed in 
1985 by the National Cancer Institute (NCI) to be a bona-fide inhibitor of HIV-1 replication (70, 
72). ZDV quickly moved through clinical trials over the next two years, where it demonstrated 
sufficient clinical efficacy to be granted FDA approval in 1987 (73, 74). 
For four years, ZDV was the sole therapeutic option for HIV/AIDS, and was administered 
as monotherapy (75). But while patients on a ZDV regimen saw an increase in survival and delayed 
AIDS progression (76), ZDV monotherapy was marred by the onset of viral resistance and 
unfavorable toxicity profiles (including nausea, anemia, and bone marrow suppression) (77). The 
appearance of additional NRTIs, including zalcitabine (ddC) and didanosine (ddI), allowed for 
initiation of  combination NRTI therapy that markedly delayed AIDS progression compared to 
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ZDV monotherapy (78). However, AIDS-related fatalities in the United States would continue to 
climb until 1995, when two new classes of antiretroviral compounds would arrive on the scene: 
non-nucleoside reverse transcriptase inhibitors (NNRTIs) and protease inhibitors (PI) (3, 79). 
NNRTIs also target HIV RT, but allosterically bind to the enzyme and impair reverse transcriptase 
without being incorporated into viral cDNA (80). Most protease inhibitors, as their name implies, 
target HIV’s ability to form mature virions via the proteolytic cleavage of Gag and GagPol 
precursors via PR (81). Introduction of the protease inhibitor saquinavir in 1995, followed by the 
NNRTI nevirapine in 1996, led to the introduction of a triple-drug regimen, referred to as highly 
active antiretroviral therapy (HAART). The use of three drugs from two different classes of 
inhibitors (commonly 2 NRTIs + 1 PI or 2NRTIs + 1 NNRTI) resulted in dramatic suppression of 
viral replication and restored CD4+ T cell counts with a lower incidence of resistance (79). The 
efficacy of HAART was soon reflected in epidemiologic data, as the following years brought the 
first decrease in US AIDS-related deaths since the start of the epidemic 10 years prior (82).  
HAART therapy has continued to improve over the last 25 years through the development 
of drugs with greater efficacy and tolerability, and today there are over 30 antiretroviral 
compounds across six classes (69, 83). Newer classes of antiretroviral drugs include integrase 
inhibitors, viral fusion inhibitors, and coreceptor antagonists (84). However, while HAART has 
forever altered the clinical implications of contracting HIV-1, there is no cure for individuals 
infected with HIV.  HIV infection still manifests as a chronic condition requiring lifelong 
adherence to an antiretroviral regimen.  Also, despite the widespread distribution of effective 
antiretroviral compounds to people infected within the developed world, only 60% of people 
currently infected with HIV today receive antiretroviral therapy worldwide (85). 
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Unfortunately, development of effective curative strategies for HIV-1 has proven to be an 
even more difficult challenge than developing drugs to control infection. For example, while six 
vaccine strategies have entered clinical trials, five out of the six showed no efficacy (86). The sixth 
vaccine candidate, which combined recombinant HIV-1 Env along with a Canarypox viral vector 
expressing Gag, PR, and Env, only achieved 31% efficacy in humans (87). Ongoing work has also 
encompassed a search for a therapeutic cure for HIV infection, which represents either complete 
clearance of the latent viral reservoir from infected patients (‘sterilizing cure’) or competent 
immune suppression of viral replication following termination of antiretroviral therapy 
(‘functional cure’)(88). One potential sterilizing cure lies in the concept of “shock and kill”, 
wherein HIV+ patients managing infection through HAART are treated with latency reversal 
agents (LRAs) to induce viral transcription and translation of viral proteins. While HAART should 
suppress further infection and replication, induction of viral transcription could potentially allow 
for immune recognition and clearance of latently infected cells (89). However, while current LRA 
candidates have demonstrated varying degrees of reactivation of latent virus in vivo (90-92), 
legitimate questions remain as to whether these agents achieve full reactivation of the latent viral 
reservoir, as well as whether effective clearance can be obtained following reactivation (93).   
Successful development of new therapies to achieve HIV-1 cure may involve drugs that 
target HIV-1 accessory proteins. The Nef protein is particularly attractive in this regard, because 
of its central role in helping HIV-infected cells avoid detection by the host immune system. The 
structure and function of Nef is described in detail in the next few sections, along with progress in 
the discovery and development of Nef inhibitors. 
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1.2 HIV-1 Nef  
1.2.1 Role of HIV Nef in viral pathogenesis 
The viral nef genes encode a relatively small (27-34 kDa, depending on the lentivirus), 
myristoylated, non-enzymatic accessory proteins that are one of the first proteins expressed during 
the viral life cycle. The ORF for HIV Nef is located at the 3’ end of the genome and overlaps with 
the ORF for Env and the 3’ LTR. Nef was initially mischaracterized based on early evidence that 
it was a “Negative Factor” of HIV-1 replication (94). To the contrary, Nef plays prominent roles 
in HIV pathogenesis by promoting viral replication and spread in vivo, and in AIDS progression 
by enabling immune escape of HIV-infected cells. Patients infected with HIV harboring deleted 
or defective Nef often display slow or stalled progression towards AIDS (95, 96), while deletion 
of Nef within SIV has similarly been shown to impair both HIV replication and simian AIDS 
progression in rhesus macaques (97). In addition, expression of HIV Nef alone within CD4+ cells 
induces an AIDS-like disease in a transgenic mouse model, suggesting a direct role for Nef in 
AIDS progression (98).  
1.2.2 General Structure of Nef 
Nef is composed of a flexible and myristoylated N-terminal arm, a conserved folded core 
with a large internal loop, and an unstructured C-terminal tail (Figure 4). As the dynamic nature 
of the N-terminal arm renders it suboptimal for crystallization, nearly all X-ray crystal structures 
of HIV-1 Nef to date have focused on the folded core region. NMR studies of the N-terminal 
anchor confirm that this region has little higher order structure (99), and current models of 
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unbound, full-length Nef have only been possible through computational assembly of the anchor 
domain with established Nef core structures (100). However, while full resolution of the N-
terminal arm region has remained elusive, partial density for the arm has been resolved in a 
structure of full-length Nef fused to a binding partners, and are described in greater detail in 
Section 1.2.5 (101).  The same holds true for the internal flexible loop, the structure of which is 
only observed in crystal structures of Nef in complex with host cell proteins. 
 
 
Figure 4: Structural Model of HIV-1 Nef at the Plasma Membrane 
1.2.3 Key Functions of Nef 
1.2.3.1 Promotion of viral infectivity  
One of the more elusive aspects of Nef function involves the mechanism behind the long-
running observation that Nef promotes the inherent infectivity of viral particles. HIV infectivity 
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typically refers to the signal from in vitro HIV reporter cell assays, including the HeLa-based 
TZM-bl reporter cell system (102). TZM-bl cells express the viral receptors CD4 and 
CXCR5/CCR5, as well as an integrated copy of the Tat-regulated HIV-1 LTR fused to luciferase 
or β-gal reporter genes (103, 104). A single round of HIV infection and integration within TZM-
bl reporter cells results in Tat-dependent induction of luciferase or β-gal activity, and the degree 
of the reporter signal normalized to the quantity of input virus provides a quantitative measure of 
“infectivity”. 
In 1994, it was first reported that deletion or disruption of full-length Nef expression 
severely impairs the infectivity of the resulting virus (105), implying a positive contribution of Nef 
towards the infectivity of viral particles. Subsequent studies showed consistent Nef enhancement 
of viral infectivity across various viral subtypes and producer cells, although the degree of that 
enhancement varied anywhere from 3- to 40-fold (106). New features and requirements of Nef 
promotion of infectivity were continually reported, including a dependence on Nef myristoylation, 
AP-2 association and clathrin-mediated endocytosis, an enhanced phenotype in lymphoid cells 
(107), and a conservation of infectivity enhancement within SIV Nef and other retroviral proteins 
(108). Despite these breakthroughs, the key mechanism behind Nef promotion of infectivity eluded 
researchers until 2015, when the existence of a novel host cell restriction factor known as 
SERINC5 was identified. A major focus of my thesis research involved the mechanisms of Nef 
interaction with SERINC5, which is reviewed in detail in Section 3.  
1.2.3.2 Alteration of host cell protein trafficking 
Nef has no known inherent enzymatic activity, and functions instead through a wide 
network of interactions with host cell proteins (109). Among the 70 host cell proteins that Nef has 
been reported to engage are essential components of the intracellular trafficking machinery, which 
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Nef hijacks to modulate the expression and trafficking of host proteins to the cell surface (110). 
HIV-1 Nef induces the downregulation of a wide variety of host cell immune receptors and other 
membrane proteins, including CD4, MHC-I/-II, CD28, CXCR4/CCR5, CD1, CD80, CD86, and 
SERINC5 (111-117). Nef expressed by SIV and HIV-2 can also downregulate CD3, and SIV Nef 
(as well as some rare subtypes of HIV-1 Nef) can downregulate the restriction factor tetherin (118). 
Nef can also increase the surface expression of host cell proteins to improve viral pathogenesis, 
notably the transmembrane lectin protein DC-SIGN (119). Two of the best-characterized Nef 
functions are downregulation of MHC-I and CD4, which are directed by unique Nef interactions 
and pathways described below. 
Downregulation of CD4 is conserved across virtually all HIV-1 subtypes (120), and while 
this function may seem counterintuitive due to CD4’s role as the viral receptor, it is in full 
alignment with the role of Nef in cell survival and immune escape. Cell surface expression of CD4 
within already infected cells can lead to cytotoxic superinfection. Furthermore, interactions 
between CD4 and Env on the surface of infected cells expose HIV to antibody-dependent cell-
mediated cytotoxicity (ADCC), which is driven by anti-Env antibodies that recognize otherwise 
cryptic Env epitopes (121, 122). In the absence of infection, downregulation of cell-surface CD4 
is mediated through phosphorylation-dependent engagement of the cytosolic tail of CD4 by the 
adaptor protein 2 (AP-2) complex, which drives clathrin-mediated endocytosis of CD4 into the 
endolysosomal pathway (123). Nef accelerates this endocytic process, engaging both the cytosolic 
tail of CD4 (124) and the α and σ2 subunits of AP-2 to promote clathrin-mediated endocytosis 
(111, 125). This critical viral function is also performed by the viral accessory protein Vpu, 
although Vpu is expressed later during infection and targets CD4 through a distinct ubiquitination-
dependent process (126).  
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The major histocompatibility complex I (MHC-I) antigen presentation pathway is another 
critical target for Nef, as it is a key component of the adaptive immune response to viral infection. 
Antigenic peptides derived from proteolytically digested viral proteins are loaded onto MHC-I 
within the ER and are then presented on the surface of infected cells. Recognition of viral peptides 
presented by MHC-I serves as an alarm of infection for CD8+ cytotoxic T lymphocytes, which 
kill the infected cell. Several viruses have developed means of downregulating MHC-I in order to 
evade immune detection (127), but the immune system counters that activity with a mechanistic 
fail-safe performed by natural killer (NK) cells. NK cells monitor expression of MHC-I on the 
surface of cells, and destroy any cells with suspiciously low levels of MHC-I surface expression 
(128). Fascinatingly, Nef manages to evade both NK and CD8+ T cell killing through selective 
downregulation of MHC-I molecules of the HLA-A and HLA-B classes (129).  However, Nef does 
not affect MHC-I molecules monitored by NK cells (HLA-C and HLA-E), allowing Nef to 
antagonize immune recognition of HIV infection without exposing infected cells to cytotoxic 
clearance by NK cells. 
In contrast to CD4, MHC-I downregulation by Nef is driven by Nef association with the 
endocytic adaptor protein complex 1 (AP-1). There are two current models for Nef downregulation 
of MHC-I. In the first model, known as the “signaling model”, Nef is recruited by the phosphofurin 
acidic cluster 2 (PACS) protein into the trans-Golgi network (TGN), where Nef drives the 
activation of Src-family kinases. Activation of the Src kinases initiates a signaling cascade that 
results in increased levels of membrane PIP3 via PI-3K, driving activation of the small GTPases 
Arf1 and Arf6 followed by endocytosis of cell surface MHC-I. Once internalized, MHC-I is 
trapped in vesicles with Nef and AP-1, preventing recycling back to the plasma membrane (130). 
In the second model,  known as the stoichiometric model, Nef associates with AP-1 and its 
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activator Arf1 to trap newly synthesized MHC-I within the TGN, and inhibit anterograde 
trafficking towards the plasma membrane (131, 132). In both models, intracellularly sequestered 
MHC-I is led into late endosomes and eventually lysosomes through the activity of the coatomer 
protein complex subunit β (β-COP). 
Endosomal and lysosomal targeting of internalized MHC-I and CD4 are directed through 
a β-COP-dependent processes, and Nef appears to associate directly with β-COP in vitro (133). 
Nef-directed intracellular retargeting is also reliant upon Nef association with the ESCRT 
machinery, which drives the sorting of intracellular cargo into late endosomal multivesicular 
bodies. Nef interacts with the ESCRT protein ALIX in late endosomes and lysosomes (134), an 
interaction proposed to control Nef-mediated targeting of endosomal cargo into lysosomes (135).  
1.2.3.3 Nef-dependent kinase activation 
Cytoplasmic kinases represent another major class of Nef binding partners, several of 
which are activated by Nef and appear to contribute to HIV replication and pathogenesis.  This 
group includes members of the Tec and Src families of non-receptor protein-tyrosine kinases, 
phosphatidylinositol 3-kinase (PI-3K) (136), and the p21-activated kinase 2 (Pak2) (137).  Nef 
binding and activation of Src-family kinases is the one of the best-characterized functions of Nef 
and has been the focus of many structural, cellular, and in vitro studies. Early work demonstrated 
that Nef preferentially binds to the SH3 domains of Hck and Lyn, two of the eight mammalian 
Src-family kinases (138). Subsequent studies established that Nef binding displaces the SH3 
domain from its regulatory position on the back of the kinase domain, resulting in constitutive 
kinase activation both in vitro and in cell-based systems (139-141). Nef-dependent Hck activation 
has been shown to play an important role in HIV replication, infection, and MHC-I downregulation 
(as described above), and activation of Hck is conserved across all HIV-1 Nef M-group subtypes 
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(142). Hck is expressed primarily in macrophages, and knockdown of Hck expression has been 
shown to compromise HIV-1 replication in this cell type (143).  Compared to Hck, Lyn, and c-
Src, Nef engagement of other Src-family members is less definitive, including the Src family 
kinase Lck. The Lck kinase is a critical component of T cell receptor signaling, and though Nef 
expression within T cell lines results in intracellular retargeting of Lck, there are conflicting reports 
on whether Nef binds directly to Lck within cells (139, 144, 145). 
More recent studies have linked Tec-family kinases to the HIV-1 life cycle and established 
a role for Nef in activation of this kinase family. HIV-1 target cells express the Tec family kinases 
Itk and Btk, both of which play important roles in antigen receptor signaling, as well as lymphocyte 
activation and development (146). Functional Itk activity has been shown to be essential for HIV-
1 replication, and pharmacological inhibition or knockdown of Itk impairs nearly every step of the 
viral life cycle (147). Subsequent studies showed that both Itk and Btk interact with Nef at the cell 
membrane, and that Itk inhibitors impair Nef-dependent enhancement of infectivity and replication 
(148, 149). Nef-dependent interaction with Itk is highly conserved across major subtypes of HIV-
1, further supporting an essential mechanistic role (148).  
1.2.4 Nef Binding Partners- Description and Structure. 
  As described in the preceding sections, host cell tyrosine kinases and endocytic adaptor 
proteins represent two major classes of binding partners essential for Nef functions related to 
enhancement of viral replication and immune escape.  The next few sections describe the structural 
features important for the natural regulation of these Nef effectors, followed by details of the 
molecular mechanisms used by Nef to hijack these proteins for the benefit of the virus. 
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1.2.4.1 Src family kinases 
 
The Src kinase family is a well-studied group of non-receptor protein-tyrosine kinases that 
play diverse roles in signal transduction. There are eight members of the Src family expressed in 
mammals (Src, Hck, Lck, Fyn, Lyn, Yes, Fgr, and Blk).  While several family members exhibit 
ubiquitous expression across multiple cell lineages (Fyn, Src, Yes), others are confined to 
particular cell types (Blk, Fgr, Hck, Lck, Lyn) (150). Despite having distinct expression patterns, 
all Src-family kinases are similarly organized with respect to structured domains. At the N-
terminus of all Src family kinases is the myristoylated and sometimes palmitoylated SH4 domain, 
which anchors the kinase to the cell membrane. Downstream of the SH4 domain is the “Unique” 
domain, the amino acid sequence of which differs for each family member and regulates 
interactions and functions specific to each kinase (151).  Next are the SH3 and SH2 domains, 
which are key regulators of kinase activity, and mediate protein-protein interactions with substrates 
and other cellular proteins. The SH3 domain is made up approximately 60 residues arranged into 
five beta strands within two anti-parallel beta sheets, and is a common structural feature found 
within nearly 200 cellular proteins (152). The SH3 domain recognizes and binds to poly-proline 
type II helices within target proteins, often referred to as PxxP motifs.  While all SH3 domains 
recognize a PxxP motif, they harbor unique preferences for the individual amino acids surrounding 
that motif (153, 154). SH2 domains recognize specific motifs centered around phosphotyrosine 
(pTyr), and electrostatically engage with pTyr through a conserved arginine (155). Like the SH3 
domain, SH2 recognition is conferred by the surrounding amino acids, which in the case of Src 
family kinases is typically a pTyr-Glu-Glu-Ile motif (156). In addition to mediating protein-protein 
interactions, both domains play a prominent regulatory role for all Src-family members, as 
intramolecular association of these regulatory domains lock the overall kinase into an inactive, 
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‘assembled’ conformation (157, 158). More specifically, the SH3 domain binds to a poly-proline 
type-II helix formed by the linker between the kinase and SH2 domains, and the SH2 domain binds 
to a pTyr located within the C-terminal tail of the kinase. Release of this auto-inhibitory regulation, 
for example through engagement of SH2 or SH3 by a binding partner, frees the kinase into an open 
partially active state. This allows the catalytic kinase domain to undergo autophosphorylation at a 
conserved Tyr within the activation loop, opening the kinase active site to allow for entry of ATP 
and substrate required for phosphorylation of kinase targets (159). One interesting exception to 
this general regulatory paradigm is Fgr, which is expressed primarily in myeloid leukocytes.  
While Fgr can adopt the ‘assembled’ conformation associated with inactive Src, this family 
member is constitutively active and not under regulatory control of its SH3 and SH2 domains 
(157). 
1.2.4.2 Adaptor protein complexes  
 
Transmembrane proteins are shuttled between cellular organelles and the plasma 
membrane through vesicles, which bud from the surface of donor organelle or plasma membranes, 
then traffic to and fuse with acceptor membranes. Vesicle formation and budding require the 
formation of a structural protein “coat”, which is composed of context-dependent scaffolding 
proteins (160). Trafficking of protein cargo from the TGN, plasma membrane, and endosomes is 
typically directed through a protein coat made up of a scaffolding coat protein called clathrin, 
which forms a polyhedral cage around the vesicle membrane (161). However, as the clathrin coat 
has no way of physically interacting with either the vesicle membrane or transmembrane protein 
cargo, connection between the membrane and coat is reliant upon cargo adaptor proteins. Two of 
the most widely studied cargo adaptor proteins are adaptor protein complex 1 (AP-1) and adaptor 
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protein complex 2 (AP-2), which control clathrin-mediated recruitment of vesicles trafficking from 
the TGN to endosomes or between endosomes (AP1-) or the plasma membrane to endosomes (AP-
2). These endocytic adaptors direct the connection of clathrin to the membrane of nascent vesicles, 
but also directly recruit and package protein cargo into vesicles (162). 
AP-1 and AP-2 share a similar subunit organization, each composed of two large (100 kDa) 
subunits (AP-1: β1 and γ, AP-2: β2 and α), one ~50 kDa medium subunit (AP-1: μ1, AP-2: μ2), 
and a small 18 kDa subunit (AP-1: σ1, AP-2: σ2)(160). The β and γ/α subunits contain two separate 
structured domains, one larger “trunk” domain that associates with the other subunits to form a 
heterotetrameric core complex, and a smaller “appendage” or “ear” domain that is connected by a 
hinge region. The ear domains participate in protein-protein interactions that mediate vesicle 
formation and uncoating, while the hinge domain recruits clathrin through a motif referred to as 
the clathrin box (160). Adaptor proteins tether clathrin to the cell membrane by associating directly 
with the plasma membrane through engagement of either PI4P for AP-1 (163) or PIP2 for AP-2 
(164). Recruitment of protein cargo is directed by the σ and μ subunits, which recognize sorting 
signals conserved within the cytoplasmic domains of proteins, including tyrosine (YxxΦ), and di-
leucine ([DE]XXXL[LI]) motifs (165, 166). 
Adaptor protein activity is controlled through “open” and “closed” conformations of the 
core, the structures of which have been captured through X-ray crystallography and cryo-electron 
microscopy studies. Alternate conformations have also been observed, including intermediate 
(167) and “hyper-open” forms (168). In the closed form of AP-1 and AP-2, binding sites within 
the core (tyrosine motif binding site, di-leucine binding site, clathrin box, and one of two 
membrane binding pockets) are either buried or partially blocked. The sole exception is a 
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membrane-associating pocket within the α subunit, which is surface-exposed within this structure 
(160, 169). 
Structures of AP-2 in the “open” conformation have been obtained following co-
crystallization with di-leucine and tyrosine motif-containing substrates, conditions under which 
the structure the binding sites for membrane, cargo, and potentially clathrin are surface-exposed 
(170). However, activation of AP-2 into the open conformation appears to be triggered through 
membrane association rather than cargo binding, although cargo binding may promote clathrin 
recruitment  (162). The structure of the “open” AP-1 core reveals a similar conformation to that of 
open AP-2.  However, AP-1 activation requires interaction with a small GTPase known as ADP 
ribosylation factor 1 (Arf1). Co-crystallization of AP-1 with Arf1 alone seems to induce the “open” 
conformation of AP-1, even in the absence of cargo containing signal sorting motifs (171). 
1.2.4.3 CD4  
 
Cluster of differentiation 4 (CD4) is a ~55 kDa type I integral membrane glycoprotein that 
serves as a co-receptor for the T Cell Receptor (TCR) and plays an essential role in T lymphocyte 
development and activation. Expression of CD4 over CD8 during lymphocyte development diverts 
T cells into a “helper” rather than a cytotoxic lineage, solidifying their immunological role of the 
cell. CD4 is also is the main receptor for HIV infection, and is bound by the Env gp120 protein to 
initiate viral recognition and fusion as described above (172). CD4 was initially characterized in 
the late 70s and early 1980s, fortunate timing considering its identification as the HIV receptor in 
1984 (173, 174). 
CD4 is composed of four extracellular immunoglobulin domains (D1-D4), a 
transmembrane domain, and a short cytoplasmic tail. The extracellular component of CD4 is the 
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largest, comprising around 370 out of the ~430 total amino acids within human CD4 (175). 
Association of both MHC-II and HIV gp120 are directed through the D1 domain of CD4. CD4 
promotes TCR recognition of MHC-II expressed on antigen presenting cells (APC), and plays a 
role in T cell activation downstream of antigen recognition through the recruitment of Lck to the 
TCR/CD3 complex (176). Interestingly, it has been suggested that this Lck-dependent mechanism 
is the more relevant activity for enhanced antigen recognition of the TCR, rather than association 
of CD4 with the MHC-II/TCR complex (177). 
1.2.4.4 MHC-I 
 
MHC-I molecules (as well as their MHC-II counterparts) play a critical role in adaptive 
immunity, as they bind and present antigenic peptides for recognition by T cells (178). However, 
unlike MHC-II molecules (which are primarily expressed by antigen-presenting cells) MHC-I is 
expressed on the surface of virtually all nucleated cells (127). MHC-I molecules present peptides 
from intracellular proteins processed by the proteasome, which are transported to the ER and 
loaded onto MHC-I molecules for presentation (127). While most of these peptides originate from 
newly synthesized but defective host cell proteins (179), virally-infected cells will present 
antigenic peptides produced from viral proteins, potentially triggering the recognition and 
clearance of infected cells (180). Unsurprisingly, several viruses (HIV-1, influenza, beta and 
gamma-herpesviruses) have evolved means of downregulating MHC-I, as antigen presentation to 
circulating cytotoxic T cells represents a major existential threat (181). MHC-I is also commonly 
downregulated within cancer, allowing tumors to similarly escape immune detection (182).  
Structurally, MHC-I is composed of a single 3-domain heavy chain (~45kDa) non-
covalently bound to a beta-2 microglobulin (β2m) light chain (12 kDa)(183, 184).  Two of the 
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MHC-I heavy chain domains (α1 and α2) form a binding groove that accommodates antigenic 
peptides spanning about 8-10 amino acids, and encompass the primary binding interface with the 
TCR (180). The heavy chain of MHC-I also contains a transmembrane helix and a cytoplasmic 
tail, which anchor MHC-I to the membrane and mediate MHC-I association with intracellular 
binding partners, respectively(185). 
In humans, MHC complexes are referred to as Human Leukocyte Antigen (HLA) 
complexes, which are divided into classical (class IA; HLA-A, HLA-B, and HLA-C) and non-
classical (class IB; HLA-E, HLA-F,HLA-G, HLA-H) families (186). While both HLA-class IA 
and HLA-class IB molecules can present intracellular peptides to T cells, class IA molecules are 
highly polymorphic and widely expressed, compared to the markedly lower polymorphism and 
expression levels displayed by class IB molecules (187). Instead of driving immune recognition of 
intracellular peptides, HLA-class 1B molecules instead play a critical role in immune regulation, 
notably the HLA-E and HLA-G directed inhibition of cellular lysis by NK cells (186, 187). As 
discussed in Section 1.2.3.2, Nef selectively downregulates HLA molecules from both class 1A 
and class 1B to evade immune detection and NK cell mediated killing (188). 
1.2.5 Critical Nef Motifs and features  
1.2.5.1 N-terminal Flexible Arm and Myristoylation Site 
Absolutely critical to Nef function is its flexible N-terminal arm, which makes up the first 
57-60 amino acids of Nef. The N-terminus of Nef contains a highly conserved recognition 
sequence (MGxxx[ST]) for the host N-myristoyl transferase protein, which allows Nef to be 
myristoylated at the second position glycine. This myristoylation site, along with a basic arginine-
rich region (Arg17, Arg19, Arg21, Arg22) direct Nef association with the membrane (189). 
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Mutation of either the critical myristoylation sequence glycine (Nef G2A mutant) or disruption of 
electrostatic interactions between the basic residues and negatively charged polar headgroups in 
the lipid membrane impair association of Nef with the membrane (190). Disruption of 
myristoylation via the G2A mutation disrupts virtually all Nef functions, demonstrating the 
essential role for myristoylation and membrane association. Myristoylation-dependent functions 
of Nef include downregulation of CD4, MHC-I (189), antagonism of the SERINC5 restriction 
factor (117), overall HIV-1 pathogenicity (191), recruitment of actin and β-COP (192, 193), and 
Lck retargeting (194).  
To date, only one structural study of the flexible N-terminal region of Nef in isolation has 
been conducted, an NMR spectroscopy study of the anchor domain in the presence and absence of 
myristoylation. That structure confirmed that while the N-terminal region of Nef is primarily 
unstructured, myristoylation stabilizes at least one helical element within the arm. This helix has 
an amphipathic nature that helps coordinate membrane association: one side with a basic residues 
associates with lipid head groups (the aforementioned Arg17, Arg19, Arg21, Arg22) while the 
opposite side consists of hydrophobic residues which may insert directly into the membrane (Trp5, 
Trp13, Ile16 and Met20) (195).  
Two points of membrane contact have suggested a two-step model for Nef association with 
the lipid bilayer.  In the initial “fast phase”, the N-terminal myristate group of Nef inserts into the 
membrane and the basic elements of the amphipathic helix associate with lipid head groups. In the 
“slow phase”, the hydrophobic side of the amphipathic helix inserts into the membrane (190). 
The possibility has been raised that Nef exists in a compact “closed” conformation prior to 
membrane insertion, wherein the myristoylated N-terminus and large internal loop are packed 
against the folded protein core (196). Indeed, both NMR and hydrogen-deuterium exchange mass 
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spectrometry (HDX MS) studies of myristoylated Nef show greater protection from solvent than 
anticipated for the anchor domain in isolation (197, 198). This ‘closed’ conformation of Nef seems 
to exist directly outside of the lipid membrane, but following insertion of the N-terminus of Nef, 
the folded core moves to a distance of 70 Angstroms away from the lipid membrane based on 
neutron reflectometry (190). This extended conformation presumably allows for the exposure of 
critical binding motifs within Nef, coordinating essential protein-protein interactions and 
potentially facilitating the dimerization of Nef (190, 196). However, a crystal structure of Nef in 
complex with MHC-I and AP-1 shows that the N-terminal arm is partially packed against the core. 
Within this structure, Trp13 and Met20 within N-terminal helix 1 associate with the folded core 
of Nef, while the myristoylation motif is still free to associate with the membrane. The authors 
propose that interaction between the Nef core and N-terminal helix pulls the complex closer to the 
plasma membrane (101), which suggests that contact between the N-terminal arm of Nef and the 
folded core may participate in Nef signaling in the context of AP-1 and endocytosis.  
1.2.5.2 PxxP Motif: Structural Basis of Kinase Engagement 
Directly downstream from the N-terminal anchor domain of HIV-1 Nef is a highly 
conserved PxxPxR motif.  This motif forms a PPII helix that serves as a docking site for 
recruitment of Src-family kinases and other proteins with SH3 domains. Unsurprisingly, this motif 
is required for Nef activation of Src family kinases, as SH3 binding by Nef alleviates the auto-
inhibitory interaction of the PPII helix within the kinase’s linker region as described above. 
Mutagenesis studies suggest that the Nef PxxP motif also appears to play a role in the recruitment 
and activation of Tec family kinases and Pak1/2 kinases, although the direct structural basis of this 
interaction is not known. Disruption of the PxxP motif also impacts Nef downregulation of MHC-
I (199), Nef promotion of viral replication, and pathogenicity of the virus in murine and primate 
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models of AIDS (200, 201). However, Nef downregulation of CD4 and promotion of infectivity 
through SERINC5 are largely unimpacted by mutation of the PxxP motif (117, 199). 
Research over the previous two decades has resulted in a sophisticated understanding of 
how Nef engages the SH3 domains of Src-family kinases. The conserved Nef motif for SH3 
recognition is comprised of Pro72 and Pro75, along with a conserved Arg at residue 77, and a 
hydrophobic residue (commonly valine) at residue 74 (202). The hydrophobic prolines and valine 
within the Nef core PxxPxR motif engage hydrophobic residues within the SH3 β-sheets, while 
Arg77 forms an electrostatic contact with a SH3 Asp100 residue (203). These core prolines are 
essential for Nef engagement of SH3, as replacement of prolines 73 and 75 with alanine abolishes 
SH3 binding (204). 
Crystal structures of Nef in complex with the SH3 domains of Fyn and Hck have 
illuminated other points of contact for SH3 engagement (Figure 5). These contacts occur in more 
variable regions of the SH3 domains and are believed to direct specificity of Nef towards different 
SH3 domains. For example, Nef has sub-micromolar affinity towards the Hck SH3 domain (KD as 
low as ~250 nM by SPR) with much lower affinity towards the Fyn SH3 (KD > 20 µM).  This 
difference in affinity is dependent upon a single residue within the variable RT loop of the SH3 
domain. The Hck SH3 contains an isoleucine residue at position 96 within the RT loop, which 
engages a hydrophobic pocket in the folded core of Nef. The Fyn SH3 has an arginine at position 
96, which is suboptimal for interaction with this Nef pocket.  Replacement of Arg96 in the Fyn 





Figure 5: X-ray crystal structures of HIV-1 Nef in complex with the SH3 domain of the Src-family kinase, 
Fyn 
A) Overall structure of the HIV-1 Nef core with the wild-type Fyn SH3 domain (right) and the high-affinity mutant, 
R96I (left).  Both Nef proteins are modeled in blue, with the SH3 domains are shown in red. The conserved PxxPxR 
motif of Nef is rendered in orange. B) Close-up view of the interface of Nef with the high-affinity SH3 R96I mutant. 
Nef residues P72 and P75 define a polyproline type II helix that meshes with the hydrophobic grooves of the SH3 
surface and is oriented and stabilized by an ionic interaction between Nef R77 and SH3 D100. High affinity interaction 
requires Ile96 from the SH3 RT loop which accesses a hydrophobic pocket by Nef residues Phe90, Trp113, and Tyr120 
(cyan). C) Close-up view of Nef interaction with the wild type Fyn SH3 domain.  The interface is the same as in 
panel B, except the wild type Fyn SH3 has arginine at RT loop position 96 which cannot access the hydrophobic 
pocket.  The Nef cores in both structures form homodimers (not shown). Both models were produced with PyMol 
using the crystal coordinates of the HIV-1 Nef core in complex with the Fyn R96I mutant SH3 domain (PDB: 1EFN) 
and the wild-type SH3 domain (PDB: 1AVZ). 
 
 
The first reported crystal structure of an SH3 domain bound to Nef is based upon this 
stabilizing Fyn SH3 R96I mutation, which shows that Ile96 contributes to SH3 engagement 
through a hydrophobic pocket within Nef formed by conserved residues Leu87, Phe90, Trp113, 
and Tyr120 (206). Another structure of Nef in complex with wild-type Fyn SH3 shows that the 























Ile96. However, while the side-group of Ile96 is fully engaged with this pocket, the basic 
guanidinium component of the Arg96 side-chain is solvent-exposed in the wild type Fyn SH3-
bound structure (207).  These two crystal structures are compared in Figure 5. 
Nef sequence variability can also influence SH3 domain affinity, particularly through the 
PxxP-adjacent residue 71. This position in Nef is typically occupied by arginine within most 
subtypes of Nef, but certain strains of HIV-1 (including the common laboratory adapted strains 
NL4-3 and LAI) contain a threonine at this position. When arginine is present at this position, it 
contributes an additional point of contact towards the SH3 domain that is absent in the Thr71 
version of Nef (205, 207). The presence of threonine at this position may be at least partially 
responsible for the reduced affinity of NL4-3 Nef towards Hck SH3 (208), as well as reduced viral 
replication for the NL4-3 virus (209-211). 
This established Nef/SH3 binding interface is consistent across other structures of Nef, 
including a structure of the Nef core in complex with a recombinant protein encompassing both 
the SH3 and SH2 domains of Hck. As expected, a similar hydrophobic interface forms between 
the SH3 domain and the PxxP helix (with the contribution of an additional proline), and 
engagement of the critical RT loop isoleucine by a hydrophobic pocket within Nef is also present. 
However, within the SH3-SH2-bound structure of Nef (which presents as a 2:2 heterocomplex), a 
novel inter-complex interaction arises between the RT loop of the Hck SH3 domain and Nef 
residues from the opposing Nef:Hck SH3-SH2 heterodimer (212). Mutation of Hck SH3 residue 
Glu94, which coordinates a salt bridge with the opposing Nef molecule via Arg105, impairs 
Nef:Hck association in cells, supporting a functional role for this intermolecular contact in Hck 
recruitment via Nef (212).  Other structures of SH3-bound HIV-1 Nef have used an artificially 
engineered SH3 construct, which replaces residues within the RT loop to maximally optimize 
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Nef:SH3 affinity. The replacement of Ile96 with five alternative RT loop residues increases 
Nef/SH3 affinity nearly 40-fold (208), and this optimized SH3 domain has been used to stabilize 
targeting of two different protein inhibitors directed against Nef (213, 214), and to crystallize the 
large internal loop of Nef (215). 
In addition to kinase activation, the PxxP motif appears to play a critical role in MHC-I 
downregulation by Nef. Since Nef activation of Hck or Lyn is an essential step for the signaling 
model of MHC-I downregulation described above, a key contribution of this motif towards MHC-
I downregulation is likely through engagement and activation of Src-family kinases (130).  Among 
all the Src-family members, only Hck and Lyn have an isoleucine residue at position 96 in the SH3 
domain, which is essential for Nef binding as described above. However, a structure of Nef in 
complex with the cytoplasmic domain of MHC-I and the μ1 subunit of AP-1 suggests an alternate, 
SH3-independent role for the Nef PxxP motif. Within this structure, the PxxP motif of Nef interacts 
directly with AP-1 μ1, and helps “clamp” the MHC-I cytoplasmic domain into a binding groove 
within the heterocomplex (101).  Thus, the Nef PxxP motif may provide not only a mechanism for 
Src-family kinase engagement and activation, but also for direct interaction with AP-1. 
Tec-family kinases share a similar domain organization to Src-family kinases and are also 
capable of binding and being activated by Nef.  Among the five mammalian Tec-family members, 
Nef selectively interacts with Itk, Btk, and Bmx (but not Tec or Txk), leading to robust kinase 
activation at the cell membrane. While there are currently no structures of Nef in complex with 
either Itk or Btk, binding studies support a similar, SH3-dependent mode of engagement for both 
kinases. An alignment of the Itk and Btk SH3 domain structures with the Src-family SH3 domain 
present in the crystal structure with the Nef core (206) predicts a similar insertion of the RT loop 
into a hydrophobic pocket of Nef, led by residue 96. Mutation of residue 96 within Itk and Btk 
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(Asn96 for Itk, Met96 for Btk) impairs Nef and kinase association in cells, implicating the SH3 
RT loop in Nef engagement for both Src and Tec family SH3 domains (148). However, mutation 
of the Nef PxxP motif only partially reduced interaction with Nef in a cell-based interaction assay, 
suggesting that Tec family kinases may make unique contacts with Nef as well (148). 
1.2.5.2.1 Dynamics of Kinase Engagement by Nef 
While structural studies have provided important snapshots into Nef and Hck engagement, HDX 
MS studies of both proteins have allowed for a greater understanding of the dynamics controlling 
this interaction (216). HDX MS takes advantage of natural exchange between the backbone amide 
hydrogens of proteins and water in a solution, the rate of which is dependent upon the solvent-
accessibility and hydrogen-bonding of each region of the protein. During HDX MS, recombinant 
proteins are incubated in buffer made from deuterated water, and exchange between the amide 
hydrogens and deuterated water proceeds for a pre-determined range of times. Exchange reactions 
are quenched at various time points (typically seconds to hours) by lowering both the pH and 
temperature of the solution, and the protein is digested into peptic peptides prior to injection into 
a mass spectrometer. Each exchange event increases the mass of a given peptide by 1.0 Da, which 
allows for determination of incorporation of deuterium into specific peptides/regions of the protein 
over time.  Peptides that show significant changes in deuterium uptake can then be related to X-
ray or NMR structures, providing meaningful temporal information regarding changes in H-
bonding or solvent exposure. Deuterium incorporation will change in the presence of protein-
protein interactions and shifts in protein conformation, allowing for a dynamic comparison of 
protein configuration states (217).  This technique has provided particularly valuable insight as to 
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the interaction of Nef with partner kinases and other proteins, as well as the effect of small 
molecule inhibitors on Nef-mediated conformational changes. 
HDX MS studies support the suspected mode of Nef binding and Nef-dependent Hck 
activation, as co-incubation of Nef with near full-length Hck causes a perturbation in the exchange 
rate for the SH3 domain and SH2-linker region of Nef. This is consistent with a release of Hck 
SH3 from its auto-inhibitory association with the SH2-kinase linker, and a small shift in exchange 
within the SH3 domain that signals a shift in binding from the Hck linker to the PxxP helix of Nef 
(218). Interestingly, exchange within the SH2 domain is undisturbed by the presence or absence 
of Nef, complementing previous cell-based data suggesting that SH3-dependent activation of Hck 
via Nef does not require release of the auto-inhibitory tail-SH2 interaction (218, 219). This SH3-
dependent mode of Hck engagement is also supported via studies examining the dynamics of full-
length or truncated core domains of Nef in the presence of Hck by both HDX MS and NMR. The 
region of Nef which contains the PxxP motif demonstrates a clear chemical shift and significant 
deuterium exchange protection following the addition of the SH3 domain (220, 221). 
1.2.5.3 Large Internal Loop: Dileucine and Diacidic motifs 
Extending from the folded core of Nef is a large flexible loop about 30 amino acids in 
length, which in solution is the second most solvent-accessible region of Nef after the N-terminal 
anchor domain (100). The loop contains three motifs that are of functional relevance to Nef 
signaling and function - a centrally located di-leucine motif ([DE]xxxL[LI]), and two acidic motif 
comprised of E154/E155, and D174/D175. These two diacidic motifs are about equally spaced at 
the beginning and end of the loop, and electrostatic repulsion between them may contribute to the 
unstructured nature of the loop in the unbound form of Nef (100, 202). Conservation of the di-
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leucine motif is complete across nearly all subtypes of Nef, while there is a lesser degree of 
conservation for the other two motifs (especially E154/E155) (202). 
The di-leucine motif is essential for the coordination of AP-2 recruitment and 
downregulation of CD4 from the surface of infected cells. In the absence of HIV infection, CD4 
is downregulated in a controlled manner through AP-2 recognition of a non-canonical dileucine 
sequence within its cytoplasmic tail (SQIKRLL). As canonical di-leucine sorting motifs contain a 
negatively charged residue at the start of the motif, the nontraditional motif in CD4 is only 
recognized by AP-2 following phosphorylation of Ser408, which mimics the necessary charge of 
an acidic residue at this position (125). This mechanism allows for a regulated and 
phosphorylation-dependent downregulation of CD4 during normal cellular conditions. However, 
Nef contains the complete dileucine motif necessary for AP-2 recruitment, and is able to drive a 
robust and phosphorylation-independent downregulation of CD4 during infection through a 
dually-coordinated recruitment of CD4 and AP-2 (135). 
Nef binds to both the CD4 cytoplasmic tail and the AP-2 α-σ2 subunit hemi-complex with 
low µM affinity (124, 222). It is suspected that the affinity for CD4 is even higher for the Nef/AP-
2 hemicomplex due to the cooperative nature of binding between these proteins (222, 223). While 
crystal structures have not been able to capture the cytoplasmic tail of CD4 bound to Nef, genetic 
and modeling studies have implicated the conserved Nef residues Trp57, Leu58, and Leu110 in 
CD4 binding (224). In contrast, a structure of Nef in complex with the AP-2 α/ σ2 hemicomplex 
has allowed for a comprehensive view of the binding interface between these proteins (222).  Over 
a dozen residues within the large internal loop of Nef interact with the AP-2 hemicomplex in this 
crystal structure, and while Nef interacts with both the α and σ2 subunits, most contacts in the 
interface are directed towards σ2 (including the dileucine motif) (222). Surprisingly, while the 
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acidic Asp174/Asp175 motif is also required for productive CD4 downregulation (225), it does 
not directly contribute to AP-2 recruitment. Instead, both acidic residues interact with the Nef core 
to stabilize the dileucine motif loop for productive AP-2 engagement (222). Though this Nef/AP-
2 structure failed to capture density for the cytoplasmic CD4 tail, the structure was later aligned 
with a structure of SIVmac239 Nef bound to an ExxxLM dileucine motif (226) and the NMR 
structure of the CD4 tail (227) to create a potential model for the AP-2/Nef/CD4 tail complex. 
Within this model, a hydrophobic pocket within SIV Nef binds to the non-canonical dileucine 
sequence of CD4, while simultaneously being bound by AP-2 via its own canonical dileucine motif 
(226).  
The dileucine and the downstream acidic loop motifs are also critical for an SIV Nef-
specific function- AP-2-dependent downregulation of the host restriction factor tetherin (228). 
Tetherin inhibits viral egress by “tethering” nascent virions to the membrane of infected cells 
during viral budding (229). SIV Nef downregulation of tetherin from the cell surface helps the 
virus overcome inhibition by simian tetherin. However, this AP-2-dependent mode of antagonism 
is reserved solely for SIV Nef. Most HIV-1 subtypes either rely on the Vpu accessory protein to 
antagonize human tetherin, or use an alternative AP-1 mechanism to antagonize tetherin (as is the 
case for HIV-1 Group O Nef proteins) (230). Still, examination of SIV Nef engagement of AP-2 
is potentially instructive for understanding the mechanistic basis of the coordinated HIV-1 
Nef/AP-2 downregulation of host cell targets. Sequence conservation between the large internal 
loops of SIV and HIV-1 Nef, particularly across the dileucine and diacidic motifs, further supports 
the functional relevance of this loop (231). With that in mind, a recent crystal structure of sooty 
mangabey-derived SIV (SIVsmm) Nef in complex with the AP-2 hemicomplex and simian tetherin 
reveals a critical role for the large internal loop and di-leucine motif not only in AP-2 recruitment, 
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but in recruiting cargo as well. The SIVsmm di-leucine motif assumes a similar conformation as 
seen in the AP-2/HIV-1 Nef crystal structure, but the backside of the AP-2- bound di-leucine loop 
directly engages a critical DIWK motif within tetherin (231).  
The large internal loop also governs Nef downregulation and/or association with several 
other host cell proteins, including CD28, CD8, and β-COP. Nef downregulation of CD28 and CD8 
appears to be driven through a common AP-2 dependent mechanism (225, 232), and mutation of 
both the di-leucine and D174/D175 acidic motif impairs Nef downregulation of both molecules 
(233, 234). While the di-leucine motif and D174/D175 acidic motif drive most internal loop 
interactions, some data suggest that the less-conserved E154/E154 acidic motif also participates in 
Nef function via recruitment of β-COP (131). Following internalization of MHC-I and CD4 into 
the endosomal compartment, Nef uses β-COP to direct the lysosomal degradation of both CD4 and 
MHC-I (133). 
The majority of Nef structures obtained in the absence of binding partners for the internal 
loop yield unresolved density for this region due to its unstructured nature (135). However, as 
discussed in the overview of the N-terminal arm of Nef, the large internal loop is somewhat 
protected from hydrogen exchange within membrane-bound myristoylated Nef, suggesting that 
interaction with the core helps shield it from solvent exposure (198). Intra-molecular association 
between the internal loop of Nef and the folded core has been captured in structures of Nef, albeit 
in the presence of partner protein binding. For example, two helical elements within the internal 
loop of Nef are packed against the Nef core in the AP-2-bound structure (222).  In addition, 
structures of both HIV-1 and SIVmac239 Nef bound to affinity-optimized SH3 domains show 
interaction between the folded core of one Nef molecule and the internal loop of another (215, 
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226). Taken together, these results point to the internal loop of Nef as an active participant in both 
intermolecular and intramolecular Nef interactions. 
1.2.5.4 Dimerization Interface 
 
Early characterization of recombinant Nef revealed a consistent tendency to dimerize in 
solution, a behavior that was initially suspected to be driven through a combination of non-covalent 
interactions and disulfide linkages between Nef monomers (235, 236). However, while 
oligomerization in these early studies was sensitive to reducing conditions in solution, deletion of 
the solvent-accessible C-terminal cysteine residue of Nef did not eliminate its ability to 
oligomerize, ruling out the contribution of disulfide contacts in dimer formation (197). 
Importantly, NMR spectroscopy shows that dimerization occurred between well-folded Nef 
proteins, arguing against the possibility that dimerization is an artifact of denatured protein (235). 
Additional biophysical and biochemical analyses of recombinant Nef point towards a reversible 
and concentration-dependent equilibrium between monomeric and dimeric Nef in solution (197, 
237), consistent with early evidence for Nef oligomerization in the cytoplasm and on the surface 
of infected cells (238).  
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Figure 6: Nef homodimer interface from the X-ray crystal structure in complex with a Src-family kinase SH3 
domain.   
Overview of the Nef dimer structure is shown on the upper left, with the Nef monomers rendered in blue and green, 
respectively. The αB helices that form the dimer interface are highlighted (SH3 domains not shown for clarity). The 
αB helices are enlarged on the lower left, illustrating the side chains of Leu112, Tyr115, and Phe121 from each 
monomer which form the hydrophobic core of the interface.  Also shown are the reciprocal ionic contacts between 
Arg105 and Asp123.  Both models are rotated 90° on the right. These models were produced with PyMol using the 
crystal coordinates of the HIV-1 Nef core in complex with the Fyn SH3 domain (PDB: 1EFN). 
 
 
The first crystal structures of HIV-1 Nef (in complex with Src-family kinase SH3 domains) also 
captured Nef within a dimeric state (203, 207), and granted the first glimpse into the structural 
basis of Nef dimerization. Within both structures, dimerization occurs between the αB helix of 

















(Ile109, Leu112, Tyr115, His116, Phe121, Pro122; key interface residues are shown in Figure 6). 
Flanking that interface is a pair of reciprocal electrostatic interactions between Arg105 and 
Asp123, which appear to stabilize the dimer interface (206, 207). All of these residues are highly 
conserved across subtypes of HIV-1 Nef (142), and most are conserved or homologous in Nef 
expressed by HIV-2 or SIV Nef (197). Mutation of hydrophobic interface residues (individually 
or as a group) has been shown to impair Nef dimerization both in cells and in solution, 
confirming the apparent contribution towards dimerization in these structures (149, 239). 
Nef dimerization, including these dimer interface residues, is also implicated in a number 
of Nef functions, including Src- and Tec-family kinase activation (149, 240), CD4 downregulation 
(239, 241, 242), and Nef enhancement of HIV-1 infectivity (this thesis) and replication (239). 
Mutation of Asp123 has also been shown to prevent MHC-I downregulation (242). However, 
another structure implicates Asp123 in the coordinated recruitment of MHC-I and the AP-1 μ1 
subunit (101), which complicates whether contribution of this residue is through dimerization, 








Figure 7: Homodimer interface from the X-ray crystal structure of Nef in complex with Hck SH3-SH2  
Three overviews of this Nef homodimer are shown on the left with the Nef monomers rendered in blue and green, 
respectively (SH3-SH2 proteins not shown for clarity). Three interfaces stabilize this homodimer, which are enlarged 
on the right. In the ‘top’ view, the side chains of Leu112, Tyr115, Phe121, and Pro1122 form a hydrophobic cup that 
interacts with Val70 from the opposing monomer in reciprocal fashion. The ‘side’ view shows the contributions of 
Ile109, Leu112, Trp113, and His116 to a hydrophobic interface between the αB helices.  The ‘bottom’ view shows 
reciprocal polar contacts formed by Ser103 and Arg106 with the main chain carbonyls of Gly95 and Gly96; Leu100 
also makes a non-polar contact in this interface. These models were produced with PyMol using the crystal coordinates 
of the HIV-1 Nef core in complex with the Hck SH3-SH2 region (PDB: 4U5W). 
 
However, a more dynamic, context-dependent dimer interface is also supported by recent 
crystal structures of the Nef dimer, wherein the conformation of the folded core for each Nef 

































found in the complex of Nef with SH3 alone (compare Figures 6 and 7) (212, 243). For example, 
in the presence of the Hck SH3-SH2 regulatory domain, the Nef dimer interface is dramatically 
rotated, and Asp123 is now solvent exposed and freed from the dimer interface, potentially 
promoting interaction with MHC-I and AP-1 (212). Comparative studies of dimeric Nef in 
complexes with SH3 vs. SH3-SH2 by HDX MS show that the two distinct dimer interfaces 
observed in the X-ray crystal structures are also present in solution (244).  Consistent with these 
structures and other models of Nef dimerization is the contribution of hydrophobic core residues 
within and around the αB helix of the Nef core (245). The contribution of both Asp123 and 
hydrophobic interface residues towards varying complexes of Nef will be explored in Chapter 3 
of this dissertation, and the role of several of these hydrophobic residues in a newly discovered 
function for Nef will be explored in Chapter 2.  
1.2.6 Nef as a pharmacologic target 
The critical role of Nef in HIV pathogenesis and immune escape makes it an attractive 
target for antiretroviral drug development. To date, only a handful of Nef inhibitors have been 
reported, with early strategies targeting the binding interface between Nef and the Hck SH3 
domain. These efforts have identified small molecules that disrupt SH3 binding by Nef (246), a 
broad small molecule inhibitor of SH3 engagement which inhibits Nef activation of Lyn and c-Src 
(139, 247), and high affinity recombinant SH3 domains to outcompete kinase binding (248). Two 
recent protein-based inhibitors combine a single chain antibody with high affinity for Nef with an 
engineered high-affinity SH3 domain to target Nef (213, 249).   
Another strategy used to identify small molecule inhibitors of Nef has focused on inhibition 
of Nef-dependent Hck activation, rather than Hck SH3 displacement. While Nef lacks enzymatic 
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activity, coupling Nef to Hck activation allowed for high-throughput chemical library screening 
and identification of Nef inhibitor candidates (250). Two classes of small molecule inhibitors were 
identified through this screening strategy. The first class, characterized by a 4-amino-
diphenylfuranopyrimidine (DFP) scaffold, was discovered in a screen of a small library of kinase 
inhibitor-biased compounds. These compounds showed enhanced inhibition of Hck in the presence 
of Nef, suggesting that Nef binding may allosterically impact the Hck active site to enhance 
inhibitor binding. DFP-based Hck inhibitors demonstrated micromolar activity against Nef-
mediated enhancement of viral replication, providing additional evidence that the Nef-Src-family 
kinase signaling pathway is important to viral replication (251). In subsequent work, the Nef-Hck 
assay was used screen a diverse library of more than 220,000 compounds. This screen identified a 
unique hydroxypyrazole-based inhibitor (designated as B9) that blocks HIV-1 replication at sub-
micromolar concentrations in a Nef-dependent manner (252). Unlike the DFP compounds, B9 has 
been shown by SPR to bind directly to recombinant Nef with nanomolar affinity.  B9 was also 
shown to impair Nef dimerization in a cell-based fluorescence complementation assay, suggesting 
that it may disrupt Nef function by impairing productive dimer formation (252). Characterization 
of both B9 and newer analogs based on their hydroxypyrazole core shows that this class of 
compounds impairs Nef activation of Tec-family kinases, and reverse Nef downregulation of 
MHC-I (253).  
Critically, treatment of latently infected CD4 T cells with B9 and the more-recent 
hydroxypyrazole inhibitors promoted CD8+ cytotoxic killing of infected cells in co-culture, likely 
through inhibitor-mediated rescue of MHC-I  cell surface expression (254). This result highlights 
the potential utility of hydroxypyrazole Nef inhibitors in shock-and-kill curative strategies. The 
dual actions of these compounds to restore immune receptor expression and cripple Nef 
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enhancement of viral replication, may help aid clearance of the latent viral reservoir following 
reactivation via LRAs. As these compounds have been shown to inhibit Nef enhancement of viral 
infectivity (252, 253), they may also impair the ability of Nef to antagonize a key host restriction 
factor that inhibits HIV-1 infectivity - the host cell transmembrane protein SERINC5. 
1.3 SERINC5  
1.3.1 Initial discovery and identification as a retroviral restriction factor 
Though the ability of Nef to enhance viral infectivity was first reported in 1995 (255), the 
primary mechanism underlying that enhancement was not determined for nearly two decades. 
Incremental work over those twenty years showed that Nef expression during viral production 
within particular cell lines dramatically enhanced viral infectivity, and that this activity was 
dependent upon Nef motifs associated with CD4 downregulation and recruitment of AP-2 (106). 
This finding was followed by the observation that the murine leukemia virus (MLV) glycoGag 
protein (a retroviral protein structurally unrelated to Nef) enhanced viral infectivity of both HIV 
and MLV in the same Nef-responsive producer cell lines (107). This led researchers to hypothesize 
that Nef and glycoGag both targeted an unknown cell-type specific inhibitor of retroviral 
replication. The search for that inhibitor continued until 2015, when the labs of Dr. Massimo 
Pizzato and Dr. Heinrich Gottlinger reported that Nef antagonism of two poorly characterized 
transmembrane proteins, serine incorporator protein 5 (SERINC5) and the related isoform 
SERINC3, were responsible for cell-type specific enhancement of viral infectivity by Nef (117, 
256). 
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Gottlinger and Pizzato took complementary approaches towards identifying the mysterious 
cellular factor. Pizzato built from the finding that Nef enhances viral infectivity to varying degrees 
in different HIV-1 producer cell lines, and used RNA-seq to compare the global transcriptome 
between producer cells that displayed a high degree of Nef-dependent infectivity enhancement 
with that of cells which saw little Nef-dependent promotion of infectivity. The group reported that 
RNA expression of SERINC5 within producer cells strongly correlates with the degree of Nef-
enhanced viral infectivity (117). Looking to answer the same question, Gottlinger’s laboratory 
took a proteomics-based approach, using mass spectrometry to identify membrane proteins that 
were differentially incorporated into HIV-1 virions in the presence or absence of Nef expression 
(256). Gottlinger found that ∆Nef virions display a clear enrichment in SERINC3 compared to 
wild-type virus, suggesting Nef-dependent exclusion of SERINC3 from the viral membrane (256). 
Having identified a link between Nef-dependent enhancement of viral infectivity and 
SERINC expression, the two groups published parallel studies in Nature characterizing the 
antiviral properties of both SERINC3 and SERINC5 and the antagonistic activity of Nef towards 
each protein. These studies demonstrated that SERINC3 and SERINC5 were incorporated into the 
lipid envelope during viral budding, and that incorporation of SERINC3/5 inhibited viral 
infectivity. They also demonstrated that Nef antagonizes SERINC3 and SERINC5 via 
downregulation through an AP-2 and clathrin-dependent mechanism, and that this antagonism 
reverses or mitigates SERINC inhibition of viral infectivity (117, 256). A mechanistic model of 
SERINC5 activity and Nef antagonism can be seen in Figure 8.  
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Figure 8: Model of SERINC5 Antagonism via HIV-1 Nef 
Overview of Nef antagonism of SERINC5 during viral production. SERINC5 is expressed endogenously on the 
surface of HIV-infected cells. In the absence of Nef antagonism (lower panel), SERINC5 is incorporated in the viral 
membrane of newly synthesized virions, and impairs viral infection. In the presence of Nef antagonism (upper panel) 
SERINC5 is downregulated from the cell surface and excluded from the viral membrane, enhancing infectivity. Model 
is adapted from Aiken 2015 (257), and produced using Biorender. 
1.3.2 Structure and critical features of SERINC5  
SERINCs are a family of multi-pass transmembrane domain proteins that are evolutionarily 
conserved across all eukaryotes, but distinct in sequence homology from all other identified protein 
families. There are five SERINC family members expressed by humans (SERINC1-5), and all 
SERINCs but SERINC2 inhibit HIV-1 infectivity following incorporation into nascent virions 
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(258). SERINC4 and SERINC5 exhibit the greatest extent of HIV-1 restriction out of all SERINC 
family members, however, SERINC4 does not appear to be highly expressed within any cells or 
tissues relevant to HIV-1 infection (259). In contrast, SERINC5 (and the less potent antiviral factor 
SERINC3), are highly expressed within lymphoid and myeloid cells (256). 
  While the ubiquity of SERINC across eukaryotic organisms hints at an ancient 
endogenous function, the role of SERINCs outside the context of retroviral infection is currently 
unknown. An early study of SERINC proteins (and the origin of the name SERINC) suggests a 
potential role in the synthesis of serine and serine-incorporated lipids (260), although such a 
function has not been supported by recent research (261, 262). And while SERINCs are highly 
expressed within some cancer cell lines and enriched within certain neuronal cell types, their 
function in the context of cancer pathogenesis and neurobiology remain to be determined (259).  
Recent work has revealed the structure, topology, and features of SERINC5 essential for 
HIV restriction (263). SERINC5 is a 10-transmembrane domain protein with five extracellular 
loops, four intracellular loops, and cytosolic N- and C-termini (264) (Figure 9). Cryo-EM 
structures of both the Drosophila ortholog of SERINC5 and human SERINC5 have confirmed the 
predicted topology and revealed that the protein assumes a dual subdomain configuration (263). 
Subdomains A and B of SERINC5 are separated by the fourth transmembrane domain, which 
bridges the second extracellular loop and intracellular loop of SERINC5, and cuts diagonally 
through the plasma membrane. Subdomain B appears to form a structural groove that can be 
accommodated both the hydrophilic head group and hydrophobic tail of a number of lipids (263).  
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Figure 9: Topology of SERINC5 
Model of the SERINC5 structural organization and topology of SERINC5. SERINC5 contains ten transmembrane 
domains, intracellular N- and C-termini. Asterisk marks the location of the SERINC5 Intracellular Loop 4 (ICL4), the 
region of SERINC5 which directs sensitivity towards Nef antagonism. Figure produced via Biorender.  
 
 
There are five alternatively spliced isoforms expressed by the SER5 gene, however only 
one isoform (Ser5-001) contains the 10th transmembrane domain that is essential for stable protein 
expression and antiviral activity (265). The majority of expressed SERINC5 is this isoform, as the 
other four isoforms exhibit poor stability and are expressed at a 10-fold lower level than Ser5-001 
(265). Stable SERINC5 expression also requires N-glycosylation at residue Asn294 on the fourth 
extracellular loop, as mutation of this N-glycosylation site decreases steady-state expression of 
SERINC5 (266). 
Another critical feature of SERINC5 is intracellular loop 4 (ICL4), both the largest loop 
within SERINC5 and the primary determinant of SERINC5 sensitivity to Nef antagonism. As Nef 
antagonism of SERINC5 is not conserved across all orthologs of the protein, replacement of the 
human SERINC5 ICL4 with the ICL4 loop from Nef-resistant frog (Xenopus tropicalis) SERINC5 
confers complete resistance to Nef antagonism (267). Nef Sensitivity of SERINC5 within the large 
intracellular loop appears to map specifically to two hydrophobic residues- Leu350 and Ile353, 
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and mutation of both residues within human SERINC5 impairs downregulation by Nef. While it 
is tempting to speculate that this loop functions as a binding site for Nef, this remains to be proven 
experimentally. However, SERINC5 and Nef do appear to associate directly in cells, and it has 
recently been demonstrated that expression of a fusion construct of Nef/SERINC5-ICL4 promotes 
complex formation with AP-2 (268, 269). 
1.3.3 SERINC5 restriction of viral infectivity 
SERINC5 inhibition of viral infectivity is conserved across all orthologs tested, including 
SERINC5 from rodent, zebrafish, frog, and rabbit (267, 270). The full mechanism controlling 
SERINC5 inhibition of viral infectivity remains elusive, but it is suspected that SERINC5 
incorporated into the viral membrane inhibits viral infectivity by targeting Env function (271). 
This is supported by the observation that virus sensitivity to SERINC5 restriction is entirely 
dependent upon Env, as HIV-1 pseudotyped with Env from VSV or Ebola is markedly resistant to 
SERINC5 antagonism (117, 256). Env proteins from different subtypes of HIV-1 also display 
varying sensitivities to SERINC5, suggesting that inhibition of viral infectivity is mediated through 
Env. SERINC5 appears to directly associate with Env, as shown through via bimolecular 
fluorescence complementation (BiFC) and immunoprecipitation assays (271, 272). Incorporation 
of SERINC5 into nascent virions inhibits viral fusion (273), and Env conformation (as detected by 
conformation-dependent neutralizing antibodies) is directly impacted by SERINC5 (271, 273). As 
Env-Env association is decreased in the presence of SERINC5, it is possible that SERINC5 
disrupts formation of the functionally competent Env trimer (272), or clustering of the handful of 
Env spikes (7-14 per virion) on the viral membrane (259). Future work will further elucidate the 
interplay between SERINC5 and Env and how it relates to restriction of HIV-1 infectivity. 
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Though SERINC5 is one of several antiretroviral restriction factors that targets HIV-1 
(tetherin, APOBEC3G and TRIM5α), there are several significant differences between SERINC5 
and other restriction factors. For example, while expression of other restriction factors is induced 
by interferon, SERINC5 is expressed at high levels within HIV-1 target cells in an interferon-
independent manner (256, 274). Still, while SERINC5 mRNA and protein levels do not increase 
following interferon stimulation, IFN-α treatment appears to increase cell surface localization of 
SERINC5 (275). Another hallmark of other HIV-1 restriction factors not shared with SERINC5 is 
a clear signature of positive evolutionary selection. While the evolutionary histories of tetherin, 
TRIM5α, and APOBEC3G display signs of an evolutionary arms race with HIV, SERINC3 and 
SERINC5 do not appear to have been shaped by positive selective pressure under the virus (276, 
277). However, positive selection could simply be confined to a few select regions with SERINC5 
rather than the entire ORF (as in seen for other restriction factors) (276). Indeed, a cluster of serines 
within SERINC3 appear to be the result of positive selective pressure (278). In any case, the lack 
of complete positive selection is interesting considering the clear antagonistic relationship between 
SERINC5 and several distinct retroviruses. 
1.3.4 Retroviral antagonism of SERINC5 
SERINC5 antagonism via Nef is driven primarily through exclusion of SERINC5 from 
incorporation into newly synthesized virions, which Nef achieves through downregulation of 
SERINC5 from the cell surface. Following Nef-directed internalization, SERINC5 is directed into 
the endosome system, colocalizing with early (Rab5+) and late (Rab7+) endosomes en route to 
lysosomal degradation (135, 268). As a result, Nef decreases both cell-surface and steady-state 
levels of SERINC5 within viral producer cells, decreasing the quantity of restriction factor that 
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gets incorporated into the membrane of nascent virions (268). While exclusion of SERINC5 from 
HIV-1 virions appears to be largely responsible for the phenotype of Nef antagonism, Nef seems 
to be able to additionally antagonize SERINC5 in the presence of high SERINC5 expression and 
virion incorporation. However, the mechanism behind this observation remains to be determined 
(279). 
Nef antagonism of SERINC5 is widely conserved across HIV-1, HIV-2, and SIV (280), 
and Nef proteins expressed by various primate lentiviruses are able to widely antagonize SERINC5 
orthologs across primate and murine species (281). There is, however, some inherent variation in 
the degree to which Nef can antagonize SERINC5, and Nef proteins from the HIV-1/SIVcpz 
lineage are more active against SERINC5 than Nef proteins from the HIV-2/SIVsmm lineage 
(281). Interestingly, the extent to which SIV Nef proteins antagonize SERINC5 directly correlates 
with how prevalent that SIV strain is within infected primate populations. This suggests that 
SERINC5 restriction is a barrier to effective lentiviral transmission within primates (281). 
In addition to SIV and HIV-2, at least two other retroviruses demonstrate the ability to 
overcome SERINC5 restriction: Murine Leukemia Virus (MLV) via the glycoGag protein, and 
Equine Infectious Anemia Virus (EIAV) via the S2 auxiliary protein. Like Nef, MLV glycoGag 
and EIAV S2 retarget SERINC5 into intracellular compartments, promoting exclusion of 
SERINC5 from newly synthesized virions (117, 282). Remarkably, despite their shared function, 
there is no sequence homology between these three proteins (259). Instead, glycoGag, S2, and Nef 
share two key molecular determinants- the ability to associate with both the plasma membrane and 
clathrin adaptor binding motifs (282). MLV glycoGag associates with the membrane as a Type II 
single-pass transmembrane protein, while Nef and S2 associate with the membrane following 
myristoylation. Mutation of the myristoylation site within S2 and Nef, or the clathrin adaptor 
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protein binding motifs (YxxL for glycoGag, di-leucine motif for S2 and Nef) completely abolishes 
SERINC5 antagonism by these proteins (282, 283). 
In addition to their critical contribution to Nef antagonism of SERINC5, the myristylation 
sequence and di-leucine motif are also essential for Nef downregulation of CD4 as described in an 
earlier section (256, 284). CD4 downregulation and SERINC5 antagonism are also both driven 
through AP-2 and clathrin-dependent internalization, and are similarly targeted by Nef into the 
endosome-lysosome pathway (268). Though a role for Nef dimerization has been established for 
Nef downregulation of CD4, it remains to be examined whether dimerization also plays a role in 
Nef antagonism of SERINC5 (239). Based on the existing mechanistic similarities between 
SERINC5 and CD4 downregulation, the Nef dimer interface could potentially represent a third 
molecular determinant shared between both Nef functions.  
1.4 Hypotheses and Specific Aims 
1.4.1 Hypothesis 1: Nef homodimerization is essential for downregulation of SERINC5 
Mutation of the Nef homodimerization interface residues Leu112, Tyr115, and Phe121 
disrupts Nef self-association in cells and solution, and impacts the ability of Nef to downregulate 
CD4 from the surface of infected cells. CD4 and SERINC5 downregulation via Nef have been 
described as mechanistically similar, with both functions dependent upon AP-2 recruitment and 
clathrin-mediated endocytosis. Furthermore, Nef re-targets both CD4 and SERINC5 into Rab7+ 
late endosomal compartments, directing them towards lysosomal degradation. Based on the 
inherent similarity of these two mechanisms, I hypothesize that Nef homodimerization is essential 
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for antagonism of SERINC5, and that disrupting the dimerization interface through L112, Y115, 
and F121 mutations impacts SERINC5 downregulation and thus reduces viral infectivity. To test 
this hypothesis, I utilized a series of viral infectivity assays, confocal microscopy studies, flow 
cytometry, virion isolation assays, and immunoblots to explore the three following experimental 
aims.  
1.4.2 Specific Aims for Hypothesis 1 
1.4.2.1 Aim 1: Explore the impact of dimerization-defective Nef mutants on HIV-1 
infectivity and virion exclusion of SERINC5.  
Using a HeLa-based HIV-1 reporter cell line (TZM-bl), we measured whether Nef 
enhancement of viral infectivity was decreased in the presence of dimer interface mutations 
(L112A, L112D, Y115D, F121A). HIV-1 encoding wild-type, mutant, or no Nef (ΔNef) was 
produced in 293T cells, Jurkat JTAg T cells, or peripheral blood mononuclear cells (PBMCs) in 
the presence and absence of SERINC5, and the resulting viral supernatants were collected, 
quantified, and incubated with TZM-bl cells to measure infectivity. We found that the L112D, 
Y115D, and F121A mutants displayed severely impaired Nef promotion of infectivity, similar to 
what was observed for the ∆Nef viral mutant. In contrast, we found that the L112A mutant had 
infectivity close to that displayed by the virus expressing wild-type Nef. This observation is 
consistent with the limited impact of the L112A mutation on Nef dimerization in cells. In order to 
connect impaired promotion of infectivity to impaired antagonism of SERINC5, we collected wild-
type, ∆Nef, and Nef dimer mutant virus produced in 293T cells transfected with SERINC5, and 
used sucrose cushion ultracentrifugation to purify the resulting virions, which were analyzed via 
immunoblot. We found that ∆Nef, L112D, Y115D, and F121A incorporated significantly more 
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SERINC5 than the wild-type and L112A Nef viruses, suggesting a reduced capability of those 
mutants to antagonize and exclude SERINC5. This observation suggests that Nef mutants known 
to display significant impairment of dimerization (L112D, Y115D, F121A) are unable to 
effectively antagonize SERINC5 or promote infectivity. 
1.4.2.2 Aim 2: Examine whether disruption of Nef dimerization impairs Nef 
downregulation and intracellular retargeting of SERINC5.  
Nef downregulates SERINC5 from the cell surface and retargets it into the 
endosome/lysosome system for degradation. In order to determine whether impaired exclusion of 
SERINC5 from nascent virions is due to dysfunctional downregulation of SERINC5 from the cell 
surface, we transfected cells with a SERINC5 construct labeled with an extracellular HA-tag 
(SERINC5-iHA) and either wild-type or Nef dimer mutants, and quantified Nef downregulation 
of SERINC5-iHA via flow cytometry. We observed downregulation of cell-surface SERINC5 in 
the presence of wild type Nef or the L112A mutant, but attenuated downregulation of SERINC5 
for the L112D, Y115D, and F121A mutants. As a control, we also compared the ability of these 
Nef mutants to downregulate endogenous cell surface CD4. As expected, wild-type Nef robustly 
downregulated CD4, while L112D, Y115D, F121A did not. The Nef-L112A mutant partially 
downregulated CD4, presenting an intermediate phenotype between wild-type Nef and the other 
mutants. In order to determine if mutation of the Nef dimer interface impaired intracellular 
targeting of SERINC5 following downregulation, we used confocal microscopy to study the 
localization of RFP-labeled SERINC5 in the presence of wild-type or mutant Nef fused to YFP. 
SERINC5 was primarily localized at the cell surface when expressed alone, but in the presence of 
wild-type Nef or the L112A mutant, SERINC5 was retargeted into intracellular compartments 
which colocalized with the Rab7+ late endosomal marker. Co-expression of L112D, Y115D, and 
58 
F121A decreased internalization of SERINC5 and colocalization with Rab7. These results show 
that Nef dimerization is required for both initial downregulation of SERINC5 as well as its 
intracellular trafficking to late endosomes. 
1.4.2.3 Aim 3: Evaluate whether dimerization interface mutations impair Nef association 
with SERINC5, AP-2, or Nef within cells.  
To determine the impact of Nef dimer interface mutations on Nef function and signaling, 
we used bimolecular fluorescence complementation (BiFC) assays to compare the association of 
Nef dimer mutants with cellular binding partners. We found that all Nef mutants retained 
functional association with SERINC5, AP-2α and AP-2σ2 in the BiFC assay, suggesting that 
disruption of Nef dimerization does not impair recruitment of either the SERINC5 cargo or 
endocytic machinery. However, Nef dimer mutants displayed reduced capability to homodimerize 
in cells by BiFC which mirrored their ability to antagonize SERINC5. In summary, our studies 
support a mechanism in which Nef homodimers serve to bridge SERINC5 with the AP-2 pathway 
for internalization, thereby excluding incorporation of this restriction factor into newly synthesized 
virions. 
1.4.3 Hypothesis 2 
Previous genetic and cellular studies of the Nef dimer interface have been based upon a 
crystal structure of the Nef:Hck SH3 “dimer of complexes” (239) (Figure 6). Hck is a member of 
the Src-kinase family expressed in monocytes and macrophages, and interaction with Nef leads to 
kinase activation that enhances replication in host cells of myeloid origin.  In this structure, two 
Hck SH3-bound Nef monomers form a dimer through a hydrophobic interface between their B 
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helices (285). This dimer interface is further stabilized by reciprocal electrostatic interactions 
between Arg105 and Asp123 on complementary Nef monomers (285). However, more recent 
structural studies of the Nef dimer bound to a Hck SH3-SH2 dual regulatory domain protein 
demonstrate a completely different orientation of the dimer interface (Figure 7), in which Nef 
Asp123 swings out of the dimer interface in the Hck SH3-SH2 bound structure (212). Dynamic 
changes suggested by the two crystal structures were further supported by HDX MS, where a 
charge reversal mutation of Asp123 disrupted dimerization in the Hck SH3 but not the Hck SH3-
SH2-bound structure in solution (244). Importantly, only the orientation of the dimer interface is 
impacted by Nef binding partners, while the overall global fold of the Nef core region is identical 
across these and other crystal structures of Nef associated with diverse binding partners (212, 222, 
239). Comparison of the Hck SH3 and SH3-SH2-bound Nef dimer structures reveals multiple Nef 
residues that contribute to the dimer interface in both structures.  Three of these residues have 
already been characterized in detail in cells – Leu112, Tyr115, and F121 (see Figures 6 and 7). 
However, the individual contribution of these residues towards the dimer interface across different 
stages of kinase regulatory domain association remain to be evaluated. In addition, further 
inspection of these crystal structures suggested important contributions of Ile109 and His116 to 
these interfaces as well as regulation of homodimer transitions in solution important for function.  
Therefore, I hypothesized that Ile109, Leu112, Tyr115, and His116 individually contribute to 
unique Nef homodimer transitions captured by the crystal structures of Nef in complexes with the 
Hck SH3 domain alone vs. the complete SH3-SH2 regulatory subunit. To test this hypothesis, I 
expressed and purified four recombinant Nef dimerization interface mutants: I109A and His116A 
along with L112A and Y115A for comparison. All four mutants yielded soluble protein in high 
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yield, and were subsequently analyzed by surface plasmon resonance, size-exclusion 
chromatography, and in vitro kinase assays as described in the following Aims: 
1.4.4 Specific Aims for Hypothesis 2 
1.4.4.1 Aim 1: Determine the binding affinity of Nef dimer mutants towards Hck SH3 and 
SH3-SH2 regulatory domain proteins 
As described in detail in Section 1.2.5.2, interaction of Nef with SH3 domains requires an 
intact Nef PxxPxR motif and a hydrophobic pocket dependent upon the appropriate 3-dimenional 
fold of the Nef core.  Prior to examining the impact of Nef dimer interface mutations on SH3/SH3-
SH2 complex formation in solution, therefore, we first compared the effect of each mutation on 
the affinity of Nef towards both the Hck SH3 and SH3-SH2 regulatory domain proteins. Using a 
flow-based surface plasmon resonance (SPR) system, recombinant purified Hck SH3 and SH3-
SH2 domains were covalently linked to the surface of a sensor chip within a flow channel, and 
each recombinant Nef protein was then flowed across the surface of the chip. We observed that 
the Nef I109A, L112A, and H116A mutants displayed similar affinities as wild-type Nef for the 
SH3 and SH3-SH2 proteins, suggesting that these dimer interface substitutions had no impact on 
SH3 binding. However, Nef-Y115A displayed about 5-fold lower affinity towards both regulatory 
domain proteins, suggesting a potential allosteric effect of this mutation on SH3 engagement.  
1.4.4.2 Aim 2: Evaluate whether Nef dimer mutants form 2:2 heterocomplexes with SH3 
and SH3-SH2 in solution 
In order to evaluate the impact of these substitutions on dimerization and complex 
formation in solution, we mixed either wild-type or Nef dimer mutant proteins with Hck SH3 and 
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SH3-SH2 in equimolar ratios, and then injected them onto an analytical size-exclusion 
chromatography column. We found that wild-type, I109A, L112A, and H116A Nef appear to form 
similarly sized complexes in the presence of SH3 and SH3-SH2, potentially corresponding to the 
2:2 heterodimer complexes observed in previous structures with wild-type Nef. However, 
complexes of Nef-Y115A with SH3 and SH3-SH2 eluted at later retention times, signaling 
impaired 2:2 complex formation. These results suggest the Y115 is essential to Hck dimer complex 
formation, with the other three residues playing a supporting role. 
1.4.4.3 Aim 3: Explore whether Nef dimer interface mutants display functional activation 
of Hck in vitro 
 In this Aim, we explored the effect of each Nef dimer interface mutant on recombinant, 
downregulated Hck activity in a solution-based assay.  We found that that the Nef I109A, L112A, 
and H116A mutants all activated Hck to a similar extent as wild-type Nef. While the Y115A 
mutant was about 2-fold less potent in terms of Hck activation, this mutant was still capable of 
fully activating Hck. These results suggest that substitution of large hydrophobic residues with 
alanine produces functionally stable Nef, but that Y115A may impact dimer formation and/or Hck 
recruitment. Furthermore, the crystal structure of the Nef dimer interface when in complex with 
the Hck SH3-SH2 region is quite complex, involving three distinct interfaces and at least 13 unique 
residues. Thus, substitution of a single residue (except for Tyr115) may not be sufficient to disrupt 
complex formation and Hck activation in solution, a conclusion supported by the SEC studies. 
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2.0 Nef homodimers couple SERINC5 to AP-2 for Downregulation in HIV-1 Producer Cells 
2.1 Chapter 2 summary 
SERINC5 is a multi-pass intrinsic membrane protein that suppresses HIV-1 infectivity 
when incorporated into budding virions. The HIV-1 Nef virulence factor prevents viral 
incorporation of SERINC5 by triggering its downregulation from the producer cell membrane 
through an AP-2-dependent endolysosomal pathway. However, the mechanistic basis for 
SERINC5 downregulation by Nef remains elusive. Here we demonstrate that Nef homodimers are 
required for SERINC5 downregulation, trafficking to late endosomes, and exclusion from newly 
synthesized viral particles. Based on previous X-ray crystal structures, we mutated three conserved 
residues in the Nef dimer interface (L112, Y115, F121) and demonstrated attenuated homodimer 
formation in a cell-based fluorescence complementation assay. Point mutations at each of these 
positions reduced the infectivity of HIV-1 produced from transfected 293T cells, Jurkat TAg T 
cells, and primary human mononuclear cells in a SERINC5-dependent manner. In SERINC5-
transfected 293T cells, virion incorporation of SERINC5 was increased by dimerization-defective 
Nef mutants, while downregulation of SERINC5 from the membrane of transfected Jurkat cells by 
these mutants was significantly reduced. Nef dimer interface mutants also failed to trigger 
internalization of SERINC5 and localization to Rab7+ late endosomes in T cells. Importantly, 
dimerization-defective Nef mutants retained interaction with both SERINC5 and AP-2 by 
fluorescence complementation assay. These results demonstrate that downregulation of SERINC5 
and subsequent enhancement of viral infectivity requires Nef homodimers and support a 
mechanism by which the Nef dimer bridges SERINC5 to AP-2 for endocytosis. Pharmacological 
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disruption of Nef homodimers may provide a new approach to control HIV-1 infectivity and viral 
spread by enhancing incorporation of SERINC5. 
2.2 Introduction 
The HIV-1 Nef accessory protein is expressed early in the HIV-1 life cycle where it 
promotes viral replication and AIDS progression (286).  Expression of Nef within the CD4-
positive cell compartment is sufficient to induce an AIDS-like disease in transgenic mice (287, 
288).  Conversely, patients harboring Nef-defective strains of HIV-1 exhibit reduced viral loads 
and delayed progression to AIDS (289, 290).  Enhancement of lentiviral pathogenicity by Nef is 
conserved across species. Disruption of the nef open reading frame of simian immunodeficiency 
virus (SIV) significantly reduces viral replication and prevents the development of AIDS-like 
disease in SIV-infected macaques (291).  These are just a few examples of the evidence supporting 
a central role for Nef in HIV-1 and SIV pathogenicity.  
Nef is a small protein (27-34 kDa, depending on the viral subtype) that is associated with 
host cell membranes by virtue of N-terminal myristylation (292). Nef lacks inherent enzymatic 
activity, functioning instead through multiple protein-protein interactions that alter host cell 
signaling and protein trafficking networks involving as many as 70 host cell proteins (109).  Nef 
selectively binds and activates members of the Src and Tec protein-tyrosine kinase families (293-
296).  Disruption of Nef-dependent kinase activation through genetic or pharmacological means 
impairs Nef-mediated enhancement of HIV-1 infectivity and replication (295-299). In terms of 
protein trafficking, Nef drives the downregulation of cell surface receptors essential for immune 
recognition and viral entry, including MHC-I, CXCR4, CCR5, and CD4 (112, 292, 300). Receptor 
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downregulation involves Nef interactions with endosomal trafficking proteins, including the 
adaptor protein complexes 1 and 2 (AP-1 and AP-2) (301, 302).  Downregulation of CD4 requires 
simultaneous engagement of Nef with both the cytoplasmic tail of CD4 and a hemicomplex formed 
by the α and σ2 subunits of AP-2 (222).  Nef•CD4•AP-2 complexes form clathrin-coated pits at 
the cell surface, leading to endocytosis and lysosomal degradation of internalized CD4 (303). 
Nef-mediated endocytosis of the SERINC5 restriction factor, essential for enhancement of 
HIV-1 infectivity, is also mediated by the AP-2 trafficking pathway. In the absence of Nef, 
SERINC5 is present on the surface of HIV-1 infected cells and incorporated into the membrane of 
newly synthesized virions (304-306).  Incorporation of SERINC5 disrupts viral fusion with host 
cells and delivery of the viral core through a cryptic, Env-dependent mechanism. Nef antagonizes 
SERINC5 in part by promoting AP-2-dependent downregulation of SERINC5 from the plasma 
membrane of infected cells, thereby preventing incorporation into budding virions (305).  
Following downregulation by Nef, internalized SERINC5 is targeted for degradation via the 
endolysosomal pathway (307). 
While Nef uses distinct structural motifs to recognize diverse host cell partners, many Nef 
functions also require homodimer formation. Mutants of Nef that are defective for 
homodimerization are unable to induce host cell tyrosine kinase activation, even though they retain 
interaction with the kinases (296).  This observation is consistent with the formation of Nef•kinase 
dimer complexes necessary for kinase activation by trans-autophosphorylation. Dimerization-
defective Nef mutants are also unable to downregulate CD4 from the host cell surface, and these 
mutations reduce HIV-1 infectivity and replication efficiency in cell lines (241, 308).  
In this study, we investigated the role of Nef homodimerization in HIV-1 infectivity and 
restriction by SERINC5. Using a series of Nef mutants defective for homodimer formation in cells, 
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we demonstrated that Nef dimers are required to enhance infectivity of HIV-1 produced from T 
cell lines and donor PBMCs as well as 293T cells co-transfected with SERINC5. These same Nef 
mutants were attenuated in their ability to exclude SERINC5 from newly synthesized virions. 
Impairment of Nef dimerization reduced downregulation of SERINC5 from the cell surface and 
prevented its intracellular trafficking to Rab7+ late endosomes. Critically, cell-based fluorescence 
complementation assays revealed that these Nef mutants retained interaction with both SERINC5 
and the AP-2 α and σ2 subunits, indicating that the reduced antagonism of SERINC5 was not due 
to loss of Nef association with either partner protein. Taken together, our data demonstrate that 
Nef antagonizes the SERINC5 restriction factor as a homodimer, which may serve as a bridge 
linking SERINC5 with AP-2 for endocytosis and degradation.  
2.3 Results 
2.3.1 Structural basis of HIV-1 Nef homodimerization 
In this study, we explored the role of Nef homodimerization in the downregulation of 
SERINC5 and promotion of HIV-1 infectivity using a genetic approach involving Nef mutants 
defective for homodimer formation. X-ray crystallography of Nef in complex with the regulatory 
SH3 and SH2 domains of Src-family kinases have shown that Nef forms homodimers through a 
hydrophobic interface involving side chains of residues in the Nef αB helices and adjacent loops 
(309, 310). An example is provided by the structure of HIV-1 Nef in complex with the SH3-SH2 
regulatory region of the Src-family kinase, Hck (a model of the overall homodimer is shown in 
Figure 10A) (310).  In this structure, three conserved residues from one Nef subunit (Leu112, 
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Tyr115, Phe121) converge to create a ‘hydrophobic cup’ that clasps the side chain of Val70 from 
the opposing Nef monomer in a reciprocal fashion (Figure 10B). A recent study has shown that 
recombinant Nef proteins in which Leu112 or Tyr115 is replaced with aspartate or Phe121 is 
substituted with alanine fail to form dimers in solution, providing direct evidence that these 
residues are essential for dimer stabilization (296).  Mutations at these positions attenuate multiple 
Nef functions, including host cell kinase activation, enhancement of HIV-1 replication, and 
receptor downregulation including CD4 (see Introduction). 
While the role of Nef homodimers in SERINC5 antagonism has not been explored, the 
mechanistic similarity between Nef-mediated downregulation of CD4 and SERINC5 suggests a 
key role. Both processes involve clathrin-mediated endocytosis via the tetrameric trafficking 
adaptor protein AP-2, which interacts directly with Nef through a hemicomplex of its α and σ2 
subunits (222, 264).  Importantly, alignment of this Nef homodimer with the crystal structure of 
Nef bound to the AP-2 α/σ2 hemicomplex shows that the Nef homodimer interface residues do not 
contact AP-2 (Figure 10C), suggesting that the dimer interface mutations described above will not 
affect AP-2 recruitment. These mutants were therefore chosen to explore the requirement for Nef 




Figure 10: Structural basis of Nef dimerization 
A) Overall structure of the HIV-1 Nef homodimer present in the 2:2 heterocomplex with the Hck SH3-SH2 regulatory 
domain proteins (PDB: 4U5W; the SH3-SH2 proteins are not shown for clarity). The Nef monomers (NefA and NefB) 
are rendered in dark and light blue, respectively. B) Zoomed and rotated view of the Nef dimerization interface in 
which conserved residues Leu112, Tyr115, and Phe121 (cyan, orange, and green, respectively) form a hydrophobic 
cup around Val70(pink) from the opposing monomer. C) One Nef monomer from the homodimer shown in part A 
was aligned with Nef  in  complex  with the AP-2 α/σ2 hemicomplex  (PDB:  4NEE). The AP-2 α and σ2 subunits are 
shown as surfaces in gray and light orange, respectively. This alignment shows that the Nef homodimer interface is 




Though Nef is present in HIV-1 virions and expressed early within the viral life cycle 
(264), previous analyses have examined the impact of mutations on Nef self-association 40-48 
hours post-transfection (241, 308) which corresponds to the end of the HIV-1 life cycle (311). We 
therefore explored the kinetics of wild-type Nef homodimer formation and membrane association 
at 12-hour intervals using a cell-based bimolecular fluorescence complementation (BiFC) assay 
(312).  In this approach, wild-type and mutant Nef coding sequences are fused to an N-terminal 
fragment of the YFP variant, Venus (Nef-VN), while complementary Nef constructs are fused to 
a C-terminal Venus fragment (Nef-VC). Co-expression of the Nef-VN and Nef-VC fusion proteins 
in the same cell results in protein-protein interaction, leading to irreversible complementation of 
the Venus fluorophore and a bright fluorescent signal (Figure 11).  
 
 
Figure 11: Overview of Bimolecular Fluorescence Complementation (BiFC) 
Schematic showing the mechanistic basis of BiFC. The Venus yellow fluorescent protein (YFP) is split into 
N-terminal and C-terminal halves (VN and VC, respectively). Each half of the split fluorescent reporter is fused to the 
C-terminus of Nef, and both are expressed within cells. Nef association in cells results in productive reconstitution of 





Figure 12: BiFC analysis of self-association kinetics of wild-type Nef and dimerization interface mutants 
293T cells were co-transfected with expression plasmids for wild-type and mutant Nef proteins fused to non-
fluorescent complementary fragments of the YFP variant, Venus. Cells were fixed 12, 24, 36, and 48 hours post-
transfection and immunostained for Nef expression prior to imaging via confocal microscopy. Nef homodimerization 
results in reconstitution of the Venus fluorophore. A) Representative images comparing  self-association  of  wild-
type  and  mutant  Nef  proteins(BiFC;  green).  Nef immunofluorescence is shown in red (Nef IF). B) Time course of 
Nef dimerization by BiFC assay. The mean fluorescence intensity ratios of the BiFC and Nef immunofluorescence 
signals were calculated from a minimum of 100 cells across the entire cell for each condition using ImageJ. The entire 
experiment was repeated in duplicate, and each data point represents the mean ratio ±SD. Complete data for a 
representative cell population are shown in the Figure 13. 
 
Cultures of 293T cells were transfected with Nef-VN and Nef-VC expression vectors 
(wild-type or the dimerization interface mutants L112A, L112D, Y115D, F121A) and fixed with 
paraformaldehyde 12, 24, 36, and 48 hours later. Cells were then immunostained to confirm Nef 
protein expression, allowing normalization of the resulting BiFC signal to Nef expression levels 
within each culture. Figure 12A shows representative confocal images of Nef BiFC (homodimer 


















































formation) and immunofluorescence (Nef protein expression) at the 48 hour endpoint of the 
experiment, while Nef BiFC to immunofluorescence intensity ratios across all four time points are 
plotted in Figure 12B. Little fluorescence complementation was observed with any of the Nef 
BiFC pairs at 12 hours, which likely reflects the low levels of Nef expression at this time point.  
After 24 hours, wild-type Nef self-association was readily observed and increased in a linear 
fashion over 48 hours. In contrast to wild-type Nef, the L112D, Y115D, and F121A mutants 
demonstrated statistically significant defects in Nef homodimerization across all time points. The 
Y115D mutant showed the lowest ratios at each time point, with the L112D and F121A mutants 
exhibiting an intermediate phenotype. By contrast, the L112A mutation had little to no detectable 
impact on Nef homodimer formation in the BiFC assay, suggesting that substitution of alanine for 
leucine does not sufficiently disrupt dimer formation to affect detection in the BiFC assay. 
Inspection of the BiFC and immunofluorescence images suggests that all four Nef mutants 
remained associated with the plasma membrane, although the Y115D mutant showed increased 
expression in the cytoplasm. Box-and-whisker plots of the BiFC-to-immunofluorescence intensity 
ratios for the wild-type and mutant Nef proteins at each time point, along with statistical 
comparisons, are shown in Figure 13. 
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Figure 13: Analysis of BiFC self-association kinetics for wild-type and dimerization interface mutants 
293T cells were co-transfected with expression plasmids for wild-type and mutant Nef proteins fused to non-
fluorescent complementary fragments  of  the  YFP  variant,  Venus. Cells were  fixed 12,  24,  36,  and 48  hours  
post-transfection and immunostained for Nef expression prior to imaging via confocal microscopy. Nef 
homodimerization results in reconstitution of the Venus fluorophore. The mean fluorescence intensities of the BiFC 
and Nef immunofluorescence signals were  calculated  from  a minimum  of  100  cells  for  each condition using  
ImageJ.  The distribution  of  BiFC:IF ratios for each cell population are plotted as box and whisker plots with the 
boxes showing the 25thto 75thpercen-tiles and the whiskers showing the 10th to 90th percentiles. Statistical analyses 
were performed via Dunnett’s multiple comparisons test with the wild-type (WT) Nef group as control (****, p≤ 
0.0001; ns, not significant).The Nef L112A mutant did not show a significant decrease in the ratio, except at the 48h  
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2.3.2 Dimerization-defective Nef attenuates HIV-1 infectivity and impairs SERINC5 
antagonism 
In order to test the role of Nef homodimerization in SERINC5 antagonism, we first 
validated a 293T producer cell system to assess virion incorporation of SERINC5 and impact on 
viral infectivity. For these studies, 293T cells were transfected with proviral plasmids encoding 
wild-type HIV-1 or a mutant that fails to express Nef (∆Nef) in the presence or absence of a 
SERINC5 expression vector. Newly synthesized virions were concentrated from the culture 
supernatant two days later and levels of virion-incorporated SERINC5 were analyzed via 
immunoblot. The infectivity of each viral supernatant was assessed in parallel using the TZM-bl 
reporter cell line (313).   Expression of SERINC5 in 293T producer cells inhibited HIV-1 ∆Nef 
infectivity in a dose-dependent manner but had little impact on the infectivity of the wild-type 
virus, consistent with previous results (Figure 14A) (304, 305). Nef antagonism of SERINC5 
within this system is consistent with levels of virion-incorporated SERINC5 observed by 
immunoblot, with wild-type virions exhibiting decreased levels of SERINC5 compared to the 
∆Nef virions (Figure 14B). Co-transfection of an expression plasmid encoding Nef along with 
SERINC5 and the ∆Nef proviral plasmid rescued infectivity (Figure 14C) and promoted exclusion 
of SERINC5 from newly synthesized virions (Figure 14D). These observations validate the use of 
the 293T producer cell system to explore the role of Nef homodimerization in SERINC5-mediated 




Figure 14: Nef expression antagonizes SERINC5 restriction of viral infectivity at the producer cell level. 
A) 293T cells  were  co-transfected  with  HIV-1  NL4-3  proviral  plasmids competent  (wild-type)  or defective 
(∆Nef) for Nef expression along with 0, 25, or 50 ng of a SERINC5expression vector. Newly released virions were 
harvested after 48h, quantified via p24 AlphaLISA, and used to infect TZM-bl re-porter cells. Luciferase activity was 
measured 48 h later and normalized to that observed  with wild-type virus produced in the absence of SERINC5. Mean 
values ± SE are shown from three independent experiments. B) Representative western blot depicting incorporation 
of SERINC5-HA into wild-type and ∆Nef virions. Virions were collected in parallel during the infectivity assays and 
purified via ultracentrifugation through a  20%  sucrose  cushion,  lysed into sample  buffer,  subjected  to  SDS-
PAGE,  and immunoblotted using antibodies to p24 Gag and the HA tag on SERINC5. C) Viral antagonism of 
SERINC5 is rescued following ectopic expression of Nef within producer cells. The ∆Nef virus was expressed in 
293Tcells in the presence  and  absence  of  SERINC5  and  Nef  expression  plasmids.  Data are  presented  as  the  
fold  enhancement of viral infectivity, defined as the ratio of infectivity between Nef-expressing and Nef-deficient 
producer  cells.  Results represent  normalized  mean  values  ±  SE  from  three  independent  experiments.  D) 
Representative immunoblots displaying incorporation of SERINC5 into purified ∆Nef virions produced in the 
presence and absence of Nef. 
 
We next transfected 293T cells with HIV-1 proviral DNA bearing the Nef dimerization 
interface mutations L112A, L112D, Y115D, and F121A in the presence or absence of the 
SERINC5 expression vector. The infectivity of HIV-1 expressing the L112D, Y115D, and F121A 
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while the L112A mutant exhibited a partial loss of function (Figure 15A). This finding is consistent 
with BiFC results, showing that L112A has little impact on Nef homodimer formation in this 
system. Immunoblot analysis confirmed that each of the Nef mutants was expressed in transfected 
293T cells (Figure 15B). 
In a complementary set of experiments, we explored the role of Nef dimerization in 
SERINC5 antagonism using the Jurkat JTAg producer cell system, which expresses a relatively 
high level of endogenous SERINC5 like that observed in normal CD4 T cells.  An isogenic Jurkat 
JTag cell population in which both SERINC5 alleles are inactivated by CRISPR/Cas9 was studied 
in parallel (304).  Wild-type and SERINC5-knockout Jurkat T cells were transfected with HIV-1 
proviral constructs bearing the same Nef dimerization interface mutations, along with wild-type 
or ∆Nef HIV-1. The infectivity of the viruses expressing the L112D, Y115D, and F121A Nef 
mutants produced in wild-type Jurkat JTAg cells was reduced to that of the ∆Nef virus, consistent 
with the results in 293T producer cells co-expressing SERINC5. The infectivity of these Nef 
mutant viruses was restored when produced in the SERINC5-knockout cells, providing rigorous 
evidence of a SERINC5-dependent mechanism in this T cell line (Figure 15C). Wild-type HIV-1 
produced from either of the Jurkat producer cell lines displayed similar infectivity, consistent with 
the ability of wild-type Nef to antagonize SERINC5. Infectivity of the Nef-L112A mutant virus 
was unaffected by the presence or absence of SERINC5, consistent with the lack of an effect of 
this mutation on Nef self-association in the BiFC assay. Expression of wild-type and mutant forms 
of Nef in Jurkat producer cells was verified by immunoblot analysis (Figure 15D). 
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Figure 15: HIV-1 expressing dimerization-defective Nef mutants exhibit reduced infectivity 
A) 293T cells were  co-transfected  with  wild-type, ∆Nef, and dimerization-defective Nef  mutant  (L112A,  L112D, 
Y115D,  F121A) proviruses in  the  presence  and  absence  of  SERINC5,  and  infectivity of  equivalent  p24 inputs 
was analyzed 48 h later in TZM-bl reporter cells. Results from three independent experiments are shown normalized 
to the infectivity of wild-type virus produced in the absence of SERINC5 (Control). The horizontal bar represents the 
mean ±SE.B) Representative immunoblots verifying expression of wild-type and  dimerization-defective  Nef  mutants 
in  lysates  of transfected  293T  cells. Actin blots  are  shown  as  a loading control. C) Wild-type and SERINC5-
knockout Jurkat TAg T cells were transfected with wild-type, ∆Nef, and dimerization-defective Nef mutant 
proviruses. Infectivity of equivalent p24 inputs was analyzed 48 h later in TZM-bl reporter cells. Results from three 
independent experiments are shown normalized to the infectivity of wild-type virus produced in wild-type Jurkat cells. 
The horizontal bar represents the mean ±SE.D) Representative immunoblots  verifying  expression  of  wild-type  and  
dimerization-defective  Nef mutants in lysates of transfected Jurkat cells. Actin blots are shown as a loading control. 
E) PBMCs from uninfected donors were activated with PHA and IL-2 for three days, then infected with 150pgp24/mL 
of wild-type, ∆Nef, and Nef dimerization-defective mutant viruses for four days. Infectivity of equivalent p24 inputs 
of the resulting viral supernatants were analyzed 48 h later in TZM-bl reporter cells. Results from three independent 
experiments are shown normalized to the infectivity of wild-type virus. The horizontal bar represents the mean ±SE. 
76 
We also addressed whether Nef dimerization is important for infectivity of HIV-1 produced 
during a spreading infection in primary host cell culture. SERINC5-mediated restriction has been 
previously observed in donor PBMCs, which also express relatively high levels of endogenous 
SERINC5 (304, 305).  For this experiment, PBMCs were infected with equivalent titers of wild-
type, ∆Nef, and Nef dimer mutant viruses (initially produced in 293T cells) and allowed to 
replicate in PBMCs for 4 days followed by infectivity assay in TZM-bl cells. As observed in the 
other two producer cell systems, viruses expressing the Nef L112D, Y115D, and F121A mutations 
showed reduced infectivity comparable to that of the ∆Nef virus following amplification in 
PBMCs, with higher infectivity for wild-type and Nef-L112A HIV-1 (Figure 15E). 
We next investigated the requirement for Nef homodimers in the exclusion of SERINC5 
from newly synthesized virions. For these experiments, 293T cells were co-transfected with HIV-
1 wild-type, ∆Nef, and Nef dimerization-defective mutant proviral DNA in the presence of the 
SERINC5 expression plasmids. Newly synthesized virions were isolated and incorporation of 
SERINC5 was assessed by immunoblotting (Figure 16A). The amount of virus-associated 
SERINC5 was then normalized to p24 Gag levels from three independent experiments (Figure 
16B).  SERINC5 incorporation into virions mirrored the infectivity data, with the L112D, Y115D, 
F121A, and ∆Nef virions exhibiting significantly higher levels of SERINC5 than the wild-type 
and L112A viruses. These findings demonstrate that enhancement of HIV-1 infectivity requires 
Nef homodimers and involves a mechanism linked to antagonism of SERINC5 incorporation by 
Nef dimers at the producer cell level. 
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Figure 16: Dimerization-defective Nef mutants display attenuated exclusion of SERINC5 from newly 
synthesized virions 
293T cells were co-transfected with wild-type, ∆Nef, and Nef dimerization interface mutant proviruses (L112A, 
L112D, Y115D, F121A) in the presence of a SERINC5-HA expression vector. Newly synthesized  virions  were  
purified  by ultracentrifugation through  a 20%  sucrose  cushion,  and SERINC5 incorporation was analyzed via 
immunoblotting along with p24 Gag as a control. A) Representative SERINC5 and p24 immunoblots. B) SERINC5 
and p24 protein expression levels were quantified by LI-COR Odyssey image analysis, and each data point represents 
the SERINC5 to p24 expression ratio for three independent experiments. Mean values in each group are indicated by 
the horizontal bar ±SE. Statistical significance relative to  wild-type (WT) was determined by Student’s t-test (**, p≤ 
0.01; ****, p≤ 0.0001; ns, not significant). 
2.3.3 Nef homodimerization is required for SERINC5 internalization and endosomal 
trafficking. 
Previous studies have shown that Nef homodimers are required for CD4 downregulation 
(241, 308), a process that requires the endocytic trafficking adaptor protein, AP-2.  Nef-mediated 





















































































the cell membrane, resulting in endocytosis and lysosomal degradation (305, 307).  Here we 
demonstrate a clear increase in virion-associated SERINC5 with HIV-1 expressing dimerization-
defective Nef (Figure 16), suggesting that impaired exclusion of SERINC5 from virions expressing 
these Nef mutants was due to dysfunctional downregulation of SERINC5 from the producer cell 
surface. To address this issue, the Jurkat SERINC5-knockout cells were transfected with 
expression vectors for Nef (wild-type or dimerization-defective mutants) which also expresses 
GFP as a gating marker and for SERINC5 with a hemagglutinin (HA) epitope tag on one of the 
extracellular loops (266). Transfected cells were then immunostained with an anti-HA antibody to 
detect cell-surface SERINC5 expression in the Nef-transfected (GFP+) cell population via flow 
cytometry. Expression of wild-type Nef decreased cell-surface SERINC5 expression by nearly 
90% relative to the GFP-only control population. In contrast to wild-type Nef, the dimerization-
defective mutants L112D, Y1125D, and F121A all showed significantly impaired SERINC5 
downregulation, ranging from 65% to 85% relative to the control (Figure 17A and 17B).  The Nef-
L112A mutant was not affected, consistent with the lack of a dimerization defect observed with 
this mutant. These results demonstrate that Nef homodimers are required for efficient 
downregulation of SERINC5 from the cell surface.  
Because of the mechanistic similarity between Nef-induced downregulation of SERINC5 
and CD4, we also explored the impact of the Nef dimer interface mutations on downregulation of 
endogenous CD4 in the CEM-SS T cell line (314).  CEM-SS cells were transfected with the same 
Nef/GFP dual expression plasmid used for the SERINC5 study, followed by immunostaining for 
endogenous cell-surface CD4 and flow cytometry. Expression of wild-type Nef reduced cell 
surface CD4 expression by more than 60%, while the L112D, Y115D, and F121A Nef mutants 
were completely defective for CD4 downmodulation (Figure 18A and 18B). Cells expressing Nef-
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L112A exhibited an intermediate phenotype, with about a 30% reduction in cell-surface CD4 
expression. While the L112A mutant does not show a decrease in homodimer formation by BiFC 
assay, alteration of the dimer interface by this mutation may impact the efficiency of CD4 
downregulation. Overall, these results are in agreement with those observed with SERINC5 and 




Figure 17: Nef dimerization is required for SERINC5 downregulation 
SERINC5-knockout Jurkat T cells were  transfected  with  a  dual promoter plasmid  expressing wild-type  or 
dimerization-defective Nef mutants as well as GFP as a gating marker. A second plasmid was included for expression 
of SERINC5 tagged with an extracellular HA epitope (SERINC5-iHA). Forty-eight hours after transfection, cells were 
immunostained with an HA antibody and cell-surface expression of SERINC5-iHA was quantified via flow cytometry. 
A) Representative flow cytometry plots showing impaired downregulation of SERINC5 by Nef dimer mutants. Cells 
were  gated  on  the  untransfected  cell  population,  and  the  percentage  of  SERINC5-positiveand GFP-
positive(marker for Nef expression) cells are indicated. B) Each data point shows percentage of cells expressing 
surface SERINC5 within the Nef-positive (GFP-positive) cell population relative to the GFP-only control from three 
independent experiments. Mean values in each group are indicated by the horizontal bar ±SE. Statistical significance 
relative to wild-type (WT) was determined by Student’s t-test (*, p≤ 0.05;**, p≤ 0.01; ns, not significant). 
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Figure 18: Nef dimerization is required for CD4 downregulation 
CEM-SS cells were transfected with a dual promoter  plasmid expressing  wild-type  or  dimerization-defective  Nef  
mutants  as  well  as  GFP  as  a gating  marker.  Forty-eight hours  after  transfection,  cells  were  immunostained  
with  a  CD4  antibody  and cell-surface  CD4  expression  was  quantified  via  flow  cytometry.  A)  Representative 
flow  cytometry  plots showing  impaired  downregulation  of  CD4  by  Nef  dimer  mutants.  Cells were  gated  on  
the  untransfected CD4-positive cell population, and the percentage of Nef-expressing cells demonstrating 
downregulation of CD4 from the cell surface(CD4-negativeand GFP-positive) are indicated for each condition. B) 
Each data point shows CD4 cell surface expression normalized to surface CD4 expression in the absence of Nef (un-
transfected) for three independent determinations. Mean values in each group are indicated by the horizontal bar ±SE. 
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Following Nef-mediated endocytosis, SERINC5 traffics through Rab7+ late endosomes on 
route to proteolytic destruction following lysosomal fusion (304, 307).  We therefore investigated 
whether mutations disrupting Nef dimerization also impact the intracellular trafficking of 
SERINC5 along this pathway. SERINC5-knockout Jurkat cells were transfected with SERINC5 
fused to the mCherry fluorescent protein in combination with wild-type or dimerization-defective 
forms of Nef fused to YFP. Two days later, transfected cells were immunostained for the late 
endosomal marker, Rab7. The expression and subcellular localization of SERINC5-mCherry, Nef-
YFP, and Rab7 were then analyzed via confocal microscopy. When expressed alone, SERINC5-
mCherry localized almost entirely to the plasma membrane with very little co-localization with 
Rab7 (confocal images of representative cells are shown in Figure 19). Co-expression of wild-type 
Nef-YFP resulted in a dramatic shift in SERINC5-mCherry localization from the cell surface into 
the Rab7+ endosomal compartment, observed as the co-localization of SERINC5-mCherry, Nef-
YFP, and Rab7 fluorescence within multiple intracellular puncta. In marked contrast, the Nef 
dimer interface mutants, L112D, Y115D, and F121A all showed reduced intracellular targeting of 
SERINC5-mCherry, with both proteins retaining co-localization to the plasma membrane. Very 
few intracellular Rab7+ endosomes were observed with these three Nef mutants, consistent with a 
defect in endocytosis and intracellular trafficking. On the other hand, the Nef-L112A mutant 
displayed an intermediate phenotype, co-localizing with SERINC5-mCherry at the plasma 
membrane and in Rab7+ endosomes. 
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Figure 19: Nef dimerization is required for internalization of SERINC5 
SERINC5-knockout Jurkat T cells were co-transfected with expression plasmids for SERINC5-mCherry together with 
wild-type or dimerization-defective Nef mutants fused to YFP, or with the empty vector as a control. Forty-eight hours 
later, cells were  fixed,  permeabilized,  and  stained  with an  antibody to the late  endosomal  marker Rab7. 
Representative single cell images of SERINC5-mCherry (red), Nef-YFP (green), and Rab7 fluorescence are shown 
along with a merged image. Scale bar, 5 am. 
SERINC5-









Figure 20: Disruption of Nef dimerization impairs internalization and trafficking of SERINC5-mCherry to 
Rab7+ endosomes 
SERINC5-knockout Jurkat T cells were co-transfected with expression plasmids expressing  SERINC5-mCherry  
together  with  wild-type  or  dimerization-defective  Nef  mutants fused to YFP and immunostained with an antibody 
to the late endosomal marker Rab7 as described in the legend to Figure 8. A) Single cell confocal images were 
subjected to Pearson’s correlation coefficient analysis to quantify the extent of SERINC5-mCherry colocalization with 
Rab7. A minimum of 18-20 cells per condition were analyzed  across  three independent experiments, and the 
Pearson’s correlation coefficient for each cell is shown with the median value indicated by the horizontal bar. 
Statistical significance among the groups was performed via one-way ANOVA with Dunnett’s multiple comparisons 
test relative to the cell population  expressing  wild-type  (WT)  Nef (****, p≤ 0.0001). B) Pearson’s correlation 
analysis of SERINC5-mCherry co-localization with Nef-YFP was performed in the same groups of cells, with median 
correlation coefficients indicated by the horizontal bars. Statistical analysis via ordinary one-way ANOVA did not 
reveal significant differences between the groups. 
 
To quantify the extent of co-localization, Pearson’s correlations were calculated for co-
localization of the SERINC5-mCherry and Rab7 fluorescence for a minimum of 18 individual 
cells (Figure 20A). In the absence of Nef, the average Pearson’s correlation coefficient was 
approximately 0.1, indicating little correlation in terms of subcellular localization and consistent 
with the lack of SERINC5 internalization in the absence of Nef.  Co-expression of Nef resulted in 
a significant increase in the correlation coefficient (mean σ > 0.5), consistent with the observed 
trafficking of SERINC5 to late endosomes.  The correlation coefficient was significantly reduced 
with all four dimerization-defective Nef mutants compared to wild-type Nef, consistent with the 
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confocal images showing retention of SERINC5-mCherry at the plasma membrane. As a control, 
we also performed correlation analysis for the co-localization of Nef-YFP and SERINC5-mCherry 
fluorescence (Figure 20B). Notably, no significant difference was observed in these co-localization 
correlations (mean σ ≈ 0.9 in each case), hinting that the Nef dimer mutations may not affect 
interaction of Nef with SERINC5. This possibility was explored directly using BiFC as described 
in the next section. 
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2.3.4 Disruption of Nef homodimerization does not impair interaction with SERINC5 or 
AP-2. 
 
Figure 21: Nef dimerization is not required for interaction with SERINC5 or AP-2 
293T cells were co-transfected with expression plasmids for SERINC5, AP-2 α or AP-2 σ2 fused to an N-terminal 
fragment of  Venus  along  with  wild-type  Nef,  the  dimerization-interface  mutants  (L112A,  L112D,  Y115D  and 
F121A)  or  myristylation-defective  Nef  (G2A)  fused  to  the  complementary  C-terminal  Venus fragment. Cells 
were fixed, permeabilized, and immunostained 48 hours later for Nef and either SERINC5 or the AP-2 subunits prior 
to confocal microscopy. A) Representative BiFC images showing interaction of each Nef protein with  SERINC5  
(upper row),  AP-2α (middle), and AP-2 σ2(bottom). B) The mean  fluorescence intensities of BiFC and Nef 
immunofluorescence (IF) were calculated for a minimum of 100 cells within each pair using Image J. The distribution 
of BiFC:IF ratios for each cell population are plotted as box and whisker plots with the boxes showing the 25th to 75th 
percentiles and the whiskers showing the 10thto 90thpercentiles. Statistical analysis was performed via one-way 
ANOVA with Dunnett’s multiple comparisons test relative to  the  cell  population  expression  wild-type  (WT)  Nef 
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Previous work suggests that Nef and SERINC5 interact directly within cells, with Nef-
mediated antagonism of SERINC5 mediated by a large intracellular loop within SERINC5 (267, 
307). While an X-ray crystal structure of SERINC5 has been elucidated recently (263), electron 
density for this intracellular loop was not observed suggesting that it is unstructured.  Furthermore, 
the specific region of Nef responsible for interaction with SERINC5 is not known.  While data 
presented above support a role for Nef homodimers in SERINC5 downregulation, the possibility 
remains that the amino acids involved in Nef homodimer formation may also contribute to 
interaction with SERINC5. To test this possibility, we employed the BiFC assay to visualize and 
quantify direct interaction of Nef with SERINC5 in cells (307).  
SERINC5-VN and each of the Nef-VC fusion proteins (wild-type and mutants) were co-
expressed in 293T cells followed by immunostaining for Nef and SERINC5 (via the HA tag) to 
control for protein expression levels. As a negative control, we also included a mutant of Nef that 
cannot be myristoylated (Nef-G2A) and therefore exhibits impaired membrane localization and 
SERINC5 interaction (307).  Co-expression of wild-type Nef-VC with SERINC5-VN resulted in 
a positive BiFC signal, supporting direct protein-protein interaction in cells (Figure 21A). 
Immunofluorescence both for Nef and SERINC5 expression was also readily observed in the same 
cells and colocalizes with the BiFC signal (Figure 22). All four Nef-VC dimer interface mutants 
also generated a BiFC signal when partnered with SERINC5-VN, while the Nef-G2A mutant 
resulted in a lower BiFC signal despite a similar level of expression as wild-type Nef based on 
immunofluorescence.  To quantify these results, the fluorescence intensity for the BiFC signal of 
each Nef interaction with SERINC5 was normalized to Nef expression levels as determined by 
immunofluorescence, and the resulting fluorescence intensity ratios are plotted for at least 100 
cells in Figure 21B. No significant difference in SERINC5 interaction was observed between wild-
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type Nef and the dimerization-defective mutants, demonstrating that disruption of the Nef 
homodimerization interface does not affect interaction with SERINC5. In contrast, the Nef-G2A 
mutant showed a significant decrease in SERINC5 interaction, consistent with the inability of this 
mutant to localize to the plasma membrane. These observations suggest that impaired antagonism 
of SERINC5 by the Nef dimer mutants is not due to a defect in SERINC5 interaction with Nef.  
 
 
Figure 22: Interaction of dimerization-defective Nef mutants with SERINC5 
293T cells were co-transfected with expression plasmids for SERINC5 fused to an N-terminal fragment of Venus 
along with wild-type Nef, the dimerization-interface mutants (L112A, L112D, Y115D and F121A) or myristylation-
defective Nef (G2A) fused to the complementary  C-terminal  Venus fragment. Cells were  fixed,  permeabilized,  and 
immunostained 48  hours  later for  Nef and SERINC5 prior to confocal microscopy. Representative BiFC images 
show interaction of each Nef protein with SERINC5 (BiFC, top row), SERINC5 immunofluorescence (middle row), 
and Nef immunofluorescence (bottom row). 
 
Nef-mediated downregulation of SERINC5 also requires interaction with AP-2 through its 
α and σ2 subunits (222), resulting in endocytosis and lysosomal degradation.  Structural alignment 
described above shows that the dimer interface of Nef does not overlap with regions of AP-2 
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whether Nef dimer interface mutations affect AP-2 subunit interaction, we employed a similar 
BiFC approach in which each Nef protein was fused to the N-terminal fragment of Venus (Nef-
VN) while the AP-2 α and σ2 subunits were fused to the C-terminal fragment (α-VC and σ2-VC).  
The AP-2 fusion proteins also included a V5 tag for immunofluorescence detection as described 
previously (241).  Each AP-2-VC construct was co-expressed with the wild-type and mutant forms 
of Nef-VN in 293T cells, followed by immunofluorescence detection of protein expression and 
confocal microscopy. Wild-type Nef as well as the dimer interface mutants all exhibited 
membrane-localized BiFC signals when co-expressed with AP-2 α-VC or σ2-VC (Figure 21A).  
We then calculated normalized BiFC interaction ratios for Nef with each AP-2 subunit as described 
above for SERINC5 (Figures 21B).  The Nef L112A, L112D and F121A mutants interacted with 
each AP-2 subunit to the same extent as wild-type Nef, while the Y115D mutant ratio was 
somewhat reduced despite membrane localization. The Nef-G2A mutant showed a significant loss 
of interaction with both AP-2 subunits, consistent with its inability to localize to the plasma 
membrane. Expression of each Nef and AP-2 protein was confirmed by immunofluorescence 
microscopy, and representative images are presented in the Figures 23 and 24. These experiments 
show that amino acids present in the Nef dimer interface are not required for interaction with AP-
2 at the cell membrane, and support the idea that the defect in SERINC5 antagonism by these 




Figure 23: Interaction of dimerization-defective Nef mutants with the AP-2 α subunit 
293T cells were co-transfected with expression plasmids for AP-2 α fused to an N-terminal fragment of Venus along 
with wild-type Nef, the dimerization-interface mutants (L112A, L112D, Y115D and F121A) or myristylation-
defective Nef (G2A) fused to the complementary C-terminal Venus fragment. Cells were fixed, permeabilized, and 
immunostained 48 hours later for Nef and AP-2 α prior to confocal microscopy. Representative BiFC images show 
interaction of each Nef protein with AP-2 α (BiFC, top row), AP-2 α immunofluorescence (middle row), and Nef 
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Figure 24: Interaction of dimerization-defective Nef mutants with the AP-2 σ2 subunit 
293T cells were co-transfected with expression plasmids for AP-2 σ2 fused to an N-terminal fragment of Venus along 
with wild-type Nef, the dimerization-interface mutants (L112A, L112D, Y115D and F121A) or myristylation-
defective Nef (G2A) fused to the complementary C-terminal Venus fragment. Cells were fixed, permeabilized, and 
immunostained 48 hours later for Nef and AP-2 σ2 prior to confocal microscopy. Representative BiFC images show 
interaction of each Nef protein with AP-2 σ2 (BiFC, top row), AP-2 σ2 immunofluorescence (middle row),  and Nef  
immunofluorescence (bottom row). 
2.4 Discussion 
Antagonism of the host cell restriction factor SERINC5 is a key mechanism by which Nef 
promotes HIV-1 infectivity. Nef triggers internalization of SERINC5 from the surface of infected 
cells, thereby preventing incorporation of SERINC5 into budding virions and subsequent 
impairment of viral entry (304, 305).  While the cellular mechanisms of Nef-mediated SERINC5 
internalization and degradation have been established, little is known about the structural features 
of Nef required for SERINC5 engagement and association with AP-2 for downregulation. In this 
study, we assessed the function of dimerization-defective Nef mutants across all stages of 
SERINC5 antagonism including viral infectivity, virion incorporation of SERINC5, 
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downregulation of SERINC5 from the surface of producer cells, and the intracellular fate of 
SERINC5.  We observed consistent impairment of all stages of SERINC5 antagonism with three 
distinct dimerization-defective Nef mutants, demonstrating that Nef counteracts SERINC5 as a 
homodimer.  Importantly, each of the dimerization-defective Nef mutants retained interaction with 
both SERINC5 and the AP-2 subunits required for internalization, supporting the idea that the Nef 
homodimer may act as a bridge to link SERINC5 to the AP-2 pathway, as illustrated in Figure 25. 
 
 
Figure 25: Model of SERINC5 interaction and downregulation by HIV-1 Nef homodimers via AP-2-mediated 
endocytosis 
Myristoylated Nef associates with the host cell membrane and forms homodimers, allowing for simultaneous 
recruitment of  AP-2and  SERINC5  through  intracellular  loop  4  (ICL4). The resulting SERINC5•Nef•AP-2 complex  
drives downregulation  of  SERINC5  from  the  cell  membrane, thereby excluding it from budding virions. The 
complex traffics through Rab7+late endosomes leading to lysosomal degradation. 
 
Our data show that dimerization is required for Nef to promote the infectivity of newly 












SERINC5-dependent manner. These results may provide a mechanistic explanation for previous 
studies in which similar mutations were shown to influence viral infectivity. For example, 
substitution of Nef amino acids Leu112 and Phe121 has been shown to negatively impact HIV-1 
infectivity and replication (315), although the role of SERINC5 was not known at that time.  These 
same residues have also been linked to Nef recruitment of the endocytic GTPase Dynamin-2 as 
well as the human peroxisomal thioesterase 8 (315, 316), suggesting that Nef homodimer 
formation may affect these interactions as well. 
Our study demonstrates that Nef dimerization is required for SERINC5 downregulation 
from the cell surface, which is mechanistically like Nef-dependent downregulation of CD4. Both 
SERINC5 and CD4 downregulation are mediated via AP-2 and clathrin-dependent endocytosis. 
Mutations that disrupt Nef myristoylation and membrane association (G2A) as well as the 
dileucine motif required for AP-2 recruitment (LL164,165AA) impair downregulation of both 
proteins (231, 304, 317).  Nef dimerization-defective mutants impaired for downregulation of 
SERINC5 were also completely unable to downregulate cell-surface CD4. Expression of wild-
type Nef in Jurkat T cells led to the re-localization of SERINC5 from the cell membrane into 
intracellular Rab7+ compartments (307) a fate also shared by CD4 (318). Intracellular trafficking 
and Rab7 co-localization were also significantly disrupted by mutations in the Nef dimerization 
interface. These findings suggest that Nef homodimers may link both SERINC5 and CD4 to the 
AP-2 endocytic pathway through separate binding surfaces on each Nef monomer (Figure 25).  
Bimolecular fluorescence complementation assays presented here demonstrate direct 
Nef•SERINC5 interaction at the plasma membrane in cells, consistent with recent work (269, 307). 
Importantly, mutations in residues essential for Nef homodimer formation do not impact 
interaction of Nef with SERINC5 in the BiFC assay, consistent with a role for the Nef αB helix in 
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homodimer formation as demonstrated by X-ray crystal structures (309, 310) rather than 
interaction with signaling partners.  While the mechanism of SERINC5 engagement by Nef 
remains enigmatic, recent studies have illuminated the regions of SERINC5 required for viral 
restriction and susceptibility to Nef antagonism (263). SERINC5 is an integral membrane protein 
with ten trans-membrane helices and four intracellular loops (263).  Sensitivity of SERINC5 to 
Nef antagonism appears to map to the fourth intracellular loop, as deletion or replacement of this 
loop with the Nef-resistant SERINC2 counterpart renders SERINC5 immune to Nef 
downregulation (267).  However, whether this loop is sole point of contact in the Nef•SERINC5 
complex remains an important open question.  
The SERINC5 binding site within Nef also remains elusive. A recent structural study of 
SIVsmm Nef in complex with AP-2 and tetherin showed that mutation of a critical residue within 
the tetherin binding site (His196; analogous to HIV-1 Nef His166) also impairs antagonism of 
SERINC5, suggesting a shared binding site (231).  This residue is distal to the Nef αB helix 
required for self-association, consistent with the idea that Nef binds SERINC5 as a dimer. 
Nevertheless, a direct role for this binding site in HIV-1 Nef SERINC5 association remains to be 
confirmed, as the proposed binding site may be unique to SIV Nef. 
Though the binding site for SERINC5 within Nef remains to be identified, our BiFC data 
clearly show that conserved residues in the dimer interface are not required for SERINC5 
engagement. Nef dimer interface mutants L112A, L112D, and F121A also retained interaction 
with the AP-2 α and σ2 subunits via BiFC, consistent with the distinct interfaces for 
homodimerization and AP-2 recruitment illustrated by structural alignment in Figure 10C. 
However, the Nef Y115D mutant demonstrated statistically lower association with both AP-2 
subunits. While the Y115D mutation may impact Nef folding or overall stability, unimpaired 
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interaction of this mutant with SERINC5 suggests otherwise. Another possibility is that Tyr115 
may have an allosteric influence on the binding site for AP-2, given its proximity to the binding 
site. 
In summary, disruption of Nef dimerization attenuates SERINC5 antagonism without 
impairing recruitment of SERINC5 or AP-2 as required for internalization. While the protein 
dynamics controlling Nef-dependent SERINC5 downregulation remain a mystery, our data 
support a mechanism in which Nef homodimers promote Nef•SERINC5•AP-2 complex formation 
at some point prior to SERINC5 internalization. One Nef monomer within the dimer may contact 
SERINC5 while the other engages AP-2, with the Nef dimer interface bridging the two proteins to 
initiate clathrin-mediated endocytosis. Understanding the molecular determinants of SERINC5 
antagonism by Nef may help to identify therapeutic strategies that promote SERINC5 virion 
incorporation and restriction of viral infectivity. Along these lines, docking studies of small 
molecule inhibitors of Nef-mediated enhancement of viral infectivity have identified potential 
binding sites within the dimer interface (297, 319, 320).  Disruption of Nef homodimer formation 
by these compounds may explain their inhibitory effects on multiple Nef functions, including not 
only infectivity but also host cell kinase activation, receptor downregulation, and viral replication. 
Thus, the homodimer interface represents an attractive target for new antiretroviral drug 
development targeting Nef. 
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2.5 Materials and Methods 
2.5.1 Cell Culture 
The human embryonic kidney cell line 293T was purchased from the ATCC.  TZM-bl 
reporter cells were obtained from the AIDS Research and Reference Reagent Program. Both cell 
lines were grown in Dulbecco’s modified Eagle’s medium supplemented with 10% fetal bovine 
serum (FBS; Gemini Bio-Products).  Jurkat JTAg T cells (wild-type and SERINC5-knockout) 
were a kind gift from Dr. Massimo Pizzato, University of Trento, while the CEM-SS T cell line 
kindly provided by Dr. Mark Brockman, Simon Fraser University.  Both T cell lines were cultured 
in RPMI 1640 medium supplemented with 10% FBS, L-glutamine, and 2 µg/mL puromycin 
(CEM-SS cells only).  Donor PBMCs were obtained from Vitalant Pittsburgh and isolated by 
Ficoll gradient centrifugation and activated for 3 days with PHA (Sigma, # L1668) and IL-2 
(Thermo Fisher, # CB-40043B) as described elsewhere (319). 
2.5.2 Antibodies 
Primary antibodies were obtained from the AIDS Research and Reference Reagent 
Program (anti-p24, # 4121; anti-Nef polyclonal, # 2949; anti-Nef 6.2, # 153) and purchased from 
Sigma-Aldrich (anti-HA, # H6908), Millipore (anti-actin, # Mab1501R; anti-V5, # AB3702), BD 
(anti-CD4-phycoerythrin, # 55534), Biolegend (HA.11-647, # 16B12), and Santa Cruz (anti-Rab7, 
# B-3).  Secondary antibodies were purchased from LICOR (IRDye 680LT Donkey Anti-Mouse, 
# 926-68022; IRDye 800CW Donkey Anti-Rabbit, # 926-32213), Thermo Fisher (anti-mouse 
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Alexa Fluor647, # A-21236), Invitrogen (anti-rabbit Pacific Blue, # P-10994), and Southern 
Biotech (anti-mouse Texas Red, # 1031-07; anti-rabbit Texas Red, # 4050-7). 
2.5.3 Plasmids  
Construction of the pUC18 HIV-1 NL4-3/SF2Nef proviral plasmid is described elsewhere 
(321). The Nef dimer interface mutations (L112A, L112D, Y115D, F121A) were introduced into 
the pUC18 NL4-3/SF2Nef and pcDNA3.1 Nef-Venus (296) constructs via the Agilent II XL site-
directed mutagenesis kit.  Expression vectors for SERINC5 (pBJ5-SERINC5-HA and pBJ5-
SERINC5-iHA) were the kind gift of Dr. Heinrich Gottlinger, University of Massachusetts 
Medical School. The pSELECTzeoGFP-based expression plasmids for wild-type and dimer 
interface mutants of Nef have been previously described (296).  SERINC5-mCherry was 
purchased from GeneCopoeia.  The pcDNA3.1 SERINC5-VN-HA construct for BiFC was the 
kind gift of Dr. Yong-Hui Zheng, Michigan State University. Construction of BiFC expression 
plasmids for AP-2 subunits in pCDNA3.1 (σ2-V5-VC, α-V5-VC) as well as pcDNA3.1 Nef-YFP 
have been previously reported (241). 
2.5.4 HIV-1 replication and infectivity assays 
Human 293T cells were transfected with proviral expression plasmids using Xtreme Gene 
9 (Sigma-Aldrich) for 48 h prior to harvesting the viral supernatant.  Jurkat JTAg wild-type and 
SERINC5-knockout cells were transfected with proviral plasmids using the Amaxa Cell Line 
Nucleofector Kit V and the resulting viral supernatant was harvested 48 h later.  PBMCs were 
infected with 150 pg/mL of HIV-1 (wild-type, ∆Nef, and Nef mutants) for 4 days prior to assay.  
98 
HIV-1 titers in clarified supernatants from all producer cells were quantified using the PerkinElmer 
p24 AlphaLISA Detection kit.  Each viral supernatant (5,000 pg/mL p24) was then used to infect 
TZM-bl cells in 96-well plates (2.5 x 104 cells/well).  After 48 h, cells were lysed in Promega 
luciferase buffer, transferred to a white 96-well plate, mixed with luciferase reagent, and measured 
using a Biotek Cytation 5 plate reader. 
2.5.5 SERINC5 incorporation assay 
Viral supernatants from 293T cells co-transfected with proviral DNA and the SERINC5-
HA expression plasmid pBJ5-SERINC5-HA were clarified by centrifugation and HIV-1 virions 
were purified through a 20% sucrose cushion at 100,000 x g for 1 h at 4 °C.  The supernatant was 
carefully removed and virions were lysed directly in SDS-PAGE sample buffer (100 mM Tris-
HCl, pH 6.8, 5 mM TCEP, 10% glycerol, 4% SDS).  The viral lysates were heated to 37 °C for 15 
min, resolved on 4-20% SDS-PAGE gradient gels, transferred to nitrocellulose membranes, and 
incubated overnight at 4 °C with primary antibodies to HIV-1 p24 (mouse monoclonal, NIH 4121, 
1:1000) or the HA tag on SERINC5 (rabbit polyclonal, Sigma H6908, 1:500).  Blots were washed 
with Tris-buffered saline with 0.1% Tween-20 (TBST), then incubated for 2 h with Licor IR-Dye 
secondary antibodies (1:10,000).  Blots were imaged using the Licor Odyssey infrared imaging 
system and the Licor ImageStudio Lite software. 
2.5.6 Immunoblotting 
Jurkat and 293T producer cells were lysed 48 h post-transfection with RIPA buffer (50 mM 
Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 0.1% SDS, 1% sodium 
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deoxycholate) supplemented with protease inhibitors.  Lysate protein concentrations were 
quantified via Bradford assay (Bio-rad Bradford reagent) and normalized to 50 μg/mL.  Aliquots 
of each lysates were heated in SDS-PAGE sample buffer at 95 °C for 10 min, resolved on 12% 
SDS-PAGE gels, and transferred to nitrocellulose membranes.  Immunoblots were blocked for 1 
h with Superblock TBS Blocking Buffer (Thermo Fisher) then probed overnight at 4 °C with 
antibodies to Nef (anti-Nef polyclonal, # 2949, 1:500) or actin (1:5,000).  Following washes in 
TBST, blots were incubated for 2 h with Licor IR-Dye secondary antibodies (1:10,000) and imaged 
using the Licor Odyssey system and software. 
2.5.7 Flow Cytometry 
Jurkat SERINC5-knockout cells and CEM-SS cells were transfected with the pSELECT-
GFPzeo expression vector encoding wild-type and mutant forms of Nef, pSELECTGFPzeo alone 
and/or pBJ-SERINC5-iHA as described above.  Forty-eight h later, cells were washed in 1X 
Phosphate Buffered Saline (PBS) supplemented with 2% fetal bovine serum and stained for 1 h at 
ambient temperature with APC-conjugated anti-HA.11 (to detect SERINC5-HA) or 
phycoerythrin-conjugated anti-human CD4 antibody (both antibodies diluted 1:200).  After 
washing, cells were analyzed for GFP (to quantify Nef expression) and either HA (to quantify 
JTAg cell surface S5-iHA expression) or phycoerythrin (to quantify CEM-SS cell surface CD4 
expression) using a BD Accuri Flow Cytometer.  Data were analyzed via BD CSampler software 
and illustrated using the FlowJo software package. 
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2.5.8 BiFC and confocal microscopy 
293T cells were plated onto 35 mm coverslip-bottom dishes (MatTek, # P35G-1.5-14-C) 
and allowed to attach overnight. Cells were then transfected with pcDNA3.1 expression vectors 
encoding complementary BiFC partners using Xtreme Gene 9. Forty-eight h later, cells were fixed 
with 4% paraformaldehyde for 10 min, permeabilized with 0.2% Triton X-100 for 15 min and 
blocked with 2% BSA in PBS for 1 h.  Cells were then stained overnight at 4 °C with primary 
antibodies directed at the V5 tag, the HA tag, or Nef (#153). Following washing, cells were stained 
for 1 h with secondary antibodies conjugated to Texas Red (1:1000), Pacific Blue (1:500), or Alexa 
Fluor 647 (1:1000). Fluorescent images were acquired with an Olympus Fluoview FV1000 
confocal microscope using the 40x objective and x-y scan mode. Immunofluorescence and BiFC 
signal intensities were quantified via Image J and are represented as the ratio of BiFC to Nef 
immunofluorescence as reported previously (296). 
To assess co-localization of SERINC5 with Nef and Rab7+ endosomes, Jurkat JTAg 
SERINC5-knockout cells were transfected with SERINC5-mCherry and/or Nef-YFP (wild-type 
and dimer mutants) expression vectors as described above. Coverslip-bottom 35 mm dishes 
(MatTek) were treated with a 0.01% poly-L-Lysine solution (Sigma) for 1 h at 37 °C, and left to 
air-dry for 30 min. Transfected cells (1.2 x 106 in 200 µL of RPMI) were added to the poly-L-
lysine-treated coverslips for 30 min at 37 °C. Cells were then fixed with 4% paraformaldehyde for 
10 min, permeabilized with 0.2% Triton X-100 for 15 min, and blocked with 2% BSA in PBS for 
1 h at room temperature.  Cells were probed with a mouse monoclonal Rab7 antibody (1:1000) 
overnight at 4 °C, and then stained with an anti-mouse Alexa Fluor 647-conjugated secondary 
antibody (1:1000).  Cells were imaged using an Olympus Fluoview FV1000 confocal microscope 
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with a 60x oil objective and x-y scan mode.  Pearson’s correlation coefficients for co-localization 
were generated using the FV1000 Fluoview software. 
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3.0 Defining the structural basis of HIV-1 Nef dimerization in functional complexes with 
host cell effectors 
3.1 Chapter 3 Summary 
The HIV-1 accessory protein Nef plays a prominent role in viral pathogenesis, particularly 
through enhancement of viral replication and downregulation of cell surface MHC-I within 
infected cells. Both functions are reliant upon Nef activation of the Src family kinases Hck and 
Lyn, which requires Nef engagement of the kinase SH3 regulatory domain. Structures of Nef in 
the presence of Src family kinase SH3 domains show that Nef engages the SH3 domain via a 
conserved PxxP motif, and that the SH3-bound form crystallizes as a dimer of Nef:SH3 complexes. 
According to these structures, Nef homodimerization occurs at a hydrophobic interface between 
the αB helices of each Nef molecule and is additionally stabilized by a pair of reciprocal 
electrostatic contacts via Asp123 and Arg105. Validation of this structure via mutagenesis of dimer 
interface residues (including Asp123) supported that dimerization occurs in cells and is linked to 
kinase activation and several other Nef functions. However, comparison of this structure with one 
in which Nef was co-crystallized with the Hck SH3-SH2 regulatory domain protein challenged the 
idea that a single Nef dimer interface is constant across all stages of Nef-dependent kinase 
activation, as it revealed a distinct orientation of the dimer interface compared to what was 
observed for the SH3-bound structure. Comparison of the structures of the two complexes 
identified dimer interface residues with differential participation in the dimer interface of one but 
not both structures (e.g. Asp123), as well as dimer interface residues that appeared to contribute 
towards dimerization in both structures (Ile109, Leu112, Tyr115, His116). Recombinant purified 
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Nef proteins harboring substitutions at these residues were used to define the dynamics and 
stoichiometry of complex formation and dimerization in solution-based assays. We found that the 
mutation of Asp123 disrupted dimerization for a complex corresponding to the SH3 but not the 
SH3-SH2 bound structure, suggesting that the dimer interface is remodeled through distinct stages 
of Hck regulatory domain engagement. We also observed that Nef-Y115A mutation disrupted 
complex formation and Hck activation in vitro, supporting the notion that it may be a consistent 
contributor to dimerization within both Nef structures, and can be used as a dimerization defective 
mutant in future studies. 
3.2 Introduction  
HIV-1 Nef is a small myristoylated accessory protein that plays an important role in 
primate lentiviral pathogenesis (286). Expression of Nef within CD4+ T cells results in the 
induction of an AIDS-like phenotype within transgenic animal models (98), and non-human 
primates infected with Nef-defective strains of SIV display reduced viral titers and stunted AIDS 
progression (289). Finally, patients infected with Nef-defective HIV-1 often display reduced 
progression towards full-blown AIDS, further suggesting the importance of Nef in viral 
pathogenesis (290).   
Nef lacks any enzymatic activity, functioning instead by interacting with a variety of host 
cell proteins, hijacking host cell protein trafficking and signaling (130). One of the better 
characterized Nef functions is an inherent ability to activate host cell kinases, including the Src 
family kinases, Tec family kinases, p21-associated kinase (PAK), and phosphatidylinositol 3-
kinase (PI-3K) (136, 140, 148, 322). Nef-dependent activation of Src family kinases contributes 
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to Nef promotion of viral replication and spread in vivo, and pharmacologic inhibition or genetic 
knockdown of Src family kinases inhibits viral replication (252). Activation of Src family kinases 
via Nef is directed through a conserved polyproline type II (PPII) helix within the folded core of 
Nef. A PxxPxR motif within the PPII helix serves as a docking site for the SH3 domain of several 
Src family kinases, including Hck and Lyn (211). In the absence of Nef engagement, the SH3 
domain of these kinases associates with an internal linker region adjacent to the kinase domain, 
driving an inactive, auto-regulated conformation of the kinase (141). Nef binds and displaces Hck 
SH3 domain from this auto-inhibitory interaction, resulting in relief of Hck from the regulated 
conformation and kinase activation (140). 
Structures of the Nef core region bound to Src family kinase regulatory SH3 domains 
reveal a 2:2 heterocomplex, with two Nef molecules bound to two SH3 domains and joined by the 
Nef homodimer into a four molecule complex (206, 207). The Nef dimer interface forms between 
hydrophobic residues within the αB helix, which are flanked on either side by a pair of electrostatic 
interactions between Asp123 and Arg105 (206, 207) (Figure 7). Mutation of Asp123 and several 
hydrophobic residues impairs self-association of Nef in cells as well as Nef-mediated CD4 
downregulation and enhancement of viral replication, suggesting that the Nef dimer is of 
functional relevance (239). In addition, mutation of Asp123 impairs Nef downregulation of MHC-
I, a process that is mediated in part through the Src family kinases Hck and Lyn (101, 323).  
Our group successfully co-crystallized Nef in the presence of a larger, more functionally 
relevant regulatory domain protein including both the SH3 and SH2 domains of Hck (212). This 
structure also produced a 2:2 heterocomplex, although the orientation of the Nef dimer interface 
within this structure is unique compared to the Nef/SH3 domain structures (212)(Figure 8). While 
the formation of the dimer interface is still driven through the contribution of hydrophobic residues 
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within the αB helix, Asp123 and Arg105 do not interact within this structure, and Asp123 is both 
surface exposed and directed away from the dimer interface. A structure of Nef bound to an AP-1 
subunit and MHC-I tail has established a role for Asp123 in the coordinated recruitment of both 
the MHC-I and AP-1, suggesting that Asp123 must be exposed for Nef-directed downregulation 
of MHC-I (101). As a result, it is possible that kinase-directed remodeling of the Nef dimer from 
an SH3 domain-specific form to an SH3-SH2 domain form allows for Nef to transition into a 
conformation amenable to Asp123 presentation for AP-1 recruitment and MHC-I downregulation. 
While Asp123 and Arg105 do not appear to interact in either the SH3-bound or SH3-SH2-
bound Nef structures, analysis of the dimer interface for both structures reveals several amino acids 
that are present in both dimer interface structures, including Ile109, Leu112, Tyr115, and His116. 
While combined mutation of Ile109, Leu112, Tyr115, and F121 to aspartate shows complete 
ablation of kinase activation (252), the individual contribution of these hydrophobic residues 
towards kinase activation has not been explored. In addition, it has not been confirmed which 
dimer interface residues consistently participate in the dimer interface of both the SH3-bound and 
SH3-SH2 bound complexes.   
In this chapter, I discuss data from a collaborative study that provides support for transient 
participation of Asp123 in the dimer interface during kinase-induced remodeling, and discuss data 
characterizing a series of Nef dimer interface mutants in vitro.  
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3.3 Results 
3.3.1 Kinetics and dynamics of Nef association with Hck regulatory domain proteins  
To test the hypothesis that the Nef dimer interface is rearranged in transition through SH3-
bound and SH3-SH2 bound states, we produced recombinant full-length and core-length (amino 
acids 58-205) Nef protein (SF2 subtype), as well as recombinant Hck SH3 and Hck SH3-SH2 
protein (wild-type Nef and Hck regulatory proteins purified by John Jeff Alvarado). We also 
created a recombinant Nef core mutant in which Asp123, which is unique to the SH3-induced Nef 
dimer interface, is replaced with asparagine (D123N). This mutant allowed us to track the 
contribution of Asp123 to dimerization across both regulatory domain protein complexes by HDX 
MS as described below. 
Prior to analyzing the dynamics of complex formation and Nef dimerization, we measured 
the binding affinity of the Nef proteins towards recombinant Hck SH3 and SH3-SH2 domain 
proteins as a control. As SH3 domain engagement requires proper folding of the 3-dimensional 
Nef core (see Figure 6), any impairment of Nef folding by the D123N mutation would likely impair 
binding to either Hck regulatory domain protein. Therefore, we quantified the binding affinity with 
surface plasmon resonance (SPR), which is an optically based, label-free methodology used to 
measure the kinetics of molecular interactions in real time. 
In SPR, a sensor chip containing a high refractive index prism is inserted into the 
instrument’s flow channel, and a protein ligand is attached (often covalently) to the surface of the 
chip. Following immobilization of the ligand, a solution containing a putative binding partner (the 
analyte) is flowed over the sensor chip, and interaction between the analyte and immobilized ligand 
increases the mass at the surface of the sensor chip. This mass increase changes the refractive index 
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of polarized light passing through the prism, and that change is detected by an optical detector 
directed at the prism and transformed into arbitrary binding response units (RUs). Plotting these 
binding response units as a function of time generates a binding curve detailing association, steady 
state, and dissociation of two molecules in solution, which can be used to generate binding kinetics 
and affinity data for a given interaction (324). 
To measure the affinity of recombinant Nef with Hck SH3 and SH3-SH2, we covalently 
immobilized the SH3 and SH3-SH2 proteins onto a carboxymethyl dextran SPR chip, and injected 
increasing concentrations of different Nef proteins (0.04 to 3.3 μM) onto the chip surface. Both 
wild-type Nef and Nef-D123N bound to Hck SH3 and SH3-SH2 with submicromolar affinity, 
suggesting that the D123N mutation does not impact Nef global structure or impair recruitment of 
Hck regulatory domain proteins (Figure 26). Interestingly, there was little appreciable difference 
in binding affinity between the recombinant Nef core protein and full-length Nef, suggesting that 
the N-terminal anchor region does not participate in this interaction (at least in solution and in a 
non-myristoylated form).  
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Figure 26: Kinetics of Nef wild-type and D123N protein interactions with Hck SH3 and SH3-SH2 domains 
Protein-protein interactions were measured in real time by surface plasmon resonance (SPR). Recombinant Hck SH3 
and SH3-SH2 proteins were immobilized covalently as ligand on carboxymethyl dextran SPR chips (Reichert) using 
standard EDC/NHS amine coupling chemistry. Nef proteins were then injected in triplicate over a range of 
concentrations (0.04 to 3.3 μM) at a flow rate of 30 μL/min for one min until equilibrium was reached, followed by a 
3 min dissociation phase. Kinetic rate constants were calculated from reference-corrected sensorgrams using 
TraceDrawer software, and were best fit by 1:1 Langmuir (SH3) or two-state (SH3-SH2) binding models. Equilibrium 
dissociation constants (KD values) calculated from the resulting rate constants are shown, ± S.D. N/A, not applicable. 
Representative sensorgrams from each experiment are shown below the Table. The SPR responses recorded at each 
concentration are shown as colored points, with the fitted curves superimposed as black lines. 
 
With the kinetics of Nef association with Hck SH3 and SH3-SH2 established, we next 
studied the dynamics of complex formation in solution using HDX-MS (see Section 1.2.5.2 for an 
overview of this method). We compared deuterium exchange between the wild-type Nef core alone 
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with wild-type Nef core co-purified as a stable complex with the Hck SH3 or SH3-SH2 domain 
proteins. Co-purification was performed by John Jeff Alvarado (Smithgall laboratory), and HDX 
MS studies were performed and analyzed by Jamie Moroco and Thomas Wales (laboratory of John 
Engen, Northeastern University) (244). Comparison of deuterium uptake between the Nef core 
alone vs. the Nef core bound to Hck regulatory domain proteins displayed early protection of the 
PxxP helix of Nef for both complexes, followed by additional protection within the αB helix at 
longer time points (Figure 27). This result is consistent with the crystal structures of the SH3- and 
SH3-SH2-bound Nef complexes (207), as it demonstrates PxxP-dependent engagement of the SH3 








Figure 27: HDX MS analysis demonstrates stabilization of the Nef dimer via kinase regulatory domain 
engagement 
a) Comparison of deuterium uptake by Nef core alone versus the core complex with Hck SH3 (left) or SH3-SH2 
(right) is presented in a vertical difference map of the Nef core secondary structure. The deuterium level in each 
peptide from the Nef core alone was subtracted from those recorded from each complex and the differences are color-
coded as indicated in the legend. The differences in non-overlapping peptides, displayed vertically from N- to C-
terminus, are indicated for the corresponding exchange times (10 s to 4 h; shown horizontally). Greater protection is 
represented as a more intense shade of blue. (b) Deuterium incorporation graphs for selected peptides i, ii, iii, iv. 
Uptake curves from Nef core peptides are shown in black, Nef core:SH3 complex peptides are shown in blue, and Nef 
core:SH3-SH2 complex peptides are shown in red. (c,d) The protection observed in Nef when bound to Hck SH3 (c) 
or Hck SH3-SH2 (d) after 10 s (left) or 4 h (right) of deuterium exchange is mapped onto the corresponding crystal 
structures as indicated. 
3.3.2 Conformation of Nef dimer interface is distinct in the presence of Src family kinase 
SH3 and SH3-SH2 regulatory domain engagement 
After determining the kinetics and dynamics of wild-type Nef association with Hck SH3 
and SH3-SH2, we next determined whether Nef-D123N impacts the dynamics of complex 
formation in solution (HDX MS performed by Jamie Moroco and Thomas Wales). Deuterium 
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exchange kinetics were compared between the D123N Nef core protein alone and in complexes 
with either Hck SH3 or SH3-SH2. For the SH3-bound complex, the D123N mutation displayed 
no deuterium uptake protection within the αB helix, in stark contrast to the protection observed 
within the wild-type Nef complex (Figure 28). In contrast, the Nef-SH3-SH2 domain complex 
displayed reduced deuterium exchange within peptides derived from the αB helix, similar to the 
results with wild-type Nef in this complex. Peptides derived from the PxxP interface of the SH3-
bound D123N Nef core complex also showed reduced protection when compared to the wild-type 
complex, a surprising result considering the similar affinity of both Nef proteins observed in Figure 
26. Still, the dynamics observed within this study support the crystal structures of the SH3 and 
SH3-SH2 bound Nef complexes, wherein Asp123 participates within the SH3-bound but not the 





Figure 28: HDX MS reveals that Nef D123N mutation impairs dimer formation for Hck SH3-bound but not 
Hck SH3-SH2-bound complex 
(a) Comparison of deuterium uptake by the Nef-D123N core alone versus Nef-D123N in complex with Hck SH3 (left) 
or Hck SH3–SH2 (right) is presented in a vertical difference map of the Nef core secondary structure. The deuterium 
level of each peptide from Nef-D123N alone was subtracted from that in Nef-D123N when part of a complex and the 
differences are color coded as indicated in the legend. The differences in non-overlapping peptides are displayed 
vertically from N- to C-terminus for each exchange time point (10 s to 4 h; shown horizontally). Greater protection is 
represented as a more intense shade of blue. The location of the D123N mutation is indicated in orange on the 
difference maps and the structures in panel d. (b) Deuterium incorporation graphs for selected peptides i, ii, iii, and 
iv. Uptake curves from Nef-D123N core peptides are shown in black, Nef-D123N core:SH3 complex peptides are 
shown in blue, and Nef-D123N core:SH3–SH2 complex peptides are shown in red. (c, d) The protection observed in 
Nef-D123N when bound to Hck SH3 (c) or Hck SH3–SH2 (d) after 10 s (left) or 4 h (right) of deuterium exchange is 
plotted onto the corresponding crystal structures as indicated. Protection in the Nef-D123N αB helix is only observed 
in the complex with Hck SH3–SH2.  
 
The stoichiometry of the Nef/Hck regulatory domain complexes was also analyzed via 
size-exclusion chromatography (SEC). Wild-type and D123N Nef core proteins were co-purified 
in the presence of Hck SH3 or Hck SH3-SH2 domain, and then injected onto an analytical size 
exclusion column (worked performed by John Jeff Alvarado). SEC of the wild-type Nef/SH3-SH2 
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domain complex resulted in an elution volume consistent with a 2:2 heterocomplex, as confirmed 
by multi-angle light scattering in a previous study (212). The D123N Nef/SH3-SH2 domain 
complex eluted in a similar volume as the wild-type Nef complex, suggesting that the D123N Nef 
complex is of a similar size and composition (Figure 29). However, the complex composed of Nef 
D123N and Hck SH3 domain alone resulted in a doublet in which one peak matched the elution 
volume of the wild-type Nef/Hck SH3 heterodimeric complex, and another peak matched 
monomeric Nef. This result supports the dynamics of the D123N Nef seen in Figure 28 and the 
notion that Asp123 participates in the SH3 domain-bound, but not the SH3-SH2-bound, complex. 
These findings further suggest that Asp123 may participate in the dimer interface during an initial 
stage of Hck engagement that involves SH3 domain binding but is then reorganized within the 








Figure 29: Analytical size-exclusion chromatography of Nef:Hck complexes 
Part (a) shows size-exclusion chromatography (SEC) elution profiles of the purified Nef core: Hck SH3 complex, the 
Nef-D123N:Hck SH3 complex, and individual proteins making up the complexes. Part (b) shows SEC elution profiles 
of the purified Nef core: Hck SH3-SH2 complex, the Nef-D123N:Hck SH3-SH2 complex, and individual proteins 
making up the complexes. The positions of the elution peaks for the protein standards bovine serum albumin (66 kDa), 
carbonic anhydrase (29 kDa), cytochrome C (12.5 kDa) and aprotinin (6.5 kDa) are indicated with grey dotted lines. 
The positions of the Nef core complexes with SH3 and SH3-SH2 are also indicated on the plots for reference (green 
dotted lines). Note that the stoichiometry of an identical Nef core complex with the Hck SH3:SH2 protein was 
previously determined by SEC combined with multi-angle light scattering to be a dimer of complexes  
3.3.3 Identification of conserved Nef dimerization interface residues  
While the participation of Asp123 in Nef dimerization is unique to the SH3-bound state, a 
commonality between both structures is the presence of a dimer interface composed of several 
highly conserved, hydrophobic residues (modeled in Figure 30). The side chains of residues 
Ile109, Leu112, Tyr115, His116, and Phe121 participate directly in dimerization in both crystal 
structures, either by projecting directly into the hydrophobic interface or through external dimer-
stabilizing interactions (engagement of Val70 in the SH3-SH2 domain dimer). Leu112, Tyr115, 
and Phe121 have been well characterized as participating in dimerization (Chapter 2), and 
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mutation of these residues disrupts Nef dimerization and function. Meanwhile, the individual roles 
of Ile109 and His116 in dimerization (both in solution and in cells) have not yet been examined.  
However, the dynamics and individual contribution of all five residues towards dimerization 
during Hck regulatory domain engagement remains an open question.  
Therefore, in order to compare the contribution of dimer interface residues on Hck 
regulatory domain engagement and complex formation in solution, we expressed and purified four 
recombinant Nef mutants I109A, L1112A, Y115A, and H116A. While substitution of these 
residues with aspartate or another charged residue was considered, we decided that alanine 
substitution may allow us to study the individual role of each residue’s side chain without gross 







Figure 30: Comparison of the SH3-bound and SH2-SH3-bound Nef dimer interfaces 
(A) List of Nef residues which participate in dimerization within two structures of the dimer interface (shown in B,C, 
PDB 1EFN and 4U5W, respectively). Side chains which participate in one dimer structure are highlighted in green 
boxes, while side chains that contribute to dimerization are highlighted in blue boxes and red text (Ile109, Leu112, 
Tyr115, His116, Phe121). (B) View of the Nef dimer interface for the HckSH3-bound structure. Side chains of Ile109, 
Leu112, Tyr115, His116, Phe121 form a hydrophobic interface between each Nef αB helix (C) View of the Nef dimer 
interface for the HckSH3-SH2-bound structure. Side chains of Ile109, Leu112, Tyr115, His116, Phe121 contribute 
towards the hydrophobic interface, or coordinate clasping of Val70 presented by the opposite Nef monomer (Leu112, 
Tyr115, Phe121). Models were produced in PyMOL (PDB 1EFN and 4U5W). 
3.3.4 Affinity of Nef dimer mutants for Hck SH3 and SH3-SH2 regulatory domain proteins 
Prior to examining the impact of these dimer interface mutations on Nef dimerization and 
complex formation in solution, we first wanted to characterize their possible effect on Hck SH3 
and SH3-SH2 domain binding. As nearly all of these residues are conserved across subtypes of 
Nef (>95% for Ile109, Leu112, Tyr115, ~60% for His116) (325), there is still a chance that 
substitution of these residues could impact Nef global structure. In order to confirm productive 
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folding of these Nef mutants and understand the kinetics of regulatory domain engagement, we 
immobilized Hck SH3 or SH3-SH2 domain onto SPR sensor chips and flowed Nef wild-type and 
mutant protein over the immobilized ligands as before. All Nef mutants associated with Hck SH3 
and SH3-SH2 domain proteins with micromolar-to-submicromolar affinity (Figure 31), with the 
affinities of wild-type Nef and several of the mutants in a similar range as previously reported 
interactions (244). The KD’s of the I109A and L112A mutants were similar to wild-type Nef for 
both the Hck SH3 and SH3-SH2 domains, while Nef H116A affinity was about 2-fold lower than 
wild-type Nef. Though Nef Y115A still displayed functional association with Hck SH3 and SH3-
SH2 domain, the affinity of that mutant was about 5-fold lower than wild-type Nef, suggesting a 
potential allosteric impact of this mutation on SH3 domain recruitment. These data demonstrate 
that substitution of individual dimer interface residues with alanine does not markedly impact Nef 
association with Hck regulatory domain proteins, suggesting a preservation of Nef global structure 
for these mutant proteins.  
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Figure 31: Binding affinity of Nef dimer interface mutants towards Hck regulatory domain proteins 
Protein-protein interactions were measured in real time by surface plasmon resonance (SPR). Recombinant Hck SH3 
and SH3-SH2 proteins were immobilized covalently as ligand on carboxymethyl dextran SPR chips (Reichert) using 
standard EDC/NHS amine coupling chemistry. Nef proteins were then injected in triplicate over a range of 
concentrations (0.04 to 3.3 μM) at a flow rate of 30 μL/min for one min until equilibrium was reached, followed by a 
3 min dissociation phase. Steady-state affinities were calculated from reference-corrected sensorgrams using 
TraceDrawer software, and Equilibrium dissociation constants (KD values) are shown, ± S.D. Representative 
sensorgrams from each experiment are shown below the Table. The SPR responses recorded at each concentration are 
shown as colored points. 
3.3.5 Impact of Nef dimer mutations on 2:2 heterocomplex formation in solution 
Having characterized the affinity of these Nef dimer mutants toward the Hck SH3 and SH3-
SH2 domain proteins, we next determined whether mutation of individual dimerization interface 
side chains was sufficient to disrupt formation of the Nef dimer and 2:2 heterocomplex in solution. 
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We mixed each recombinant Nef protein with an equimolar ratio of Hck SH3 or SH3-SH2 protein, 
and injected these complexes onto an analytical size exclusion column. Injection of the wild-type 
Nef complexed with Hck SH3 and SH3-SH2 domain resulted peak elution volumes of about 10 
mL and 10.5 mL (respectively) (Figure 32). The elution volume of these peaks was lower but 
within a similar range to those observed for complexes of the wild-type Nef core with SH3 and 
SH3-SH2 proteins (244), suggesting the presence of 2:2 heterodimeric complexes in the presence 
of full-length Nef. The somewhat lower elution volume is likely accounted for by the higher mass 
of full-length Nef protein.  
Analysis of the elution profiles for the I109A, L112A, and H116A Nef proteins revealed 
complexes which are of a similar size as the wild-type complex, potentially signifying the 
preservation of Nef dimerization and 2:2 heterocomplex formation in the presence of these mutants 
(compare the peak positions of the black and blue elution profiles of each complex in Figure 32). 
However, complexes of Nef-Y115A with both the SH3 and SH3-SH2 domains resulted in a clear 
rightward shift in the elution volume, consistent with disruption of complex formation.  The 
simplest interpretation of these results is that the Y115A mutation disrupts formation of the dimer 
complex, with 1:1 Nef-Y115A:SH3 and Nef-Y115A:SH3-SH2 complexes eluting from the 
column.  In either case, no free SH3, SH3-SH2, or Nef is seen, suggesting that Nef remains bound 
to SH3 under these conditions despite the somewhat lower affinity measured by SPR.  Thus, the 
Nef-Y115A mutant may represent a very useful tool to study the importance of Nef homodimer 
formation in solution, because it disrupts Nef dimer formation even in complex with SH3-SH2. 
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Figure 32: Analytical size-exclusion chromatography of Nef dimer mutants with Hck regulatory domain 
complexes 
Size-exclusion chromatography profiles of Nef proteins mixed with either (A) HckSH3 or (B) HckSH3-SH2. Elution 
of wild-type Nef complex and wild-type Nef alone are denoted by black and grey curves, respectively. Mutant Nef 
elution profiles (in complex and in isolation), are indicated by blue and cyan curves, and the identity of each Nef 
mutant is indicated above each panel. Proteins were injected onto the analytical SEC column at 12.5uM, and 
complexes were mixed 1:1 at equal molar ratios for 15min prior to injection. Previously determined elution profiles 
of standards bovine serum albumin (66 kDa), carbonic anhydrase (29 kDa), cytochrome C (12.5 kDa) and aprotinin 
(6.5 kDa) are indicated with gold dotted lines. 
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3.3.6 In vitro activation of the Src-family kinase Hck by Nef dimer interface mutants 
Nef engagement of Hck results in the release of the kinase from an auto-inhibitory 
conformation (stabilized by self-association with the SH3 and SH2 domains), and subsequent 
activation of the kinase (139). The presence of the Nef dimer within the Hck SH3- and SH3-SH2-
bound crystal structures supports the notion that dimerization may play an important role in kinase 
activation, which is supported by cellular data implicating Nef dimerization in the activation of 
both Src and Tec-family kinases (149, 240). Analysis of Hck SH3 and SH3-SH2 engagement and 
complex formation described above allowed for an early glimpse into the role of individual Nef 
dimer interface residues in Hck recruitment, but we were curious how each Nef mutant would 
impact Hck activation itself.  
Therefore, we used an in vitro kinase assay (Z’-Lyte Kinase Assay) to compare the degree 
of Hck activation displayed by each Nef mutant. This assay utilizes a FRET-peptide substrate 
flanked on either side by a donor (coumarin) and acceptor (fluorescein) fluorophore, which are 
positioned at a distance that allows for productive fluorescence resonance energy transfer (FRET). 
In the absence of phosphorylation, this substrate is sensitive to digestion by a specific protease, 
disrupting FRET within the substrate. As a result, kinase activation can be quantified by measuring 
the preservation of FRET following substrate phosphorylation and protease digestion.  
In a cellular context, Hck is self-regulated via SH2 engagement of a pTyr motif within the 
C-terminal tail, and phosphorylation of this Tyr residue is performed by the host cell tyrosine 
kinase Csk (139). For in vitro kinase assay, we use a form of recombinant Hck in which the C-
terminal tail sequence adjacent to the Csk site is modified to pTyr-Glu-Glu-Ile (Hck-YEEI)(326, 
327).  When expressed in insect cells and purified, this form of Hck retains the ‘assembled’ 
conformation, with the tyrosine-phosphorylated tail bound to the SH2 domain and the SH3 domain 
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engaged with the SH2-kinase linker as shown by X-ray crystallography and HDX MS.  Previous 
studies from our group have shown that Hck-YEEI is readily activated by recombinant Nef (142) 
(252). 
As previously observed, incubation of wild-type Nef with Hck-YEEI promoted activation 
of the kinase. This is indicated by a leftward shift in the kinase activation titration curve and a 
decrease in the reported EC50 value for the “Hck and WT Nef” condition when compared to “Hck 
alone” (Figure 33). Compared to wild-type Nef, the I109A, L112A, and H116A Nef mutants 
activated Hck-YEEI to a similar extent, suggesting these mutations had no clear impact on Nef-
dependent kinase activation. However, Nef-Y115A demonstrated a 2-fold reduction in kinase 
activation compared to wild-type Nef and the other mutants, suggesting a critical contribution of 
the Tyr115 residue towards kinase activation.  The defect in Hck activation by Nef-Y115A may 
reflect its inability to form dimers, its reduced capacity for SH3 domain engagement, or a 
combination of both factors.  
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Figure 33: Y115A Nef displays reduced kinase activation in vitro 
Hck alone or Nef and HckYEEI at a 10:1 molar ratio were titrated across a series of 2-fold dilutions and incubated 
with ATP and a FRET-based tyrosine substrate to measure substrate phosphorylation/kinase activation (see methods, 
Section 3.5.7). Kinase activation was measured in quadruplicate and normalized to unphosphorylated and fully 
phosphorylated peptide controls. Degree of kinase activity for each Nef/Hck condition across increasing quantities of 
Hck is presented ± S.D. via protein titration curves (colored curves). Nef activation of Hck is indicated through a 
leftward shift in the kinase activation curve when compared to Hck alone (black curve). EC50 values (per ng of Hck) 
were calculated by non-linear regression analysis of the “Hck alone” and “Hck + Nef” curves. Assay was repeated in 
quadruplicate across two independent experiments.  
3.4 Discussion 
Dimerization is a consistent structural feature of Nef, one that has been observed in cells, 
in solution, and in structures of Nef co-crystallized with SH3 domains and the Hck SH3-SH2 
regulatory region (149, 206, 212, 239). However, while the overall fold of the Nef core remains 
constant in complexes with different effector proteins (Figure 34), the orientation and contribution 
of individual residues to the dimer interface varies dramatically between the SH3- and SH3-SH2-
bound structures of Nef. Indeed, a key electrostatic contact for the SH3-bound Nef dimer (Asp123) 
becomes surface-exposed in structures of Nef in complex with HckSH3-SH2 or AP-1/MHC-I, 
suggesting the orientation of the dimer interface is dynamically remodeled during transition from 
SH3 to SH3-SH2 domain engagement. To test this hypothesis, we tracked the impact of dimer 
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interface mutations (both Asp123 and hydrophobic interface residues) on complex formation 
across both the SH3- and SH3-SH2-bound conformations of the Nef dimer.  
 
 
Figure 34: Global fold of the Nef core is conserved across protein partners 
Folding of Nef core protein from three separate crystal structures- Nef:SH3 (PDB: 1EFN), Nef:SH3-SH2 
(PDB:4U5W), and Nef:AP-1μ1/MHC-I tail (4EMZ). Alignment of the Nef core from each complex (performed via 
PyMOL) shows preservation of global overall fold of the Nef core structures across distinct structures despite 
association with different partners. 
 
Our data support the existence of Nef dimers within the Hck SH3- and SH3-SH2-bound 
structures of Nef. Comparison of solution dynamics between Nef alone vs. Nef in complex with 
SH3 vs. SH3-SH2 by HDX MS showed increased protection of the αB helix from deuterium 
uptake for complexed Nef, consistent with promotion of dimerization in solution. Analysis of these 
complexes via size-exclusion chromatography also supported Nef dimerization, with elution 
profile consistent with 2:2 heterodimeric complexes. This is consistent with prior validation of 
SH3 and SH3-SH2 bound structures of Nef, which confirmed the presence of the Nef dimer in 
solution across several biochemical and/or biophysical methods as described in the Introduction 
(197, 212). 
Distinct orientation of the Nef dimer interface in the presence of SH3 vs. SH3-SH2 domain 
proteins may represent individual stages of Hck engagement. Primary recruitment of Hck SH3 by 
Nef may initiate an initial SH3-specific conformation of the dimer, which is reorganized into a 
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different interface following participation of the SH2 domain within the complex. Analysis of the 
dynamics for these complexes leaves room for this possibility, as it reveals a temporal order for 
Hck engagement in solution. Deuterium protection at the Nef PxxP motif (suggesting SH3 
engagement) occurs at the earliest labeling times for both complexes, while protection within the 
αB helix (consistent with Nef dimerization) appears later in the assay.  However, the relatively 
slow rate of deuterium uptake by the helical interface may also reflect hydrogen bonding within 
the αB helix. 
Analysis of the D123N mutant also supports the transition of Nef through two distinct 
dimer interfaces during Hck SH3 and then SH3-SH2 engagement, and complements the different 
positions assumed by this residue within each Nef dimer structure. While introduction of the 
D123N mutation had no impact on the kinetics of SH3 or SH3-SH2 association, protection from 
deuterium uptake observed at the dimer interface with the wild-type Nef-Hck SH3 complex was 
eliminated for the Nef-D123N:SH3 complex. Introduction of this mutation also seemed to 
destabilize complex formation as observed by size-exclusion chromatography. Meanwhile, the Nef 
D123N/Hck SH3-SH2 complex eluted at the same volume as the wild-type complex, and 
protection at the αB helix was still evident for the mutant complex. This supports the existence of 
two structurally separate dimer interfaces, only one of which is dependent upon the Asp123-
Arg105 ionic interactions observed by X-ray crystallography. 
To track the contribution of hydrophobic dimer interface residues to dimerization within 
Hck SH3 and Hck SH3-SH2 bound complexes, we developed four recombinant Nef mutants 
(I109A, L112A, Y115A, H116A). We considered that this mutagenesis strategy which involved 
the substitution of these bulkier hydrophobic residues with alanine would allow us to study the 
contribution of these residues without disrupting other dimer interface residues or dramatically 
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impacting Nef global structure. For three of the Nef mutants (I109A, L112A, H116A), alanine 
substitutions had little impact on Nef dimerization or complex formation, with each mutant 
displaying similar affinity for SH3 binding via SPR and Hck activation compared to wild-type 
Nef. This may not be particularly surprising for the I109A and L112A Nef mutants, as the change 
in residue size is not as dramatic as what is expected for Nef-His116 or Nef-Tyr115. It is also 
possible that elimination of bulky hydrophobic side chains from one of these three residues is not 
enough to weaken the overall dimer interface, especially when Nef is complexed to the Hck SH3-
SH2 domain protein (see Figure 8).  In this case, alanine substitution of a single residue may not 
be sufficient to disrupt the entire interface. Creation of Nef mutants with alanine substitutions at 
least two dimer interface residues may allow for a more complete disruption of the Nef dimer. 
Also, while this study was performed prior to the experiments detailed in Chapter 2, the very 
limited impact of the L112A substitution on Nef dimerization and function observed in these 
experiments is consistent with what was observed for this mutant in cellular studies (Figure 12 and 
Figure 13). 
In contrast, the Nef Y115A mutation appeared to have a noticeable impact on both Hck 
SH3 and SH3-SH2 complex formation in solution and displayed a functionally impaired ability to 
activate Hck-YEEI compared to wild-type Nef. While it is tempting to speculate that mutation of 
Tyr115 disrupts dimerization in complexes with both Hck SH3 and SH3-SH2, (thus impairing 
Nef-dependent Hck activation), the exact stoichiometry of the resulting Y115A complex is needed 
to confirm this notion. In addition, this idea is confounded by the apparent impact of this mutation 
on Hck SH3 and Hck SH3-SH2 domain affinity, which is around 5-fold lower than what is 
observed for wild-type Nef.  
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In future work, we plan to use HDX-MS to characterize the dynamics of dimerization 
within complexes of Nef bound to Hck SH3 and Hck SH3-SH2 for these and similar dimer 
interface mutations. While a Nef Phe121 mutant was not included within this study, the 
contribution of this residue to both Nef dimer interface structures suggests it is worth further 
investigation. We also hope to further understand the full mechanistic basis behind the phenotype 
demonstrated by Nef-Y115A, starting with confirmation of the stoichiometry of the Y115A 
complex via size-exclusion chromatography with multi-angle light scattering. As Nef dimerization 
appears to be a critical component of Nef-dependent Src family kinase activation (and by 
extension, MHC-I and viral replication), building a complete understanding of the dynamics and 
structure of Nef dimerization during Nef function could allow for development of antiretroviral 
agents with broad activity against Nef in the future. 
3.5 Methods  
3.5.1 Bacterial expression vector construction (adapted from Moroco 2017) 
The bacterial expression plasmids encoding the C-terminally His6-tagged human Hck 
SH3–SH2 tandem regulatory domains [residues 72–242; numbering based on the crystal structure 
of human c-Src (PDB 2SRC)] and both the full-length and core domain of HIV-1 Nef [SF2 allele 
residues 1–205 and 58–205, respectively; numbering based on the crystal structure of Nef NL4-3 
(PDB 1EFN)] are described in Alvarado et al (212).  Plasmids encoding the C-terminally His6-
tagged human Hck SH3 (residues 77–140; numbering was based on the structure of human c-Src) 
were constructed by PCR amplification of the corresponding coding regions. The SH3 and Nef 
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core PCR products were subcloned via Nde I and Xho I restriction sites into the 
bacterial expression vectors pET-21a(+) and pET-21b(+) (EMD Millipore), respectively. A 
fragment of the Nef-SF2 coding region of pET-14b/Nef-D123N was excised with KpnI 
and EcoRI and subcloned into a pET-30a plasmid encoding the Nef-SF2 core sequence plus the C-
terminal His6 affinity tag. Alanine substitutions were introduced into the Nef dimer interface of 
the pET-21b(+) full-length Nef SF2 (I109A, L112A, Y115A, H116A0 via the Agilant QuikChange 
II XL Site-Directed Mutagenesis Kit. The coding regions of all final bacterial expression plasmids 
were confirmed by DNA sequencing.  
3.5.2 Protein expression and purification (adapted from Moroco 2017) 
Expression and purification conditions for recombinant Nef (full-length, core, D123N 
mutant) and Hck (SH3 and SH3–SH2) proteins in  E. coli are described in detail elsewhere with 
slight modifications(212). For ion-exchange and Ni-IMAC column chromatography steps, the 
flow rate was increased to 2 mL/min, and buffer exchange after IMAC chromatography involved 
dialysis against 3 × 1 L of anion-exchange buffer at 4 °C. Purification of the four protein 
complexes used in this study (wild-type and D123N forms of the Nef core in complex with either 
Hck SH3 or SH3–SH2) is also based on our previously published methods, in which cell pellets 
from cultures expressing the individual protein components were combined prior to lysis 
and column chromatography (212) 
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3.5.3 Surface plasmon resonance (adapted from Moroco 2017) 
Recombinant, purified Hck SH3 and SH3–SH2 proteins were exchanged into HBS-EP 
buffer [10 mM Hepes (pH 7.4), 150 mM NaCl, 3 mM EDTA, 0.05% v/v Surfactant P20], while 
recombinant Nef proteins were exchanged into HBS-EPD (HBS-EP buffer supplemented with 
1 mM DTT) prior to analysis on a two-channel Reichert SR7500DC or a Reichert 4SPR instrument 
SPR platform. The Hck SH3 and SH3–SH2 proteins were covalently immobilized onto carboxy-
methyl dextran SPR chips (Reichert) using standard EDC/NHS amine coupling chemistry. Nef 
proteins were then injected in triplicate over a range of concentrations (0.041–3.3 μM) at a rate of 
30 μL/min for 1 min until equilibrium was reached, followed by dissociation in HBS-EPD for 
3 min. Kinetic rate constants were calculated from reference-corrected sensorgrams using 
TraceDrawer software, and were best fit by 1:1 Langmuir (SH3) or two-state (SH3–SH2) binding 
models. Steady-state affinities of Nef dimer interface mutants to Hck SH3 and Hck SH3-SH2 were 
also calculated using TraceDrawer software. 
3.5.4 Analytical SEC (adapted from Moroco 2017) 
Analytical SEC was conducted using a Superdex 75 10/300 GL column (GE Healthcare 
Life Sciences) equilibrated with running buffer [20 mM Tris–HCl, 150 mM NaCl, 10% (v/v) 
glycerol, 2 mM TCEP, pH 8.3]. All SEC runs were conducted at a flow rate of 0.5 mL/min, with 
each protein sample at a final concentration of 12.5 μM in a volume of 100 μL. SEC protein 
standards (Sigma-Aldrich) included bovine serum albumin (66 kDa), carbonic anhydrase (29 kDa), 
cytochrome C (12.5 kDa), and aprotinin (6.5 kDa). 
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3.5.5 Deuterium labeling (adapted from Moroco 2017) 
Stock solutions of individual proteins and complexes were prepared to final concentrations 
of 65 μM in 20 mM Tris–HCl (pH 8.3), 100 mM NaCl, and 3 mM DTT. Each protein or complex 
(110 pmol in 1.7 μL) was diluted 15-fold into identical buffer prepared with D2O. Labeling 
reactions were quenched after various times (10 s, 1 min, 10 min, 1 h, 4 h) with an equal volume 
of ice-cold quench buffer (100 mM K2HPO4/KH2PO4, pH 2.3). Undeuterated controls were 
prepared in the same way using the H2O-based buffer and quenched for digestion. One 
unique protein expression and purification prep was used for all protein samples, with the 
exceptions of the Nef core: Hck SH3 and Nef core: Hck SH3–SH2 complexes, for which two 
independent samples were prepared and analyzed. All labeling reactions were performed in 
duplicate, and a representative experiment is shown for each sample. 
3.5.6 Online protein digestion and mass analysis (adapted from Moroco 2017) 
After quenching, samples were injected onto a Waters nanoAcquity with HDX technology 
for online pepsin digestion at 15 °C and UPLC peptide separation at 0 °C. Samples were digested 
on a 2.1 × 50-mm stainless steel column packed with POROS 20AL resin coupled to porcine 
pepsin (Sigma). Peptides were trapped and desalted on a VanGuard Pre-Column trap (2.1 × 5 mm, 
Acquity UPLC BEH C18, 1.7 μm) for 3 min. Peptides were eluted from the trap and separated 
using an Acquity UPLC HSS T3 1.8 μm 1.0 × 50-mm column with a 5%–35% gradient of 
acetonitrile over 6 min at a flow rate of 65 μL/min. Mass spectra were acquired using a Waters 
Synapt G2Si mass spectrometer. Peptides were identified from triplicate undeuterated samples of 
each protein alone and in complexes using Waters MSE and Waters Protein Lynx Global Server 
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(PLGS) 3.0. Peptide maps were generated and deuterium incorporation was analyzed using Waters 
DynamX 3.0 software. 
3.5.7 In vitro kinase assay 
Assay was performed in a 384-well format using the Z’-Lyte kinase assay system 
(ThermoFisher). Near-full-length Hck-YEEI (a downregulated form of the kinase) was used for 
this assay, and was expressed from SF9 insect cells and purified as previously described (328). 
Hck-YEEI alone (200 ng) or Nef and Hck-YEEI at a 10:1 molar ratio, respectively, were titrated 
across a series of 2-fold dilutions and transferred in quadruplicate 10 μL volumes to a 384 plate. 
Kinase activation reactions within each well were initiated through the addition of 100 μM of ATP 
and 1 μM of a fluorescence resonance energy transfer (FRET)-based tyrosine peptide substrate 
(Tyr2), and wells were incubated for 45 min prior to the addition of 5 μL of substrate-specific 
development protease for 60 min. The development protease specifically cleaves 
unphosphorylated Tyr2 substrate, breaking FRET that occurs between the peptide’s donor 
fluorophore (coumarin) and acceptor fluorophore (fluorescein). Fluorescence of the reporter 
substrate following kinase activation and protease development was measured via SpectraMax M5 
microplate reader at 445 and 520 nm (allowing for measurement of coumarin and fluorescein 
emission ratios) following excitation at 400 nm. As maintenance of FRET within the peptide 
(indicated by a low ratio of coumarin:fluorescein emission) is the result of substrate 
phosphorylation, the degree of kinase activation corresponds directly to the emission ratio between 
these two fluorophores. Emission ratios for each reaction were normalized to 0% and 100% 
phosphorylation controls. 
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4.0 Overall Discussion 
4.1 Summary and discussion of major findings  
Though both halves of this dissertation work centered around the impact of dimerization 
on Nef function, each story involved the exploration of this important issue using two very 
different methodologies. The first half of my thesis, which investigated the role of Nef 
dimerization in antagonism of the SERINC5 host restriction factor, focused on virology and 
microscopy techniques, looking at the Nef dimer from the context of viral and cellular membranes. 
The second half explored changes to the dimer interface across two dynamic and structural stages 
of Hck regulatory domain association, and involved the use of structural, biochemical, and 
biophysical methodologies to study the Nef dimer in solution. 
4.1.1 Homodimerization is required for Nef antagonism of SERINC5 
For the first part of my thesis, I examined the role of Nef dimer interface residues (Leu112, 
Tyr115, Phe121) in Nef promotion of viral infectivity, a phenotype driven by Nef antagonism of 
the host restriction factor SERINC5. While the impact of these dimer interface residues has been 
previously examined in the context of viral replication and CD4 downregulation (239), these initial 
studies predate the discovery of SERINC5 in 2015 (117, 256). Based on the kinetics of 
dimerization measured by in-cell BiFC across a time scale consistent with single-round virion 
production (48 h), I identified three dimerization-defective Nef mutants - L112D, Y115D, and 
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F121A. As a L112A mutant showed functional dimerization, I included this mutant as a control 
throughout the subsequent assays. 
I was able to show that dimerization defective Nef mutants (L112D, Y115D, F121A) 
demonstrated impaired Nef enhancement of viral particle infectivity, and impairment in infectivity 
was largely due to reduced antagonism of SERINC5 following disruption of Nef dimerization. 
Although Asp123 had previously been implicated in this function (117), this project represents the 
first demonstration that hydrophobic dimer interface residues are required for Nef antagonism of 
SERINC5. Using a single-round infectivity assay, I demonstrated that mutation of dimer interface 
residues inhibited Nef promotion of viral infectivity in a primarily SERINC5-dependent manner. 
This finding was confirmed within an artificial 293T producer cell system, as well as a functionally 
relevant T cell line (Jurkat JTAgs) and donor-derived PBMCs. 
Interestingly, some of my data also seem to suggest an impact of dimerization defective 
mutants on infectivity even in the absence of SERINC5 expression. As only SERINC5 expression 
was modulated within these experiments, it is possible that Nef antagonism of other endogenous 
SERINC proteins is similarly impacted by Nef dimerization. However, the HIV-1 Nef subtype 
used in this study (B-clade SF2) does not antagonize SERINC3, and while mRNA transcripts of 
SERINC1 are highly expressed in myeloid and lymphoid cells, SERINC1 displays weak inhibition 
of viral infectivity (258, 262). Finally, while the expression of SERINC4 within these cell lines 
was not examined, a recent analysis of gene-expression data sets was unable to identify any human 
tissues with detectable SERINC4 expression (259).Taken together, it seems unlikely that other 
SERINC proteins are contributing to Nef promotion of infectivity within this experimental system. 
The possibility remains that Nef antagonizes other yet-unknown restriction factors via a 
dimerization-dependent mechanism. Indeed, a recent study identified a SERINC5-independent 
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means of Nef enhancement of viral replication, which researchers hypothesized was mediated 
through an unidentified cellular factor (329). In addition, Nef has been shown to antagonize at 
least two other cellular factors that can restrict HIV-1: TIM-1 and Ezrin (330, 331). While 
disruption of Asp123 impairs Nef internalization of TIM-1, involvement of the dimerization during 
Nef antagonism (and the contribution of these proteins to the Nef enhancement of infectivity) 
remains an open question. 
I also demonstrated that dimerization is essential for Nef exclusion of SERINC5 from 
newly synthesized virions and downregulation of SERINC5 from the cell surface. A limitation of 
these analyses was a reliance on the detection of transfected SERINC5 via an HA tag, due to the 
lack of a commercial antibody that can detect endogenous SERINC5 (275). However, phenotypic 
trends observed for the mutants in terms of Nef enhancement of viral infectivity appeared to mirror 
the degree of SERINC5 incorporation into each corresponding virus. In addition, Nef 
downregulation of cell-surface CD4 was compared for each mutant as a control, and dimerization-
defective mutants that displayed reduced SERINC5 downregulation did not antagonize CD4. 
These confocal and flow-cytometry-based results enforce the validity and relevance of these data, 
even though Nef downregulation and exclusion of endogenous SERINC5 could not be explored.   
Using confocal microscopy, I found that Nef dimerization is required for the retargeting of 
SERINC5 into the endosome-lysosome system. Wild-type Nef and SERINC5 were shown to co-
localize within the Rab7+ late endosomal compartments, consistent with previous reports (117, 
268). Disruption of Nef dimerization impaired trafficking of SERINC5 into late endosomes, which 
is the first reported evidence that the Nef dimer may be required for Nef sequestration of proteins 
into the endo-lysosomal pathway. Interestingly, while the L112A mutant had no effect on Nef 
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downregulation of SERINC5 or its exclusion from the membrane, L112A was less able to redirect 
SERINC5 into Rab7+ endosomes, compared to wild-type Nef. 
Finally, as Nef antagonism of SERINC5 appears to involve coordinated recruitment of both 
the AP-2 hemicomplex and SERINC5 (269), I used BiFC to explore whether mutation of the dimer 
interface impacted Nef association with SERINC5, AP-2 α, and AP-2 σ2 in cells. As Nef 
association with AP-2 and SERINC5 is predicted to occur at the cell surface, I used a 
myristoylation-defective mutant of Nef (Nef-G2A) as a negative control. While Nef-G2A has been 
previously shown to disrupt association of Nef and SERINC5 in cells  (via BiFC) (268), this is the 
first reported use of this control for Nef:AP-2 hemicomplex association in a BiFC system. 
However, for both sets of interactions, Nef-G2A showed cellular expression but impaired 
association with SERINC5, AP-2α, and AP-2 σ2, supporting the utility of this mutant as a negative 
control. 
Through BiFC analysis, I observed that genetic disruption of dimerization had no 
detectable impact on SERINC5 association. The same observation was true for Nef-L112D and 
Nef-F121A and both the AP-2α and AP-2 σ2 subunits, as no decrease in association was detected 
for those mutants. However, while Nef-Y115D still bound to AP-2α and AP-2 σ2 at a level above 
the G2A control, this demonstrated a significant decrease in Nef association compared to wild-
type Nef. Since crystal structures of Nef and the AP-2 α/σ2 hemicomplex show no overlap between 
the AP-2/Nef interface and the dimer interface (222), this decrease is likely due to an allosteric 
impact on the mechanism for AP-2 engagement. 
In summary, these data suggest that the Nef homodimer is required for bridging AP-2 and 
SERINC5 together into a complex that productively drives Nef internalization of SERINC5 from 
the cell surface. While AP-2 releases from the clathrin-coated vesicle following endocytosis (332), 
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the Nef dimer also appears to coordinate intracellular retargeting of SERINC5 following 
internalization. However, the mechanistic contribution of the Nef dimer during this stage of Nef 
antagonism remains underexplored and will hopefully be examined in future studies.  
4.1.2 Defining the structural basis of HIV-1 Nef dimerization in functional complexes with 
host cell effectors 
For the second half of this dissertation, we compared the contribution of individual dimer 
interface residues to dimerization in two stages of Hck regulatory domain engagement. This study 
began with an observed discrepancy in the participation of Nef Asp123 across two structures of 
the Nef dimer- one in which Nef is bound to a Src-family kinase SH3 domain, and a second in 
which Nef is bound to an expanded SH3-SH2 domain. In the SH3 domain-bound structure, Asp123 
participates directly in the stabilization of the dimer interface, whereas the second SH3-SH2 bound 
structure features an Asp123 that is positioned away from the dimer interface and solvent-exposed.  
This raised the possibility that the Nef dimer transitions through two stages of Hck 
regulatory domain engagement, and that transition through these stages involves reorientation of 
the dimer interface. To test this hypothesis, I developed, expressed, and purified a recombinant 
Nef mutant where Asp123 was substituted with asparagine (D123N). This mutation eliminated a 
stabilizing electrostatic interaction present within the Nef:SH3 dimer complex but not the SH3-
SH2 domain bound structure of the Nef dimer. To ensure that introduction of this mutation did not 
impact proper folding of the 3-dimensional Nef core, I used surface plasmon resonance to measure 
the affinity of binding between the Nef core and the Hck SH3 and SH3-SH2 domain proteins. I 
observed no difference in SH3 affinity between wild-type and D123N, suggesting that this 
substitution does not destabilize the Nef core in solution. In addition, there was no apparent impact 
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of the D123N substitution on solubility of the mutant protein during expression and purification, 
further supporting that the D123N mutant is properly folded and viable. However, additional 
examination of the D123N mutant via circular dichroism or thermal stability assays could confirm 
this further, as well as crystallization of the mutant protein. 
We next examined the dynamics of Nef complex formation in solution. Using HDX MS, 
we were able to compare the dynamics of complex formation between wild-type and D123N Nef 
in both the SH3- and SH3-SH2-bound complexes. In contrast to the wild-type Nef:SH3 complex, 
the D123N Nef:SH3 complex displayed a complete lack of deuterium uptake protection within the 
αB helix, consistent with disruption of dimerization following mutation of Asp123. However, the 
D123N Nef:SH3-SH2 complex retained significant protection within the same region (as seen in 
the wild-type complex), consistent with the crystal structure which shows that this residue does 
not participate in the SH3-SH2 domain-bound Nef dimer structure. We also analyzed the 
stoichiometry of complex formation in solution and observed that Nef D123N is able to form a 
stable 2:2 heterodimeric complex with the SH3-SH2 but not the SH3 protein. Both results support 
the hypothesis that the Nef dimer interface is remodeled during transition from an initial SH3 
bound conformation of the 2:2 heterodimer to the SH3-SH2 bound state.  
Taking an additional look at the crystal structures of the SH3 and the SH3-SH2 domain 
bound Nef dimers, I observed several hydrophobic residues that participated to the Nef dimer 
interface in both Nef dimer structures- Ile109, Leu112, Tyr115, His116, and Phe121. Three of 
these residues (Ile109, Leu112, Phe121) have already been characterized as driving Nef 
homodimerization in cells by BiFC, and mutants harboring substitutions at these residues have 
been validated as bona-fide dimerization defective mutants (Chapter 2, (149, 239). Although the 
contribution of these three residues towards dimerization in this context has not been examined, 
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their participation in the dimer interface seems consistent across both structures, and they play a 
clear role in Nef dimerization in cells. In addition, two of the hydrophobic residues in both dimer 
interface structures (Ile109 and His116) have not been studied to the same extent, and their 
contribution to the dimer interface in general remains to be further evaluated. 
Therefore, I chose to survey the contribution of four hydrophobic residues towards 
dimerization - two of the well-characterized residues (Leu112 and Tyr115) and two of the poorly 
characterized dimer residues (Ile109 and His116). I expressed and purified four recombinant Nef 
mutant proteins- I109A, L112A, Y115A, and H116A. I first performed the same quality control 
experiment used in the D123N study, using SPR to assess whether introduction of these alanine 
substitutions impaired proper three-dimensional folding of Nef. I observed that three of the Nef 
mutants (I109A, L112A, H116A) bound to Hck SH3 and Hck SH3-SH2 with similar affinity as 
wild-type Nef. Nef-Y115A, also displayed productive association with both regulatory domain 
proteins, albeit with about 5-fold lower affinity than wild-type Nef. 
Curiously, SPR studies of Hck SH3 and SH3-SH2 demonstrated a similar, submicromolar 
affinities towards wild-type Nef. While binding of both Hck proteins is primarily directed through 
Nef association with SH3, and the Nef:SH3 interface is largely conserved across both complexes, 
there are differences between both structures that might be expected to manifest as changes to the 
affinity (212). For example, Arg105 (a residue which coordinates with Asp123 to stabilize the 
SH3-bound Nef dimer) makes a novel ionic contact with Glu93 in the SH3 domain of the SH3-
SH2 dual domain protein, and the SH2 associates with the Nef core via Van der Waals interactions 
(212). However, these novel contacts within the secondary SH3-SH2 bound structure may serve 
to remodel the dimer interface or induce a conformational change, rather than impact recruitment 
or affinity of the SH3 domain.  
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Next, I used analytical size exclusion chromatography to compare the stoichiometry of 
complex formation between each Nef protein in the presence of the SH3 or SH3-SH2 domain. I 
observed similar complex formation between wild-type Nef and the I109A, L112A, and H116A 
mutants, consistent with 2:2 heterocomplex formation. However, the Nef-Y115A/regulatory 
domain complexes displayed a larger elution volume, consistent with disrupted complex 
formation, likely through disruption of Nef homodimerization.  
Finally, I examined the ability of each Nef mutant to activate Hck in an in vitro kinase 
assay. Mirroring the results of complex formation in the analytical size exclusion chromatography 
studies, we observed that I109A, L112A, and H116A mutants displayed kinase activation on par 
with that of wild-type Nef. However, Nef-Y115A activation of Hck was 2-fold lower than what 
was observed with wild-type Nef. Reduced kinase activation of this mutant could be due to a defect 
in dimerization, consistent with the observed disruption to complex formation in solution. Indeed, 
forced dimerization of the Nef dimer in cells (via a Nef-estrogen receptor fusion construct and 4-
hydroxytamoxifen) has been shown to increase Hck activity in cells compared to unfused Nef 
(240), and mutation of the Tyr115 residue also disrupts Nef activation of the similarly organized 
(i.e. SH3 and SH2 domain containing) Tec family kinases in cells (149). And while the reduced 
affinity of this mutant towards Hck SH3 and SH3-SH2 could also have contributed towards 
decreased Hck activation, the affinity of these two regulatory domain proteins may not completely 
reflect the affinity of Nef towards full-length kinase especially when considered in the context of 
the lipid bilayer where the effective concentrations of each protein is much higher. Taken together, 
these data suggest a role for Tyr115 in the dimer interface of both SH3 and SH3-SH2 bound dimer 
structures, and suggest that mutants with multiple alanine substitutions or more aggressive 
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substitutions may be required to properly examine the contribution of Ile109, Leu112, and His116 
towards dimer formation. 
In summary, the studies described in this chapter support a 2-step model in which Nef 
interacts with Hck to trigger kinase activation as well as reorganization of Nef to enable interaction 
with AP-1 for MHC-I downregulation and immune escape (Figure 35). In the first step, Nef 
recruits Hck through its SH3 domain, resulting in the formation of a ‘loose’ dimer structure in 
which Asp123 is buried in the dimer interface. This Nef: Hck complex then undergoes dynamic 
reorganization, resulting in a more compact dimer consistent with kinase activation, as well as 
surface exposure of Asp123 for recruitment of MHC-I and AP-1 as required for downregulation. 
The crystal structures that support this model offer only snapshots in time of the overall dynamic 
transitions that occur.  However, our HDX MS data support the existence of distinct dimer forms 
in solution, and potentially in cells.   
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Figure 35: Interaction of HIV-1 Nef with the Src-family kinase Hck may induce conformational changes 
consistent with MHC-I/AP-1 recruitment 
Left: Crystal structure of the HIV-1 Nef core in complex with the SH3 domain of Fyn (high affinity R96I mutant; 
PDB: 1EFN). Nef forms a dimer of Nef•SH3 complexes in this structure (NefA, blue; NefB, green). The dimer interface 
is formed by the Nef αB helices (highlighted; see Figure 4 for details). The SH3 domains shown at the top in red. The 
helical dimer interface is enlarged in the lower panel and highlights the reciprocal polar contacts between Nef Asp123 
and Arg105, which are buried in the core of this structure. Center: Top panel shows the crystal structure of the Nef 
core in complex with the Hck SH3-SH2 region (PDB 4U5W). Color scheme as per the left panel with a single SH3-
SH2 unit shown for clarity. Nef also crystallizes as a 2:2 complex Nef•SH3-SH2 dimers in this structure. However, 
the helical interface is completely re-oriented relative to the Nef•SH3 complex, such that the Nef Asp123 side chain 
(orange) is now pointed toward the solvent.  One of the Asp123 residues is enlarged in lower panel. Right: Structural 
alignment of one of the Nef core proteins in the Nef•SH3-SH2 complex (PDB 4U5W; green ribbon) with the Nef core 
in complex with the AP-1/μ1 subunit (pink) and MHC-I tail peptide (purple); (PDB 4EN2; Nef core from this complex 
in cyan). The Nef core proteins from each complex adopt very similar conformations, with nearly identical positioning 
of Nef Asp123 (enlarged in lower panel).  Nef Asp123 forms part of an ionic bond network with Arg393 from AP-1 





















4.2 Future directions 
4.2.1 Exploring the mode of Nef and SERINC5-ICL4 association  
Since the discovery of Nef antagonism of SERINC5 in 2015, one of the larger questions 
surrounding this function is the mode of binding between the two proteins. Indeed, the ability of 
Nef to antagonize SERINC5 appears to be mediated through the intracellular loop 4 region (ICL4) 
of SERINC5. Substitution of this loop with the loop from Nef-resistant orthologs of SERINC5 
from other species eliminates Nef antagonism, suggesting a role for this region in Nef recruitment. 
And while this dissertation and other studies have demonstrated Nef: SERINC5 association via 
BiFC, a direct interaction between these two proteins remains to be confirmed. However, 
downregulation of SERINC5 appears to depend upon the formation of a trimeric complex between 
SERINC5-ICL4, Nef, and AP-2, and a fused Nef-ICL4 construct appears to promote recruitment 
of AP-2 μ2/σ2/α via GST pull-down (269). In order to confirm that Nef and SERINC5-ICL4 
interact directly, we can measure the interaction of Nef and a recombinant protein of SERINC5-
ICL4, and see if they associate, via SPR, and form a complex in solution, via size exclusion 
chromatography. If binding requires the presence of the AP-2 hemicomplex, recombinant versions 
of AP-2 subunits can be developed and introduced into both systems. Additionally, analytical size 
exclusion chromatography coupled to multi-angle light scattering may provide a more quantitative 
assessment of the stoichiometry and composition of the complex, potentially implicating the Nef 
dimer in S5-ICL4 engagement and recruitment. 
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4.2.2 Track dynamics of Nef dimer formation via fluorescence complementation and live-
cell imaging   
These data show for the first time that alteration of Nef dimerization in cells appears to 
impacts intracellular retargeting of SERINC5 into late endosomes. While our proposed mechanism 
offers an explanation of how the Nef dimer participates in the initial stage of clathrin-mediated 
endocytosis, the role of the Nef dimer in downstream endosomal trafficking (following release of 
AP-2) is unknown. One downside of BiFC is the irreversibility of fluorophore formation, which 
prevents the study of the dynamics of an interaction within a cell. However, the recent development 
of  a fast and reversible fluorogen-based complementation assay, ‘Splitfast’, may allow us to track 
Nef dimer assembly and disassembly in real time within live cells (333). We could follow Nef 
dimer formation throughout the entire course of SERINC5 internalization and retargeting and use 
co-localization and small molecule inhibitors of endosomal trafficking to understand where the 
Nef dimer is present and which proteins it may be recruiting. 
4.2.3 Solution dynamics of Nef dimerization in the membrane-associated state 
While this study analyzed the dynamics of dimerization and Hck regulatory domain 
complex formation in solution, membrane association is a shared feature of both Src family kinases 
and Nef (334). HDX MS has recently been shown to be amenable to the incorporation of a 
Langmuir monolayer, which allow for the dynamics of membrane-associating proteins to be 
examined (198). Disruption of myristoylation appears to impair both Nef dimer formation and 
kinase activation in cells, suggesting that the membrane-associated conformation of Nef is the 
functionally relevant form (149). To extend the results from the previous study into a more 
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physiologically relevant context, we can measure the dynamics of complex formation in the 
presence of myristoylated Hck regulatory domain proteins and Nef. If stabilization of the dimer 
interface by regulatory domain proteins is preserved within this system, we can then explore the 
contribution of individual dimer interface residues toward the dimerization interface in the 
presence and absence of membrane association.  
4.3 Closing remarks 
The year 2021 will bring us into a fifth decade of contending with HIV/AIDS as a species. 
Despite major leaps in antiretroviral therapy, prevention via education and PrEP, and 
breakthroughs in understanding the intricacies of HIV-1 infection and latency, we are still left 
without a cure for infection. There is an urgent need to identify novel ways to target the virus, 
especially in the context of therapeutic strategies that may aid in clearing the latent viral reservoir. 
The potential of Nef as a novel drug target is exceptionally strong, through both its essential role 
in viral pathogenesis and its various contributions towards immune escape. Early drug 
development strategies sought to target single protein-protein interaction interfaces within Nef 
(e.g. the PxxP motif) (249, 335). However, the widespread contribution of Nef dimerization 
towards Nef function could allow for a nearly comprehensive disruption of Nef function, making 
it an exceptional drug target. Our lab is working to develop a class of inhibitors that potentially 
target productive dimer formation, an effort that benefits from having a complete understanding 
of the dynamics of dimer interface formation during Nef function, and the role of dimerization in 
essential Nef activities. I hope to have contributed to that understanding in both halves of my 
dissertation work. First, I was able to implicate the Nef dimer in antagonism of SERINC5, 
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suggesting that disruption of Nef dimerization could force HIV-1 to succumb to a potent inhibitor 
of viral infectivity. I also helped to show that the Nef dimer interface can be dynamically 
remodeled in different stages of binding partner engagement, and worked to identify 
commonalities between remodeled dimer interfaces. This work helps support a deeper 
understanding of how the dimer interface can be pharmacologically targeted across different stages 
of Nef function and regulatory protein engagement. I sincerely hope my previous contributions 
and future work will help our lab develop an effective therapeutic for HIV-infected individuals. 
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